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Toll-like receptors (TLR) are pathogen recognition receptors which are 
able to sense the presence of foreign microbial agents by recognizing 
pathogen-associated molecular patterns. Chen et al (2008b) has previously 
reported the up-regulation of TLR6 during dengue virus (DV) infection using 
Real Time PCR arrays. In this study, the up-regulation of TLR6 during DV 
infection was further validated in K562 cells. TLR6 and TLR2 were found to 
be up-regulated in DV-infected human PBMC. IL-6 and TNF-α, cytokines 
downstream of TLR6 and TLR2 were also found to be up-regulated in DV-
infected PBMC. Gene silencing of TLR6 in DV-infected K562 cells lowered 
IL-6 production compared to DV-infected K562 cells transfected with shRNA 
control plasmid. Similar result was obtained when TLR2/6 of PBMC was 
blocked during DV infection.  These results suggest that TLR6 pathway is 
activated during dengue virus infection and its activation contributes to IL-6 
production. DV NS1 protein was found to significantly increase the 
production of IL-6 and TNF-α when added to PBMC. The amount of IL-6 and 
TNF-α stimulated by DV NS1 protein was decreased when TLR2/6 was 
blocked, suggesting that DV NS1 protein is the viral protein responsible for 
the activation of TLR2/6 during DV infection. Using HUVEC endothelial 
permeability cell model, TLR6 activation during dengue virus infection was 
shown to increase permeability of human endothelial cells. In addition, using 
TLR6
-/-
 murine model of dengue virus infection, TLR6 was found to 




via DV NS1 protein could potentially play an important role in the 
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1.0 LITERATURE REVIEW 
1.1 FLAVIVIRUS CLASSIFICATION 
Flaviviruses consist of a group of more than 70 enveloped positive-
sense RNA viruses which are known to cause serious diseases in humans and 
animals (Fernandez-Garcia et al, 2009a). Most of these viruses are arthropod-
borne viruses which are transmitted by either mosquitoes or ticks to the 
vertebrate hosts. Among the flaviviruses, approximately 40 are mosquito-
borne, 16 are tick-borne and 18 have no known vectors (Mackenzie et al, 
2004).  Flaviviruses, such as dengue virus (DV), West Nile virus, Japanese 
encephalitis virus and yellow fever virus are highly pathogenic to humans and 
constitute an immense global health problem (Fernandez-Garcia et al, 2009b).  
 
1.2 DENGUE VIRUS 
Dengue virus (DV) is a member of the Flavivirus genus of the 
Flaviviridae family. DV is an enveloped virus with a diameter of about 50 nm. 
Dengue virus is a positive-sense, single-stranded RNA virus and it has five 
distinct serotypes (DV1 to 5). DV serotype 5 was recently discovered and 
characterized (Normile, 2013). Among the four classical serotypes, infection 
by one serotype only confer resistance to the other three serotypes for a few 
months and subsequent secondary infection of a different serotype has a 
higher risk of developing into the more severe forms of dengue infection; the 
dengue hemorrhagic fever or dengue shock syndrome (Goncalvez et al, 2007; 
Guzman et al, 2007; Guzman et al, 1990; Halstead et al, 1970; Sabin, 1952). 
Dengue virus genome encodes for a single polyprotein that consists of 3 




structure of the virus particle and 7 non-structural proteins (NS1, NS2a, NS2b, 
NS3, NS4a, NS4b, NS5) which are necessary for the viral replication and 
assembly (Henchal & Putnak, 1990).  
 
1.3 CELLULAR TROPISM OF DENGUE VIRUS 
When a mosquito carrying DV feeds on human, DV enters the host and 
gets into contact with epidermis and dermis, resulting in infection of the 
epidermal dendritic cells and keratinocytes (Limon-Flores et al, 2005; Wu et 
al, 2000). Infected cells migrate to lymph nodes where monocytes and 
macrophages are recruited. DV is then spread to the monocytes and 
macrophages (Durbin et al, 2008). The infection is amplified and DV gets 
disseminated through the lymphatic system, resulting in the infection of many 
other cells including Kupffer and sinusoidal endothelial cells of the liver; 
lymphoid cells in the spleen and vascular endothelial cells in the lung (Jessie 
et al, 2004). DV has also been documented to be present in cells of kidney, 
bone marrow, thymus and brain (Balsitis et al, 2009; Basilio-de-Oliveira et al, 
2005; Guzman et al, 1999; Miagostovich et al, 1997; Nisalak et al, 1970). 
However, in most cases, DV could only be isolated from liver and peripheral 
blood mononuclear cells (Martina et al, 2009).  
 
1.4 REPLICATION CYCLE OF DENGUE VIRUS 
After being introduced into the host, the virus binds to and enters a 
susceptible host cell via receptor-mediated endocytosis [Figure 1.1, (Clyde et 
al, 2006)]. The receptor involved in this internalization of the virus into the 




proposed to be the receptor involved (Table 1). Carbohydrate molecules like 
sulfated glycosaminoglycans (GAGs) and glycosphingolipid (GSL) can 
enhance the efficiency of virus entry and were proposed to be a co-receptor for 
dengue virus (Aoki et al, 2006; Chen et al, 1997; Kato et al, 2010; Lee et al, 
2006). A carbohydrate-binding protein, DC-specific ICAM3-grabbing non-
integrin (DC-SIGN) molecule was shown to function as a DV-binding lectin 
by interacting with envelope glycoprotein (Navarro-Sanchez et al, 2003). 
Infection of dendritic cells by DV was found to be blocked by anti-DC-SIGN 
antibodies (Tassaneetrithep et al, 2003). The structure of DV in complex with 
the carbohydrate recognition domain of DC-SIGN was further shown by cryo-
electron microscopy (Pokidysheva et al, 2006). Mannose receptor, another 
lectin, was shown to mediate DV infection of macrophages (Miller et al, 
2008). Heat shock protein (HSP) 90 and HSP70 participate in dengue virus 
entry as a receptor complex in human monocytes/macrophages, determined 
using infection inhibition assays (Reyes-Del Valle et al, 2005). The HSPs 
associate with lipid rafts in response to DV infection and raft-disrupting drug 
inhibits DV infection. Binding immunoglobulin protein (BiP), a member of 
the HSP70 was also identified as a receptor element for dengue virus serotype 
2 (DV2) on human liver cells (HepG2) using the Viral Overlay Protein 
Binding Assay (VOPBA) technique and mass spectrometry fingerprinting 
(Jindadamrongwech et al, 2004). Antibodies directed against BiP affected 
both the binding of DV to the cell surface and the infectivity of HepG2 cells. 
Another independent study carried out by another research group supported 
the role of BiP as a dengue virus receptor protein (Upanan et al, 2008). The 




the initiation of a DV infection as LPS was found to block DV entry into 





Figure 1.1 Intracellular life cycle of dengue virus  
Schematic representation of DV replication cycle (Clyde et al, 2006). 
 
Upon internalization, acidification of the endosome occurs. The 
lowering in pH results in the trimerization of the viral envelope protein. This 
exposes the fusion domain and allows the fusion of viral membrane with 
vesicular membrane. The fusion process releases the nucleocapsid into the 
cytoplasm. The viral RNA is first uncoated before translation of the positive-
strand viral RNA take place at the ER-derived membranes. A polyprotein 
containing three structural and seven non-structural proteins is synthesized and 
processed into individual proteins to form the viral replication complex. The 
virus then switches from translation to synthesis of a negative-strand 




of more copies of positive-strand viral RNA. Rounds of translation which 
generate large amount of viral proteins subsequently occur, followed by 
assembly of virions in the ER. The virion passes through the Golgi 
compartment and gets maturated. Finally, the matured virion is secreted out as 
infectious virions via the host secretory pathway. 
 
 Table 1.1: List of proposed Dengue Virus Receptor [from: Dengue virus 









1.5 DENGUE VIRUS STRUCTURAL PROTEIN 
 1.5.1 Capsid (C) Protein       
Mature dengue virus capsid (C) protein is a 12-kDa protein. It is 
required for virion assembly and the specific encapsulation of the viral RNA 
genome. Encapsulation of the viral RNA genome forms a spherical 
nucleocapsid with a single copy of the single-stranded RNA molecule (Kuhn 
et al, 2002). DV C protein has 3 nuclear localization signals and is known to 
translocate to the nucleus and nucleoli of infected cells (Bulich & Aaskov, 
1992). DV C protein translocation into the nucleus is reported to be mediated 
by importin-α (Bhuvanakantham et al, 2009). The biological significance of 
DV C protein nuclear localization remains largely unclear. However, it was 
demonstrated by Netsawang and co-workers (2010) that the nuclear 
localization of DV C is required for its interaction with Daxx, a Death domain-
associated protein to induce Fas-mediated apoptosis (Netsawang et al, 2010). 
DV C protein is also found to bind core histones to prevent histone 
dimerization and nucleosome formation in cells (Colpitts et al, 2011). This 
binding may disrupt normal host cell genetic machinery and favour viral 
replication.  
 
 1.5.2 Precursor Membrane Glycoprotein (PrM)   
The prM of DV consists of an N-terminal pr domain followed by the 
M protein. The function of prM is to prevent newly synthesized virus from 




network and exosomes (Zhang et al, 2012). In the neutral pH environment of 
the endoplasmic reticulum where the virus is synthesized, the prM-E 
heterodimers are organized as 60 trimeric spikes (Figure 1.2). In the acidic pH 
environment, the prM-E proteins undergo configuration change and form 
dimers which expose the furin cleavage site on prM. The furin cleavage site is 
between the pr molecule and the M protein (Stadler et al, 1997). The cleaved 
pr molecule and M protein remain associated due to the acidic pH 
environment. The pr molecule separates from the virus when released out of 
the cell due to the change in pH. The presence of pr molecule on the virion in 
the trans-Golgi network prevents the progeny virus from fusing with the host 
cell (Yu et al, 2009). This allows the progeny virus to be successfully released 
out of the cells and become mature virus when the pr molecules dissociate. 
 
 
Figure 1.2 Structural rearrangement of virus surface proteins during 
dengue virus maturation. E and pr molecules are gray and cyan respectively. 
(Zhang et al, 2012) 
 
 
 1.5.3 Envelope Glycoprotein   
The envelope glycoprotein is present on the surface of the virus. The 




internalization of the virus. Envelope glycoprotein has three functional 
domains, domain I to III. Domain I acts as a hinge linking the other two 
functional domains. Reorientation of the hinge at the domain I – domain II 
interface during external pH changes is responsible for the changes in 
structure of the envelope glycoprotein (Modis et al, 2003; Modis et al, 2004). 
Domain II contains a hydrophobic ‘fusion’ peptide which is involved in 
membrane fusion and dimerization of envelope glycoprotein (Allison et al, 
2001; Modis et al, 2003; Zhang et al, 2003). Domain III is proposed to be 
involved in the binding to host cell receptor. Binding of envelope glycoprotein 
to the cellular receptor induces receptor-mediated endocytosis which the virus 
is internalized and transported in an endosome. The reduced pH in the 
endosome causes the envelope proteins to undergo rearrangement (Modis et 
al, 2004). The rearrangement allows envelope proteins to interact with lipids 
on the bilayer of endosomal membrane to bring about membrane fusion. 
During dengue virus infection, antibodies against E proteins will be generated. 
The amino acid sequences of the E proteins determine the antibody 
neutralising activity that classifies DV into the 4 classifcal serotypes: DV1, 
DV2, DV3 and DV4 (Kyle & Harris, 2008). 
 
1.6 DENGUE VIRUS NON-STRUCTURAL PROTEIN 
Non-structural proteins of DV play major roles in viral RNA 
replication, viral protein processing and virus assembly. However, the specific 
functions of some of these viral proteins are relatively unknown. Some 




other flaviviruses and their functions were inferred from experiments carried 
out using other flaviviruses.  
 
 1.6.1 Dengue Virus NS1 Protein      
Dengue NS1 is a 46-kDa non-structural glycoprotein. It can be found 
in virus- induced intracellular organelles where viral replication takes place 
(Mackenzie et al, 1996). NS1 protein is believed to play a role in RNA 
replication due to its colocalization with the viral dsRNA replicative form and 
NS1 protein of Yellow fever virus has been shown to play a role in early RNA 
replication (Lindenbach & Rice, 1997). DV NS1 protein can also be found on 
the surface of dengue-infected mammalian cells. DV NS1 protein will undergo 
dimerization soon after synthesis and traffic through the Golgi system where it 
is processed to a complex form. A portion of the NS1 proteins are processed to 
a glycosyl-phosphatidylinositol (GPI) -anchored form which allows them to 
bind onto the surface of cells (Jacobs et al, 2000). A portion of the NS1 
proteins are secreted out of the DV-infected mammalian cells into the blood 
stream (Flamand et al, 1999). Dengue NS1 protein can be detected in the sera 
of patients from the first day after the onset of fever and up to day 9 (Alcon et 
al, 2002). The level of NS1 protein in the sera varied among individuals, 
ranging from several nanograms per millilitre to several micrograms per 
millilitre. The presence of dengue NS1 protein in the bloodstream stimulates a 
strong humoral response. Dengue NS1 protein has been implicated in the 
pathogenesis of DV. High level of dengue NS1 protein in the blood during the 
early phase of dengue illness has been found to correlate with the severity of 




rarely found in patients with primary infections but commonly found in 
secondary infection (Kuno et al, 1990). An association between the presence 
of anti-NS1 antibody and the development of DHF has been reported (Brandt, 
1988). One explanation for such phenomenal is anti-NS1 antibody cross-react 
with human fibrinogen, thrombocytes and endothelial cells which results in 
disruption of normal haemostasis (Chuang et al, 2013). It was reported that 
recognition of cell surface NS1 on endothelial cells by anti-NS1 antibodies 
could contribute to the selective vascular leakage syndrome that occurs during 
severe secondary DV infection (Avirutnan et al, 2007). The proposed 
pathologic mechanism is that high intravascular soluble dengue NS1 protein 
could promote binding and surface expression of NS1 on selective endothelial 
cells without direct viral infection. Dengue NS1 protein was also shown to be 
able to bind to mesothelial cells that line pleura and peritoneum, which could 
be contributing to the pleural effusions or ascites that are observed in 
DHF/DSS patients (Avirutnan et al, 2007). The binding of soluble dengue 
NS1 protein to endothelial and mesothelial cells could lead to tissue-specific 
vascular leakage after recognition by anti-NS1 antibodies, immune complex 
formation and inflammatory damage.  
 
 1.6.2 Dengue Virus NS2A Protein    
 Dengue NS2A is a 22-kDa hydrophobic membrane protein (Chambers 
et al, 1989). Results from studies using mutagenesis suggested that dengue 
NS2A protein is essential for DV RNA synthesis, virion assembly and 
maturation (Xie et al, 2013). Dengue NS2A protein was also found to be able 




cells (Munoz-Jordan et al, 2003). IFN-α/β/γ play pivotal role in protection 
against dengue virus infections. IFN-α/β/γ receptors knockout mice develop 
severe infections after a challenge with dengue virus while wild type mice are 
resistant to dengue virus infection (Johnson & Roehrig, 1999; Shresta et al, 
2004).   
 1.6.3 Dengue Virus NS2B Protein     
Dengue NS2B protein associates with dengue NS3 protein to form the 
viral proteinase which is required for the proteolytic processing of the dengue 
virus polyprotein (Arias et al, 1993). It cleaves in the non-structural region of 
the viral polyprotein at the NS2A/NS2B, NS2B/NS3, NS3/NS4A, and 
NS4B/NS5 junctions (Niyomrattanakit et al, 2004). Like dengue NS2A 
protein, dengue NS2B protein has been shown to interfere with type I IFN 
signalling pathway (Munoz-Jordan et al, 2003). 
 
 1.6.4 Dengue Virus NS3 Protein      
Dengue NS3 is a 69-kDa multifunctional protein. It has protease, 
helicase, nucleoside 5’-triphosphatase and 5’-terminal RNA triphosphatase 
activities (Benarroch et al, 2004). Its serine protease activity requires NS2B 
protein as a cofactor (Niyomrattanakit et al, 2004). DV NS2B3 protease 
complex not only processes the viral polyprotein but also antagonize the host 
immune system by cleaving human adaptor molecule STING, resulting in the 
inhibition of type I interferon (Aguirre et al, 2012). The same group also 
found that DV NS2B3 protease complex cannot cleave murine STING and 




NS3 protein also acts as a helicase which unwinds duplex RNA structure by 
breaking the hydrogen bonds between the two strands. The unwinding process 
requires energy from the hydrolysis of the nucleoside triphosphate (NTP) γ-
phosphate, which can also be catalyzed by NS3.  
 
 1.6.5 Dengue Virus NS4A Protein     
Dengue NS4A protein is a small hydrophobic protein of size 16-kDa. 
Dengue NS4A protein is poorly characterized. It was found using yellow fever 
virus that the interaction of flavivirus NS4A protein with the NS1 protein is 
important for replicase function (Lindenbach & Rice, 1999). In another study, 
dengue NS4A protein with 2k fragment removed was shown to induce 
cytoplasmic membrane rearrangements and result in redistribution of the ER 
as observed in infected cells (Miller et al, 2007). These membrane 
rearrangements may be necessary for the formation of convoluted membranes 
which are the sites of viral polyprotein processing or smooth membrance 
structures which represent the sites of viral RNA replication. Interaction of 
NS4A protein with vimentin was also recently documented (Teo & Chu, 
2013). The membrane rearrangement induced by NS4A may be through 
vimentin reorganization to provide anchorage support for the formation of DV 
replication complex.  
 
 1.6.6 Dengue Virus NS4B Protein     
Dengue NS4B is the largest of the small hydrophobic non-structural 




Similar to NS4A, NS4B is also an integral membrane protein. There are 
evidences that NS4B is part of the viral replication complex (Miller et al, 
2006). NS4B accumulates at the ER of DV-infected cells and localizes to the 
sites of viral RNA replication. NS4B is proposed to enhance NS3 helicase 
activity by dissociating NS3 protein from single-stranded RNA (Umareddy et 
al, 2006). Like dengue NS2A and NS2B proteins, dengue NS4B protein is 
implicated as an IFN-signaling inhibitor which blocks IFN signaling during 
dengue virus infections (Munoz-Jordan et al, 2003).  
 
 1.6.7 Dengue Virus NS5 Protein      
NS5 protein has a size of 105-kDa and is the largest protein of dengue 
virus. NS5 protein is the most well conserved of the flavivirus protein. It 
functions as methyltransferase and guanylyltransferase which are essential for 
the capping of the RNA genome (Egloff et al, 2002; Issur et al, 2009). NS5 
protein is also a RNA-dependent RNA polymerase which is needed for the 
replication of the RNA genome (Tan et al, 1996). In addition, NS5 has been 
shown to perturb the host immune response. Dengue NS5 protein binds to 
STAT2 and induces STAT2 degradation (Ashour et al, 2009). Degradation of 
STAT2 can result in inhibition of IFN-dependent signalling. Together, NS2A, 
NS4A, NS4B and NS5 proteins inhibit IFN-dependent signalling, showing the 







1.7 DENGUE PREVALENCE AND GLOBAL IMPACT   
Dengue is a mosquito-borne viral disease transmitted through a 
human-to-mosquito-to-human transmission cycle by the Aedes mosquitoes: 
Aedes aegypti and Aedes albopictus (Rezza, 2012). DV infection remains the 
most prevalent mosquito-borne viral disease and the geographical regions at 
risk are continually growing due to globalisation and climate change (Gubler, 
1998a). Dengue is endemic in more than 100 countries. It is estimated that 2.5 
billion people are at risk of dengue infection and 100 million cases of dengue 
infections occur worldwide each year (Gubler, 1998b; Gubler & Clark, 1995; 
Kyle & Harris, 2008; Monath, 1994; Srikiatkhachorn, 2009). Of which, an 
estimation of 500,000 cases are life-threatening dengue hemorrhagic fever/ 
dengue shock syndrome and 20,000 cases are fatal. The risk and burden of 
dengue in 2010 are illustrated in Figure 1.3. In the 1970s, DV1 and DV2 were 
present in Central America and Africa while all serotypes were found in 
Southeast Asia (Figure 1.4 a) (Guzman et al, 2010). By 2004, all four classical 
serotypes of dengue circulate in tropical and subtropical regions of the world 
(Figure 1.4 b). Despite the prevalence of dengue virus, current management of 
DV infection are only supportive. No effective treatment and vaccine are 









Figure 1.3: The risk and burden of dengue in 2010.  
a) National and subnational evidence consensus on complete absence (green) 
through to complete presence (red) of dengue. b) Areas with a high probability 
of dengue occurrence are shown in red and areas with a low probability in 
green. c) Cartogram of the annual number of infections for all ages as a 






Figure 1.4: Distribution of dengue serotypes in the world.  
The map shows the serotypes which were circulating in different regions of 
the world in 1970 (a) and 2004 (b). (Guzman et al, 2010) 
 
1.8 CLINICAL SYMPTOMS OF DENGUE VIRUS    
The clinical manifestations of dengue virus infection in different 
individuals can be quite varied (Figure 1.5). Mild dengue virus infections 
cause flu-like symptoms such as fever, headache, muscle and bone pain. This 
kind of infection is termed dengue fever. Some patients when infected by 




dengue hemorrhagic fever or dengue shock syndrome. The evidence of plasma 
leakage is the clinical feature that distinguishes dengue hemorrhagic fever 
from dengue fever. A 20% increase in haematocrit is widely used as an 
indicator of plasma leakage (Srikiatkhachorn, 2009). In cases of dengue 
hemorrhagic fever and dengue shock syndrome, the patients have plasma 
leakage, thrombocytopenia, coagulopathy and hemorrhagic tendencies. 
Dengue hemorrhagic fever patients who have narrow pulse pressure (< 20 
mmHg), hypotension or other signs of shock are classified as dengue shock 
syndrome cases.  
Atypical manifestations of dengue, such as central nervous system and 
cardiac involvement, have been increasing reported (Hendarto & Hadinegoro, 
1992; Miranda et al, 2013). In one such case, multifocal areas of muscle 
necrosis and intense interstitial oedema were associated with clusters of 
dengue virus particles inside the cardiomyocytes and in the interstitial space, 
providing evidence of a possible direct action of dengue virus on myocardium 
(Miranda et al, 2013). For the case of encephalitis, the presence of IgM 
antibody to dengue in the cerebrospinal fluid and virus isolation from both 
brain tissue and cerebrospinal fluid of patients with neurological symptoms 
suggest firect virus invasion of the central nervous system (Garcia-Rivera & 
Rigau-Perez, 2002). Neurological complications can arise in dengue fever and 
dengue haemorrhagic fever. Some of the neurological manifestations are 
headache, dizziness, delirium, seizures, meningismus, coma, paralysis of 
lower or upper extremities, amnesia, dementia and Guillain Barre syndrome. 
Most reported cases of these neurological manifestations recover without 





Figure 1.5 Clinical manifestations of dengue virus infection in human  
This diagram depicts the clinical symptoms and pathogenesis of dengue in 
humans, across the spectrum of mild to severe disease. Clinical manifestations 
associated with DF are listed in blue boxes, those associated with DHF are 
listed in purple boxes, and more rare complications of DV infection are listed 
in the green box. (St John et al, 2013) 
 
1.9 MANAGEMENT OF DENGUE VIRUS INFECTION 
No effective treatment and vaccine are available for DV infection. 
Currently, management of DV infection is only supportive. Due to fever, lack 




Intravenous fluid treatment with crystalloid solutions or colloids is given to 
cases with severe dehydration or depleted intravascular volume due to plasma 
leakage. Lactated Ringer’s solution or 0.9% saline are the most commonly 
used crystalloid solutions (Hung, 2012). Colloids slightly differ from 
crystalloid solutions in that they contain a high molecular weight substance 
which cannot be diffused through semi-permeable membranes. The use of 
crystalloid solutions and colloids must be closely monitored to prevent serious 
side effects like pulmonary oedema and respiratory failure (Srikiatkhachorn, 
2009). 
 
1.10 PATHOGENESIS OF DENGUE VIRUS INFECTION   
The pathogenesis of dengue is not well-understood. The mechanism 
underlying the wide range of dengue manifestations remains largely unknown. 
However, the observation that plasma leakage in DHF developed not when the 
viremia was at its peak in infected patients but when viremia had been 
significantly reduced or cleared, suggested that host immune response is 
responsible for the development DHF (Hober et al, 1993). In addition, studies 
have demonstrated that the host immunological mechanism could play a key 
role in the manifestation of dengue infection (Burke et al, 1988; Halstead et al, 
1970; Sangkawibha et al, 1984; Thein et al, 1997). Up-regulation of 
proinflammatory cytokines such as TNF, IL-1, IL-2, IL-6, complement 
activation products and immune cells during dengue virus infection could lead 
to increased vascular permeability and leakage (Azeredo et al; Chaturvedi et 




enhancement (ADE) of infection and original antigenic sin are some of the 
theories proposed to explain the underlying mechanism that contributes to the 
manifestation of the more severe forms of the dengue infection during 
secondary infections (Chareonsirisuthigul et al, 2007; Halstead et al, 1983; 
Mady et al, 1991; Mongkolsapaya et al, 2003). The factors of dengue virus 
infection pathogenesis include virulence of DV and host factors as well. 
 
1.11  FACTORS INFLUENCING PATHOGENESIS OF DENGUE 
VIRUS INFECTION  
 1.11.1 Virulence 
The four classical serotypes of DV vary in pathogenicity and virulence 
but the basis for these differences is unclear (Halstead, 2012). The outbreak of 
DV2 infection in the Pacific island Kingdom of Tonga in 1974 had relatively 
mild clinical disease compared to the outbreak of DV1 in the same location in 
1975 (Gubler et al, 1978). The 1981 DV2 epidemic in Cuba presented 
evidences that as the dengue virus circulates and passages in hosts during an 
epidemic, it can become more virulent to result in more cases of DHF/DSS 
and fatalities toward the end of an epidemic (Kouri et al, 1989). Another such 
example is the 1992 DV epidemic in Townsville, Australlia (Streatfield et al, 
1993). In this epidemic, the proportion of cases with spontaneous 
haemorrhagic symptoms increased as the epidemic progresses. Analysis of DV 
genomes provided evidences that DV does evolve during an epidemic. DV2 
sequences from plasma of patients during the 2001 and 2002 outbreaks in 




2002 viruses descended from a minor variant of the 2001 viruses in less than 6 
months. Six DV2 isolates sampled at different times during the 1997 Cuba 
dengue outbreak were sequenced (Rodriguez-Roche et al, 2005). Analysis of 
the sequences revealed a clear pattern of virus evolution during the epidemic. 
However, the observation that DHF/DSS occurred in a relative small 
percentage of secondary infections and even a smaller percentage of primary 
infections when infected with allegedly virulent strains suggests that host 
factors play critical roles in the development of DHF/DSS (Martina et al, 
2009). 
 
1.11.2 Host Immunity 
1.11.2.1 Antibodies present in the patient 
When a patient is infected with dengue virus, the outcome of the 
disease is affected by the presence of existing antibodies in the patient. 
Homologous antibodies provide complete protection while heterotypic 
neutralising antibodies can suppress the disease (Halstead, 2009). Heterotypic 
non-neutralising antibodies on the other hand can enhance infection and 
increase disease severity. This enhancement is termed antibody-dependent 
enhancement of infection (ADE). How ADE works at the molecular level still 
remains not well understood. DHF/DSS in infants has been linked to ADE. 
Maternal dengue antibodies were found to give infant protection against 
dengue infection initially but increase the risk of development of DHF/DSS 
when maternal neutralizing antibodies degrade below a protective level (Kliks 




Viral yield in K562 cells increased by 10- to 1000-fold, depending on the DV 
serotype when antibodies of subneutralizing concentrations were added 
(Goncalvez et al, 2007). Similar results were also obtained using non-human 
primate model (Halstead, 1979). It was observed that passively transferred 
antibodies enhanced dengue viremia in the non-human primate model.   
Anti-dengue antibodies generated during a DV infection have been 
shown to cross-react with some self-antigens of the human host. For example, 
antibodies against DV envelope protein were found to bind human 
plasminogen and inhibit plasmin activity (Huang et al, 1997; Markoff et al, 
1991). Plasmin digests fibrin and plays an important role in fibrinolysis. The 
inhibition of plasmin activity may enhance clot formation at dengue virus-
infected sites and disturb the balance between coagulation and fibrinolysis. 
This unbalance in combination with vasculopathy and thrombocytopenia may 
lead to haemorrhage (Chungue et al, 1994). In another example, antibodies 
against DV NS1 protein can cross-react with endothelial cells and platelets 
(Cheng et al, 2009; Lin et al, 2003; Oishi et al, 2003; Sun et al, 2007a). In the 
study reported by Lin and co-workers, the cross-reactivity of dengue patient 
sera with endothelial cells was shown (Lin et al, 2003). The percentage of 
endothelial cells reactive with DHF/DSS patient sera was higher than that of 
DF patient sera. For the case of cross-reactivity with platelets, protein 
disulfide isomerise (PDI) on the platelet surface was found to be recognized 
by anti-NS1 antibodies (Cheng et al, 2009). Anti-NS1 antibodies cross-react 
with platelets and inhibit platelet aggregation. In a study using murine model, 
anti-NS1 antibodies caused thrombocytopenia and mortality in mice (Sun et 




immunoglobulins (IgG or IgM) were significantly higher in DHF than those in 
DF (Saito et al, 2004). These platelet-associated immunoglobulins play an 
important role in the induction of thrombocytopenia. Thus, mechanisms of 
molecular mimicry in which antibodies directed against DV NS1 cross-react 
with human platelets and endothelial cells may cause damage and dysfunction, 
resulting in dengue clinical features like endothelial permeability and 
thrombocytopenia. However, it is unclear why the autoimmune phenomenon 
is only transient.  
 
1.11.2.2 T-cell responses 
Another factor in host immunity that can affect the severity of dengue 
virus infection in a patient is the T-cell responses. The role of T cells during 
dengue virus infection is unclear. T-cells may play an important role in the 
clearance of the virus but they may also contribute to the pathogenesis of the 
disease. DV-specific memory T cells were produced in volunteers injected 
with a live attenuated DV candidate vaccine (Friberg et al, 2012; Mathew et 
al, 1996). All the volunteers had T cell proliferation to other flaviviruses 
(West Nile virus or yellow fever virus) and some volunteers had serotype-
cross-reactive responses. 
 It has been proposed that T-cells from a first virus infection are 
inefficient at killing cells infected with a second virus and produce high level 
of cytokines, which may contribute to vascular leakage characteristic of DHF 
and DSS (Mongkolsapaya et al, 2006). PBMC from dengue-immune donors 




stimulation with dengue antigens. The IFN-γ produced can increase the 
number of dengue virus-infected monocytes in the presence of cross-reactive 
anti-dengue antibodies, contributing to the pathogenesis of DHF and DSS 
(Kurane et al, 1989). Higher levels of the T cell activation markers, soluble 
CD4, soluble CD8, and soluble IL-2 receptor were detected in the sera of 
children with DHF compared to DF (Kurane et al, 1991). In the same study, 
higher levels of soluble IL-2 receptor, soluble CD4, IL-2 and IFN-γ were 
detected in children with dengue infections compared to healthy controls. 
These data suggest that T cells are activated in vivo during DF and DHF. 
Furthermore, the level of activation is higher in DHF than in DF. As soluble 
CD8 level was elevated in patients with DHF but not DF, activation of CD8+ 
T cells is evident in DHF but not in DF. All these suggest that cross-reactive T 
cells may play a role in the pathogenesis of dengue virus infection by 
increasing production of inflammatory cytokines. 
 
1.11.2.3 Activation of the Complement system 
The complement system is a main component of innate immunity and 
it was proposed to be interacting with the coagulation system (Amara et al, 
2008). In dengue infection, around the time of defervescence, when plasma 
leakage usually become apparent, high levels of the activation products C3a 
and C5a were detected in the plasma, followed by a dramatic reduction of the 
complement components in patients with DSS (Churdboonchart et al, 1983; 
Nishioka, 1974; Shaio et al, 1992). This may suggest that complement 




study done by Yamanaka and colleagues which assessed the complement 
haemolytic activity (CH50), levels of complement components and related 
factors (C1q, C2, C4, fB, fD, fH, fI and MBL) in dengue patients was carried 
out in Indonesia (Yamanaka et al, 2013). The DHF pre-critical phase group 
has significantly lower mean CH50 values and levels of C2, C4, factor B and 
factor H than those in the DF group. C4, factor B and factor H levels were 
found to be significantly correlated with CH50 values. In addition, DV NS1 
protein was detected in 78% of patients in the DHF pre-critical phase group, 
significantly higher than that of the 33% of patients in the DF group. Together, 
these data suggests that the complement haemolytic activity, levels of 
complement components and presence of DV NS1 protein during the acute 
phase were associated with the severity of the disease. Furthermore, the mean 
CH50 value in patients who were strongly positive for the DV NS1 protein 
were significantly lower than those in NS1-negative patients suggesting that 
there could be a relationship between complement activity and the presence of 
the NS1 antigen in patient sera. DV NS1 protein was tested for its capacity to 
activate human complement in its membrane-associated and soluble forms 
(Avirutnan et al, 2006). Soluble DV NS1 protein was found to be able to 
activate complement to completion. Polyclonal and monoclonal antibodies 
against NS1 protein can also enhance the activation. Pleural fluids from 
patients with DSS were found to contain large amounts of NS1 protein, 
complement anaphylatoxin C5a and the terminal complement complex SC5b-
9. It was proposed that complement activation mediated by DV NS1 protein 




contributing to the development of vascular leakage observed in patients with 
DHF/DSS. 
 
1.11.2.4 Genetic factors 
Human genetic factors are implicated in pathogenesis of dengue virus 
infection due to the observations that certain human genes may contribute to 
the susceptibility or resistance of individuals to DHF/DSS. These genetic 
factors can be broadly classified into two main groups, the human leukocyte 
antigen- (HLA) and non-HLA-associated genetic factors. Case-control studies 
of serologically determined HLA class I alleles in dengue virus-infected 
patients have been performed in Thai and Vietnamese patients (Chiewsilp et 
al, 1981; Loke et al, 2001). These studies have suggested that alleles of the 
HLA-A locus was associated with susceptibility to DHF. Polymorphism in the 
HLA class I region, particularly of the HLA-A gene, was a significant 
determinant of genetic susceptibility to DHF (Loke et al, 2001). HLA-A*0207 
was associated with susceptibility to the more severe DHF in patients with 
secondary DV1 and DV2 infections only (Stephens et al, 2002). HLA-B*51 
was associated with the development of DHF in patients with secondary 
infections (Stephens et al, 2002). The crystal structures of the human MHC 
class I allele HLA-B*5101 in complex with viral peptide revealed nonstandard 
peptide binding (Maenaka et al, 2000). The alpha1-helix C-terminal region for 
B51 has electrostatic differences compared to other MHC class I alleles, which 
might impact the specificity of killer cell immunoglobulin-like receptor (KIR) 




cells, and regulate their immune response through specific binding to MHC 
class I (Lanier, 1998). In a case study done on Mexicans, HLA-DR4 was 
found to be protective against DHF (LaFleur et al, 2002).  
Non-HLA-associated genetic factors are also found to be involved in 
the development of DHF/DSS. In a large case-control study conducted in 
Vietnam, with 400 DHF patients and 300 matched controls, the less frequent t 
allele of a variant at position 352 of the vitamin D receptor (VDR) gene was 
associated with resistance to severe dengue (Loke et al, 2002). The 
immunoregulatory effects of 1,25-dihydroxyvitamin D3 (1,25D3) is mediated 
by VDR. These immunoregulatory effects include activating monocytes, 
lymphocyte proliferation, suppressing immunoglobulin production and 
stimulating cellular immune responses (MacDonald et al, 1994). The tt 
genotype was proposed to be associated with a stronger TH1-type cellular 
immune response than the TT genotype (Loke et al, 2002). In the same case-
control study, homozygotes for arginine variant at position 131 of the FcγRIIA 
gene were found to have protection from DHF. These individuals have less 
capacity to opsonise IgG2 antibodies. Fcγ receptor II (FcγRII) is able to 
mediate ADE in vitro by binding to virus-IgG complexes (Littaua et al, 1990). 
The homozygosity for the arginine variant might be associated with a reduced 
risk of DHF caused by ADE. 
TNF-α-308A allele was also identified as a possible severity risk factor 
of hemorrhagic manifestation in dengue fever patients (Fernandez-Mestre et 
al, 2004). This polymorphism has been shown to be a stronger transcriptional 
activator and is associated with higher TNF-α production in vitro (Braun et al, 




polymorphism could produce higher TNF-α when infected by dengue virus, 
leading to a greater chance of developing hemorrhagic manifestation.   
The G allele of the variant CD209, DCSIGN1-336 was associated with 
strong protection against DF but not against DHF (Sakuntabhai et al, 2005). 
DC-SIGN as mentioned earlier is an attachment receptor of dengue virus. This 
polymorphism affects an Sp1-like binding site and transcriptional activity in 
vitro. The decrease expression of CD209 carrying the G allele at DCSIGN1-
336 may result in a lower susceptibility of dendritic cells to dengue virus in 
the early stages of infection (Tassaneetrithep et al, 2003). The authors’ 
explanation for the selective protection of the CD209 variant against DF but 
not DHF was that there may be an alternative pathway to the CD209-mediated 
dengue virus entry to dendritic cells.  
A combination of Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and 
Transforming growth factor β-1 (TGFβ1) polymorphisms was found to be 
associated with the susceptibility of DHF and higher virus load (Chen et al, 
2009). CTLA-4 is a receptor that downregulates T cells. This study shows that 
regulatory T lymphocyte and immunosuppressive cytokines, such as TGFβ1 
may have a role in enhancing the severe dengue disease.  
The increasing number of defined polymorphism in the human genome 
will greatly help genetic susceptibility studies in dengue virus infection. These 
studies will provide insights into possible mechanisms of pathogenesis of 





1.12 ANIMAL MODELS 
 The lack of suitable animal models has impeded understanding the 
pathogenesis of dengue. Non-human primates can be infected with dengue 
virus but they do not develop overt disease (Zompi & Harris, 2012). 
Furthermore, mice, the most commonly used animals for research, do not 
support the replication of dengue virus clinical isolates well. High-dose 
injections of mouse-adapted dengue virus via the intracranial route were 
required to produce symptoms in wild-type mice (Raut et al, 1996). However, 
some of the symptoms produced like neurological disease and paralysis were 
not the usual symptoms observed in human patients suffering from dengue 
infection. Evidences suggest that IFN-α, -β and -γ were involved in human 
dengue infections (Cole & Wisseman, 1969; Kurane et al, 1993; Kurane et al, 
1991). Mice deficient for IFN- α, -β and -γ receptors (AG129) were tested for 
susceptibility to dengue virus. Groups of five AG129 aged 4, 6, 8 and 12 
weeks old were inoculated intraperitoneally with 10
6
 PFU of a mouse-adapted 
dengue 2 virus strain, New Guinea C (Johnson & Roehrig, 1999). By day 7 
post-inoculation, mice of all age groups began to show neurological 
abnormalities, including hind-leg paralysis and blindness. The mice were dead 
by day 12 post-infection. The AG129 mice is the first animal model in which 
dengue virus has been both 100% lethal in mice and consistently present in the 
sera and tissues following intraperitoneal injection into mice. However, some 
clinical symptoms like hemorrhagic development and thrombocytopenia were 
not reported in the model. In a more recent report, massive organ damage, 
cytokine storms and severe vascular leakage, leading to hemorrhagic and rapid 




mouse-adapted strain of dengue virus serotype 2 (D2Y98P) (Tan et al, 2010). 
In another report, immunological competent mice injected with dengue virus, 
16681 strain showed hemorrhagic development and thrombocytopenia (Chen 
et al, 2007a). The development of better animal model for dengue virus 
infection will definitely help in understanding the underlying mechanism of 
dengue virus pathogenesis.  
 
1.13 CYTOKINES IMPLICATED IN THE 
IMMUNOPATHOGENESIS OF DENGUE 
1.13.1 Interleukin 6 
IL-6 is an important cytokine with many functions. IL-6 is secreted by 
a wide variety of cells including monocytes, endothelial cells, T cells, B cells, 
fibroblasts, keratinocytes and mast cells during infection or trauma (King et al, 
2002; Kupper et al, 1989; Romano et al, 1997; Simpson et al, 1997). IL-6 
target cells express IL-6 receptor on their surface. IL-6 receptor does not 
possess transducing activity. Binding of IL-6 to IL6 receptor induces the 
homodimerization of a signal-transducing component, gp130 (Kishimoto et al, 
1995). Gp130 dimers activate cytoplasmic tyrosine kinases and subsequent 
modification of transcription factors. Interestingly, cells that do not express 
IL-6 receptor on their surfaces can also response to IL-6 if they express gp130 
(Romano et al, 1997). Soluble forms of IL-6 receptor can bind with IL-6 and 
associates with gp130 to activate signal transduction. Shedding of the 
membrane-bound IL-6 receptor and mRNA alternative splicing can generate 




only plays an important role in host immunity but also has hematopoietic 
activities and ability to induce the acute phase response. The effects of IL-6 on 
cells are dependent on the type of the target cell (Figure 1.6).   
 
 
Figure 1.6: Biological activities of interleukin 6. The biological effects of IL-
6 are diverse and they are dependent on the cell type of the target cell. (Bauer 
& Herrmann, 1991) 
 
IL-6 is an inducer of the acute phase response. Acute phase response is 
a condition characterized by fever, leukocytosis, increased vascular 
permeability, negative nitrogen balanace, alterations in plasma metal and 
steroid concentrations, and an increase in the synthesis of hepatic acute phase 
proteins (Van Snick, 1990). The acute phase response is triggered by 




Effects of IL-6 can also be detrimental to the host. It has been 
implicated in the pathology of numerous diseases. Those diseases are 
rheumatoid arthritis, Castleman’s disease, osteoporosis, AIDS, Kaposi’s 
sarcoma, including DHF/DSS (Hirano et al, 1988; Jilka et al, 1992; Miles et 
al, 1990; Poli et al, 1990; Rachman & Rinaldi, 2006; Yoshizaki et al, 1989). 
In the case of autoimmune diseases like rheumatoid arthritis and Castleman’s 
disease, IL-6 has been found to express constitutively or in large quantity, 
leading to hyperactivation of autoantibody-producing B cells (Hirano et al, 
1988; Yoshizaki et al, 1989). On the other hand, in the case of osteoporosis, as 
IL-6 can promote hematopoiesis and osteoclastogenesis, inhibition of IL-6 by 
estrogen leads to osteoporosis (Jilka et al, 1992). While in the case of AIDS, 
IL-6 was found to increase HIV expression at the transcriptional and post-
transcriptional levels (Poli et al, 1990). For dengue, IL-6 could increase blood 
vessel permeability, generation of anti-platelet or anti-endothelial 
autoantibody, leukocyte recruitment, fluid-phase endocytosis and transcytosis, 
leading to increasing vascular permeability and bleeding tendency, the two 
major pathophysiological changes in severe dengue infection (Duchini et al, 
1996; Lei et al, 2001; Rachman & Rinaldi, 2006). In addition, there are 
evidences to suggest that IL-6 play a critical role in capillary leakage (Juffrie 
et al, 2001). For patients with elevated IL-6 levels, the incidence of ascites 
was increased. Ascite is a sign of plasma leakage. IL-6 was proposed to exert 
its pro-inflammatory effects by induction of mediators such as secretory 
phospholipase A2. Another way IL-6 could have an effect on vascular 
permeability is by decreasing cell surface expression of vascular endothelial 




function and expression levels of VE-cadherin at endothelial cell junctions are 
central determinants of the control of vascular permeability (Dejana & 
Vestweber, 2013). 
 
1.13.2 Tumor necrosis factor-α 
TNF-α was first isolated in 1975 and as the name suggests is a factor 
that is able to induce necrosis of tumours (Carswell et al, 1975). TNF-α is first 
produced as a type II membrane protein of about 26-kDa before being 
proteolytically cleaved by serine protease to give a 17-kDa active form (Idriss 
& Naismith, 2000). In solution, TNF-α exists as a homotrimer of 52-kDa. 
TNF-α binds to two receptors, TNFR-1 and TNFR-2.  TNFR-1 contains a 
death domain which can recruit an adaptor protein through homophilic 
interaction (Schulze-Osthoff et al, 1998). The adaptor protein then binds a 
proximal caspase, activating apoptosis. Hence, TNF-α can also induce 
apoptosis (Robaye et al, 1991). TNFR-1 can also activate gene expression via 
indirect recruitment of TNF receptor-associated factor (TRAF) family (Wajant 
et al, 2003). TNFR-2 on the other hand, directly recruits TRAF2 to induce 
gene expression and crosstalk with TNFR-1.   
TNF-α has a major role in early inflammatory responses and the host 
response to intracellular organisms. TNF-α is important in the development of 
the humoral response. Anti-TNF-α monoclonal antibody has been shown to 
inhibit both anti-Ig- and anti-CD40-induced B-cell proliferative responses 
(Boussiotis et al, 1994). In addition, TNF-α deficient mice demonstrated the 
importance of TNF-α in formation of germinal center (GC) and follicular 




deficient mice failed to form both GC and FDC network in B cell follicles. 
The formation of GC and FDC is important for humoral immune responses. 
Besides immune responses, TNF-α also has an effect on vascular permeability 
like IL-6. TNF-α can decrease VE-cadherin gene expression on the 
transcriptional level, leading to a down-regulation of the VE-cadherin 
expression (Hofmann et al, 2002). 
TNF-α together with IL-6 primarily mediate the acute-phase response 
(Beutler & Brown, 1991). The transcriptional regulation of TNF-α is both 
tissue-specific and stimulus-specific (Falvo et al, 2000a; Falvo et al, 2000b; 
Tsai et al, 2000). Long-term inhibition of TNF-α through therapy has been 
found to increase infections and lymphoma (Cassaday et al, 2011; Gomez-
Reino et al, 2003; Parakkal et al, 2011). This suggests that TNF-α play 
important role in fighting infections and suppressing cancer development. 
Many cells express TNF-α but the more dominant producers are myeloid cells 
and T-cells (Beutler & Brown, 1991). Upon stimulation of Toll-like receptors, 
activation via cytokines or activation via lipid mediators, myeloid-lineage cells 
produce TNF-α. TNF-α like other early response genes has rapid transcription 
after stimulation, independent of new protein synthesis. TNF-α is rapidly up-
regulated with transcription initiating within minutes and protein synthesis 
starting within a few hours. Secondary response genes include other 
inflammatory mediators such as IL-6 and IL-12. Although early response 
genes and secondary response genes typically rely on similar transcription 
factors (NFκB, AP-1, and C/EBP), the binding of NF-κB is delayed in the 




Many studies have shown that TNF-α is implicated in the pathogenesis 
of dengue. The hallmarks of the pathophysiologic characteristics of DHF/DSS 
can be observed in animals injected with sublethal doses of TNF-α (Tracey et 
al, 1987; Tracey et al, 1988). These hallmarks include thrombocytopenia, 
hemorrhage, tissue necrosis and extravasation of fluid from the vascular 
compartment. Antibodies against TNF-α was used to treat a lethal mouse 
model infected with DV2 (Atrasheuskaya et al, 2003a). The mortality rate 
dropped from 100% to 40%. This model showed that modulation of mediator 
release could be beneficial in dengue infection. In a small clinical study, 
patients with DF had TNF-α levels equivalent to that in healthy controls while 
patients with DHF/DSS had significantly higher serum TNF-α level than that 
in DF patients and healthy controls (Yadav et al, 1991). This suggests that 
TNF-α has a role in the development of DHF/DSS.  
As pro-inflammatory cytokines have been shown to possibly play 
detrimental roles during dengue virus infection, compounds that can suppress 
cytokines production were explored as possible treatment for dengue virus 
infection. Corticosteroids which are potent modulators of the immune system 
have been tested for their potential as treatment for dengue virus infection 
(Rajapakse et al, 2014). A retrospective study of methyl prednisolone (1 g 
intravenous over 20 mins) treatment on adult patients with dengue shock 
showed a significant reduction in mortality with corticosteroid therapy (Tam et 
al, 2012). In another study, oral prednisolone therapy of low-dose (0.5 mg/kg) 
or high-dose (2mg/kg) was given to Vietnamese patients aged 5-20 years old 
for 3 days (Tam et al, 2012). However, no reduction in the development of 




Thus, more studies are required to validate the efficacy of corticosteroid 
therapy for the treatment of dengue virus infection. 
 
 
1.14 TOLL-LIKE RECEPTOR (TLR)      
Toll-like receptors (TLRs) are pathogen recognition receptors (PRRs). 
PRRs are a group of receptors that play a key role in immune surveillance. 
Pathogen recognition receptors are important as they alert the immune system 
of the presence of foreign microbes by recognizing pathogen-associated 
molecular patterns (PAMPs) and links innate immunity to adaptive immunity 
upon detection of PAMPs. In human, 10 functional TLRs are documented and 
each has similar structural characteristics. TLRs consists of a single 
membrane-spanning domain, ectodomain which composes of leucine-rich 
repeats interacts with PAMPs and cytoplasmic tail which is responsible for 
initiating intracellular signals (Boehme & Compton, 2004). When TLR is 
activated, adapter molecules like MyD88, TIRAP (toll-interleukin 1 receptor 
(TIR) domain containing adaptor protein) /MAL (MyD88-adapter-like), TRIF 
(TIR domain-containing adaptor-inducing IFN-β) or TRAM (TRIF-related 
adaptor molecule) are recruited (Figure 1.6). These adapter molecules in turn 
activate other downstream transcriptional gene regulators like activating 
protein-1, NFκB and interferon regulatory factors which induce expression of 
chemokines, proinflammatory cytokines (TNF-α, IL-6, IL-1β and IL-12) or 
costimulatory molecules (Kawai & Akira, 2006). The up-regulation of 




adaptive immune responses (Akira, 2006). Thus, TLRs can activate both the 
innate and adaptive immune responses.  
 
 
Figure 1.7: Schematic of TLR signalling pathways  
Binding of ligand to TLR triggers NFκB and interferon pathway through 
adaptors like MyD88, TIRAP/MAL, TRIF or TRAM. (Boehme & Compton, 
2004)   
 
TLR can recognize both bacterial and viral PAMPs. TLR can 
recognize viral pathogen via a number of different viral ligands. Generally, 
TLR9 recognizes viral CpG DNA, TLR3 detects double-stranded viral RNA, 
TLR7/8 binds single-stranded viral RNA while TLR2 and TLR4 sense the 
presence of virus via their proteins (Barton, 2007). Besides direct sensing of 
pathogen through recognition of PAMPs, TLR can also sense the presence of 
viral pathogen by detecting host factors that are present in aberrant locations 
due to infection, inflammation or cellular stress (Mogensen & Paludan, 2005). 
One such example is heat-shock protein (HSP) which is able to trigger TLR2 




stressful stimuli (Asea et al, 2002; Beg, 2002). Among the TLR, TLR3 and 
TLR7 have been found to trigger IL-8 production when stimulated by dengue 
viral RNA (Tsai et al, 2009; Wang et al, 2006).  Toll-like receptor 6 (TLR6) 





 PCR arrays in our previous study (Chen 
et al, 2008b). Although TLR6 was previously known only to be activated by 
diacylated lipoprotein of bacteria (Nakao et al, 2005), recent studies have 
found that TLR6 can be activated by viruses including hepatitis C virus and 
respiratory syncytial virus (Chang et al, 2007; Murawski et al, 2009). Viral 
infection induces various TLR-mediated innate responses, which subsequently 
play a pivotal protective or pathogenic role in conjunction with virus-specific 
adaptive immune responses (Boehme & Compton, 2004; Mogensen & 
Paludan, 2005).  
 
 
1.15 FAMILY OF TLRs        
 1.15.1 TLR1, TLR2 and TLR6    
 TLR2 detects bacterial lipoproteins. It heterodimerizes with TLR1 or 
TLR6. TLR2/TLR1 complex recognizes triacylated lipoprotein while 
TLR2/TLR6 complex recognizes diacylated lipoprotein (Takeuchi et al, 2001; 
Takeuchi et al, 2002). Besides lipoprotein, a wide variety of bacterial ligands 
has been documented for TLR2 (Lien et al, 1999; Schwandner et al, 1999). 
Apart from bacterial components, data from recent studies showed that TLR2 
can detect virus components as well in spite of the paradigm that the innate 




(Bieback et al, 2002; Compton et al, 2003; Dolganiuc et al, 2004; Murawski et 
al, 2009). It was also found that activation of TLR2 by viral ligands can 
induce type I interferon which is one of the key components of antiviral 
immunity (Barbalat et al, 2009). CD14 is involved in corecognition by TLR2 
of various ligands (Compton et al, 2003; Janot et al, 2008).  
 
 1.15.2 TLR3        
TLR3 recognizes dsRNA which is characteristic of RNA virus 
replication. For human fibroblasts, TLR3 are expressed on the cell surface and 
acts on the cell surface to sense viral infection but for monocyte-derived 
immature dendritic cells, TLR3 resides inside the cells (Matsumoto et al, 
2003). Using the model of human monocytic cells U937, DV was found to 
induce IL-8 production via activation of TLR3 (Tsai et al, 2009). It was 
reported that WNV NS1 could inhibit TLR3 signaling (Wilson et al, 2008). 
However, the finding is controversial as another group did not observe such 
inhibition by NS1 protein from WNV, DV or Yellow Fever virus (Baronti et 
al, 2010).  
 
 1.15.3 TLR4        
TLR4 forms a heterodimer with myeloid differentiation factor 2 (MD-
2). The large hydrophobic pocket in MD-2 interacts with the LPS of Gram 
negative bacteria (Park et al, 2009). Two accessory proteins, LPS-binding 




TLR4-MD-2 (Erridge et al, 2002; Hailman et al, 1994). TLR4-MD-2 complex 
was being questioned as to whether it is the sole signalling receptor for LPS 
when many groups observed responses to their LPS preparations that were 
independent of TLR4. It appeared to many that TLR2 was involved in these 
responses. It was revealed later that common commercial LPS are 
contaminated with bacterial lipoprotein which is responsible for activating 
TLR2 (Hirschfeld et al, 2000). Nevertheless, two exceptions were reported. 
LPS from porphyromonas gingivalis and Leptospira interrogans activate 
TLR2 but not TLR4 (Hirschfeld et al, 2001; Werts et al, 2001). These studies 
provided evidences for the diverse ligands that TLR can recognize. Similar to 
TLR2, CD14 also seems to play a part in TLR4 recognition of ligand. It was 
observed that LPS-induced responses were dependent on CD14 and especially 
so when the LPS is present in low quantity (Jeyaseelan et al, 2005).  
 
 1.15.4 TLR5        
TLR5 recognizes flagellin from both Gram-positive and Gram-
negative bacteria (Hayashi et al, 2001).  The recognition site is a conserved 
site on the flagellin which is necessary for bacterial motility and protofilament 
formation (Smith et al, 2003). However, ε and α Proteobacteria have amino 
acid changes in the recognition site that prevent TLR5 recognition but still 
preserved the motility (Andersen-Nissen et al, 2005). As bacterial flagellin is a 
major stimulus of human epithelial cells, this evasion of TLR5 may explain 
the persistence of these bacteria at the mucosal surfaces (Gewirtz et al, 2001a; 




1.15.5 TLR7, TLR8 and TLR9     
TLR7, TLR8 and TLR9 reside intracellularly on endosomal 
membranes to detect foreign genetic materials which are indicative of 
infection. Phylogenetic analysis of human TLR7-9 showed that they belong to 
a new sub-family of the human TLRs (Chuang & Ulevitch, 2000). UNC93B1, 
a polytopic membrane protein is found to be involved in the trafficking of 
TLR7 and TLR9 from the endoplasmic reticulum to endosomes (Kim et al, 
2008). This trafficking process is essential for the function of TLR7 and 
TLR9. TLR7 recognizes single-stranded RNA viruses like vesicular stomatitis 
virus and influenza virus (Lund et al, 2004). Plasmacytoid dendritic cells and 
B cells recognize these viruses through TLR7 and results in activation of 
costimulatory molecules and production of cytokines. Intact endocytic 
pathways are found to be required for this recognition. TLR8 also recognizes 
single-stranded RNA which is guanosine and uridine rich (Heil et al, 2004). 
TLR8 is expressed primarily in monocytes, macrophages and myeloid 
dendritic cells (Cervantes et al, 2012). TLR9 recognizes unmethylated CpG 
motifs which are prevalent in bacterial and many viruses but not vertebrate 
genomic DNAs (Krieg, 2002). Plasmacytoid dendritic cells and B cells 
express TLR9. CpG-A motifs are potent at inducing IFN-α expression by 








1.15.6 TLR10   
TLR10 is the only member of human TLRs whose agonist and function still 
remain undefined (Guan et al, 2010). However, using phylogenetic analysis, it 
was predicted that TLR10 agonist should be very similar to TLR1 and TLR6. 
It was found that TLR10 like TLR1 and TLR6, requires TLR2 for innate 
immune recognition. Surprisingly, TLR10, alone or when heterodimerized 
with TLR2 could not trigger the usual TLR-induced signalling, including 
NFκB-, IL-8-, or IFN-β-driven reporters. This suggests that human TLR10 is 
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 Dengue virus infection is an immense global health problem which is 
not just a huge economic burden but lives are also at stake. Despite its 
prevalence, currently anti-viral treatment and vaccine are unavailable. There is 
a need to better understand the immunopathogenesis of dengue to pave the 
way of devising strategies to better control dengue virus infection and also to 
prevent it from progressing to the more severe forms which are life-
threatening.  
 In this study, the roles in which TLR6 played during dengue virus 
infection are being investigated. The specific objectives in this study are as 
follow: 
1. Validate the activation of TLR6 in human myelogenous leukemia cell 
line, K562 cells and investigate the effect of TLR6 activation on 
proinflammatory cytokines using TLR6 knock-down K562 cells. 
2. To set up an in vitro primary human PBMC cell model for DV2-
infection using blood from healthy anonymous donors.   
3. To further confirm TLR6 activation using NFkB reporter system in 
HEK293 cells and TLR6 blocking antibodies in PBMC cell model. 
4. Determine which dengue viral protein(s) is/are responsible for 
activating TLR6.  
5. Determine whether TLR6 activation can contribute to increased 
endothelial permeability using HUVEC cell permeability model. 
6. To evaluate the involvement of TLR2 in dengue virus infection. 
7. The role TLR6 play in the immunopathogenesis of dengue virus 































2.0 MATERIALS AND METHODS     
2.1 CELL CULTURE TECHNIQUES      
 2.1.1 Propagation of suspension cells     
All cell cultures and media preparation works were carried out under 
asceptic conditions in an ESCO Type II A2 biological safety cabinet (ESCO, 
Singapore). The human myelogenous leukemia cells, K562 cells were a kind 
gift from Emeritus Professor Chan Soh Ha, Department of Microbiology, 
National University of Singapore (Lozzio & Lozzio, 1979). The cells were 
grown in RPMI-1640 (Appendix 1b) supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (PAA, Piscataway, USA) in sterile vented 75 cm
2
 tissue 
culture flasks (Corning, New York, USA). The tissue culture flasks are placed 
in a 37 ºC, 5% CO2 humidified incubator (Thermo Scientific, Massachusetts, 
USA). To expand or maintain the cells, 10% of the total cells were transferred 
to a new tissue culture flask when the cells reached full confluency.  
 
 2.1.2  Propagation of adherent cells 
Baby Hamster Kidney-21 (BHK-21) cells (ATCC, Manassas, USA) 
were grown in RPMI-1640 (Appendix 1b) supplemented with 10% heat-
inactivated FCS (PAA, Piscataway, USA) in sterile vented tissue culture flasks 
(Corning, New York, USA) (Neufeld & Gospodarowicz, 1985). The tissue 
culture flasks are placed in a 37 ºC, 5% CO2 humidified incubator (Thermo 
Scientific, Massachusetts, USA). Upon reaching confluency, the confluent cell 
monolayer was washed with 5 ml of phosphate buffered saline (PBS) 




was then incubated with 2 ml of trypsin-versene (Appendix 1c) for 1 min at 37 
ºC (Thermo Scientific, Massachusetts, USA) to detach the cell monolayer 
from the flask. The cell monolayer was observed under the light microscope 
(Olympus, Tokyo, Japan) to check for the rounding of the cells. 3 ml of 
RPMI-1640 (Appendix 1b) supplemented with 10% heat-inactivated FCS 
(PAA, Piscataway, USA) were then added immediately to stop the enzymatic 
activity of trypsin. Half a ml of suspended cells was transferred into new 
sterile vented tissue culture flasks (Corning, New York, USA) and fresh 
RPMI-1640 (Appendix 1b) supplemented with 10% heat-inactivated fetal calf 
serum (PAA, Piscataway, USA) was added. The tissue culture flasks are 
placed in a 37 ºC, 5% CO2 humidified incubator (Thermo Scientific, 
Massachusetts, USA).  
 
Human Embryonic Kidney (HEK) 293 cells (a kind gift from Prof Ng 
Mah Lee, Department of Microbiology, National University of Singapore) 
were grown in DMEM (Appendix 1e) supplemented with heat-inactivated 
10% FCS (PAA, Piscataway, USA) (Graham et al, 1977). The cells were 
propagated in a similar fashion as mentioned in the above paragraph. Aedes 
albopictus C6/36 cells were grown in L-15 medium (Appendix 1d) 
supplemented with heat-inactivated 10% FCS (PAA, Piscataway, USA) 
(Igarashi, 1978). The cells were propagated in a similar fashion, as above 
except for the volume of cell culture transferred to the new sterile flasks. 1.5 
ml of cell culture was transferred instead of half a ml. The C6/36 cells were 
cultured in sterile non-vented cell culture flasks (Nunc, Roskilde, Denmark) 




Primary human umbilical vein endothelial cells (HUVEC) were purchased 
from Lonza and were grown in EBM-2 supplemented with 10% FCS (Thermo 
Scientific Hyclone, Rockford, USA) and growth supplements provided by the 
manufacturer (Lonza, Walkersville, USA). The cells were propagated in 
similar fashion as BHK-21 cells except for the volume of cell culture 
transferred to the new flask was 1.5 ml. 
 
 2.1.3 Harvesting and culturing of human peripheral blood 
monocytes 
Human peripheral blood mononuclear cells (PBMC) were isolated with 
informed consent from healthy blood donors as whole blood donation, from 
the Blood Transfusion Service, Department of Laboratory Medicine, National 
University Hospital, Singapore. The use of anonymous human blood for this 
study was approved by National University of Singapore Institutional Review 
Board (NUS-IRB: 10-072E). PBMC were isolated from the donors’ buffy 
coats by centrifugation on a density gradient. The blood was diluted 2-fold 
with equal volume of PBS (Appendix 1a). In a sterile 50-ml Falcon centrifuge 
tube (Becton Dickinson, New Jersey, USA), 4 volume of diluted blood was 
carefully layered onto 3 volume of Ficoll-Paque
TM
 PLUS lymphocyte isolation 
reagent (GE Healthcare, Piscataway, USA) using Pasteur pipette. The tubes 
were then centrifuged at 400 x g for 30 mins at 19 ºC.  After centrifugation, 4 
layers were formed. The uppermost layer was formed by plasma. The second 
layer consisted of lymphocytes, monocytes and platelets. Ficoll-Paque PLUS 
formed the third layer and the bottommost layer consisted of erythrocytes and 




leaving the second layer undisturbed. Using a new Pasteur pipette, the second 
layer was transferred to a clean 50-ml Falcon centrifuge tube (Becton 
Dickinson, New Jersey, USA). 3 volumes of PBS (Appendix 1a) were added 
to the 50-ml Falcon centrifuge tube (Becton Dickinson, New Jersey, USA) 
containing the second layer to wash the cells. The cells were suspended by 
shaking the tube and then centrifuged at 100 x g for 10 mins at 19 ºC. The 
supernatant was removed, leaving behind a pellet of cells. 50 ml of PBS was 
added to the tube and cells were resuspended.  The tube was centrifuged at 
100 x g for 10 mins at 19 ºC. A third wash was carried out using the same 
conditions. The cell number was then determined using a haemocytometer. 
Isolated PBMC were first subjected to treatment before growing in RPMI-
1640 (Appendix 1b) supplemented with 10% heat-inactivated FCS (PAA, 
Piscataway, USA) and 1% penicillin/streptomycin (Life Technologies, 
California, USA).  
 
 2.1.4 Cryopreservation of cells 
Cryopreservation of cells was performed using confluent 75 cm
2
 
flasks. For adherent cell lines, the cells were trypinized as described in Section 
2.1.2. The cryopreservation steps described below were used for both 
suspension and adherent cell lines. The cell suspension was centrifuged at 300 
x g for 5 min in a sterile 15-ml Falcon centrifuge tube (Becton Dickinson, 
New Jersey, USA). The cell pellet was then resuspended in 5 ml cell culture 
medium supplemented with 10% heat-inactivated FCS and 10% dimethyl 
sulfoxide (Sigma Diagnostics, St.Louis, USA). One ml of the suspension was 




cryo-freezing container (Thermo Fisher Scientific, Waltham, MA, USA). The 
cryofreezing container was then put in a -80 ºC freezer (Thermo Scientific, 
Massachusetts, USA) overnight. The cryovials were then transferred to liquid 
nitrogen tank (Thermo Scientific, Massachusetts, USA) for long-term storage. 
 
 2.1.5 Thawing of frozen cells 
The cryovials containing frozen cells obtained from liquid nitrogen 
tank were thawed rapidly at 37 ºC in a water bath (Mickley Diagnostics 
GmbH, Berlin, Germany). The thawed cell suspension was transferred into a 
sterile 75 cm
2
 tissue culture flask (Corning, New York, USA) containing 20 
ml of cell culture medium supplemented with 10% heat-inactivated FCS 
(PAA, Piscataway, USA). The flask was incubated at the appropriate 
temperature and incubator overnight. The medium containing DMSO was then 
replaced the next day. For suspension cells, the cell culture was spun in a 50-
ml Falcon centrifuge tube (Becton Dickinson, New Jersey, USA) at 300 x g 
for 5 mins to remove the medium. The cell pellet was resuspended in fresh 
RPMI-1640 (Appendix 1b) supplemented with 10 % heat-inactivated FCS 
(PAA, Piscataway, USA) and transferred to a tissue culture flask and placed in 








2.2  INFECTION OF CELLS 
 2.2.1  Viruses        
Dengue virus serotype 2 (DV2), strain (Den2STp7c6), a low passage 
isolate from a dengue-infected patient in Singapore and DV2 strain 16681, a 
kind gift from Professor Gubler from DUKE NUS were used in this study 
(Okamoto et al, 2012). The virus was propagated in Aedes albopictus C6/36 
cells and all virus work was done in an ESCO Type II A2 biological safety 
cabinet.  
 
 2.2.2 Propagation of dengue viruses 
Confluent flasks (75 cm
2
) of Aedes albopictus c6/36 cells were used 
for the propagation of dengue viruses. The cell culture medium was discarded 
and rinsed with 5 ml of PBS (Appendix 1a). One ml of virus was added into 
each flask and incubated at 37ºC for an hour with gentle rocking at every 15 
min interval. Ten ml of L-15 medium (Appendix 1d) supplemented with 2 % 
heat-inactivated FCS (PAA, Piscataway, USA) was added into each flask. The 
flasks were incubated at 28 ºC (Memmert, Schwabach, Germany) until 
extensive syncytial formation was observed. The cell culture medium 
containing the same virus strain was pooled from the flasks and was 
transferred to a 50-ml Falcon centrifuge tube (Becton Dickinson, New Jersey, 
USA). Aedes albopictus C6/36 cells infected with DV2 strain 16681 did not 
show extensive syncytial formation. The cell culture medium containing the 
virus was harvested when some cells were observed to be lifting off from the 
flask instead. The cell culture medium was centrifuged at 450 x g for 5 mins at 




Falcon centrifuge tube (Becton Dickinson, New Jersey, USA). The 
supernatant was then aliquoted into cryovials, 1 ml each and stored in -80ºC 
freezer (Thermo Scientific, Massachusetts, USA).  
 
 2.2.3 Preparation of C6/36 cell culture supernatant for mock-
infection 
The C6/36 cell culture supernatant used for mock-infection was 
prepared in the same fashion as the dengue virus stock in Section 2.2.2 except 
for the step in which 1 ml of dengue virus was added into each flask and 
incubated at 37 ºC for an hour with gentle rocking at every 15 min interval. 1 
ml of L-15 medium (Appendix 1d) supplemented with 2 % heat-inactivated 
FCS (PAA, Piscataway, USA) was added instead. The harvesting of the mock-
infected Aedes albopictus C6/36 cell culture was done after the same number 
of day of incubation as the DV2-infected Aedes albopictus C6/36 cell culture.  
 
 2.2.4 Plaque assay to quantify DV infectious titer 
A confluent flask (75 cm
2
) of BHK-21 cells was trypsinized and top up 
to 150 ml with RPMI-1640 (Appendix 1b) supplemented with 10 % heat-
inactivated fetal calf serum (PAA, Piscataway, USA). The suspension was 
mixed well before 1 ml was dispensed in each well of 6 sterile 24-well tissue 
culture plates (Nunc, Roskilde, Denmark) and incubated overnight at 37 ºC in 
a 5 % CO2 humidified incubator (Thermo Scientific, Massachusetts, USA). 
The confluency of the wells was checked under the light microscope 
(Olympus, Tokyo, Japan) the next day. The culture medium of the wells were 




(Appendix 2a). One hundred μl from the appropriate dilutions were inoculated 
onto cells in triplicate wells. The plates were then incubated at 37 ºC in a 5% 
CO2 humidified incubator (Thermo Scientific, Massachusetts, USA) for 1 hr 
with rocking at every 15 mins interval. After 1 hr, the wells were washed with 
PBS (Appendix 1a) and 1 ml of RPMI-1640 overlay medium (Appendix 2b) 
were added to each well. The plates were incubated at 37 ºC in a 5 % CO2 
humidified incubator (Thermo Scientific, Massachusetts, USA) for 6 days. 
RPMI-1640 overlay medium (Appendix 2b) was then removed from each well 
and 200 μl of 0.5% crystal violet / 25% formaldehyde solution (Appendix 2c) 
were added. The plate was put on an Orbit
TM
 LS Low Speed shaker (Labnet 
International, Edison, USA) overnight at room temperature. The 0.5% crystal 
violet / 25% formaldehyde solution (Appendix 2c) was removed from the 
wells and the wells were washed with water. The washed plates were dried in 
warm room at 37 ºC before the viral plaques within each well of the plates 
were counted. 
 
2.2.5 Preparation of UV-inactivated virus pool 
A fresh stock of DV2 without prior freezing was dispensed onto a 
sterile petri dish (10 cm diameter) to a depth of less than 5 mm. The volume of 
DV2 added into the petri dish was noted and one ml of the stock DV2 was 
transferred to a cryovial and stored at -80 ºC to be titered by plaque assay 
later. The petri dish containing DV2 was placed 10 cm away from a UV lamp 
in an ESCO Type II A2 biological safety cabinet (ESCO, Singapore) under 
sterile conditions. The virus was subjected to UV-irradiation for 1.5 hr. After 




Centrifugal Filter Unit (with a cut-off of 100 kDa) (Millipore, Schwalbach, 
Germany). The Centrifugal Filter Unit containing the UV-irradiated virus was 
centrifuged at 4000 x g for 25 mins in a swing-out centrifuge (Sigma 
Laborzentrifugen, Ostrode, Germany). The Centrifugal Filter Unit was washed 
with L-15 medium (Appendix 1d), then centrifuged again. L-15 medium 
(Appendix 1d) supplemented with 2% FCS was added to the residual fluid in 
the Centrifugal Filter Unit to top it up to the original volume. The inactivation 
of DV was confirmed via plaque assay and the amount of viable virus particles 
present in the UV-irradiated DV2 stock prior to UV-irradiation was 
determined using the one ml of DV2 virus kept for titering initially. 
 
2.2.6 Infection of K562 cells or PBMC 
K562 cells and PBMC were infected with DV2 at a multiplicity of 
infection (M.O.I.) of 10. K562 cells were first harvested by centrifuging at 300 
x g for 5 min while PBMC were centrifuged at 100 x g for 5 min. The cells 
were washed with PBS (Appendix 1a) and counted using haemocytometer. 
The required volume of DV2 to give M.O.I. of 10 was added into the Falcon 
centrifuge tube containing the cell pellet. The cell pellet was resuspended and 
incubated at 37 °C for 1 hr with gentle agitation at every 15 mins interval. The 
cells were then washed with 10 ml of PBS (Appendix 1a). For K562 cells, 
RPMI-1640 (Appendix 1b) supplemented with 2% heat-inactivated FCS was 
added to give a cell concentration of 5 x 10
5
 cells per ml of medium. For 
PBMC, RPMI-1640 (Appendix 1b) supplemented with 10% heat-inactivated 
FCS and 1% penicillin/streptomycin (Life Technologies, California, USA) 
was added to give a cell concentration of 2 x 10
6




mock-infected cells, similar volume of mock-infected C6/36 supernatant 
(described in section 2.2.3) was added instead of the DV2 virus. For UV-
inactivated virus treatment, the volume of UV-inactivated virus added gave 10 
virus particles per cells. 
 
2.2.7 Infection of HEK293 cells 
HEK293 cells were seeded in each well of 24-well plates 1 day before 
infection. Prior to infection, the wells were checked for confluency and culture 
medium was aspirated from the wells. The HEK293 cells were infected with 
DV2 at an M.O.I of 10 with incubation at 37 ºC for 1 hr with intermittent 
shaking. The cells were subsequently washed with PBS before DMEM 
(Appendix 1e) supplemented with 2% heat-inactivated FCS was added to the 
cells. 
 
 2.2.8 Preparation of infected cell culture medium free of virus 
particles  
Infected cell culture medium free of virus particles were added to 
HUVEC cells seeded in hanging cell culture inserts (3.0 µm pore, 6.5 mm 
diameter) (Millipore, Schwalbach, Germany). This is to investigate the effect 
of the cellular factors induced by DV2-infected K562 cells without the direct 
effect of DV2 infection on endothelial integrity of HUVEC cells. DV2-
infected cell culture medium was prepared as described in section 2.2.2. The 
cell culture medium was transferred into Millipore Amicon Ultra-15 
Centrifugal Filter Unit (with a cut-off of 100 kDa) (Millipore, Schwalbach, 




(Sigma Laborzentrifugen, Ostrode, Germany) to remove virus particles from 
the DV2-infected cell culture medium. The residue was reconstituted to the 
original volume by adding L-15 medium (Appendix) supplemented with 2% 
heat-inactivated FCS (PAA, Piscataway, USA). 
 
2.3 BIO-IMAGING                      
 2.3.1 Pretreatment of coverslips 
Glass coverslips of 13 mm diameter (Chance Propper, Liecester, UK) 
were washed with 95% ethanol (Merck, Darmstadt, Germany) for two times 
and followed by deionized water for three times before leaving out to dry. The 
dried glass coverslips were sterilized at 160 ºC (Memmert, Schwabach, 
Germany) for 2 hrs. 
 
 2.3.2 Indirect immunofluorescence microscopy 
K562 cells in culture medium after infection or treatment were 
transferred to Falcon centrifuge tube (Becton Dickinson, New Jersey, USA) 
and centrifuged at 300 x g to remove the culture medium. The cells were 
washed with PBS (Appendix 1a) once and centrifuged at 300 x g again to 
remove the PBS (Appendix 1a). The cells were stained with anti-TLR6 
antibody (Santa Cruz Biotechnology, Santa Cruz, USA) at a dilution of 1:200 
for 1 hr. The cells were washed with PBS once and then stained with 
Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG secondary 




fixed using 4 % paraformaldehyde (Sigma-Aldrich Chemical, St.Louis, USA). 
The cells were washed twice with PBS (Appendix 1a) before incubating with 
4’-6-Diamidino-2-phenylindole (DAPI) at a concentration of 300 nM for 10 
mins at room temperature. The cells were centrifuged and washed twice with 
PBS (Appendix 1a). The cells were resuspended in 50 μl of PBS (Appendix 
1a) and placed onto a glass slide. A coverslip was put on top of the cell 
suspension, sealed with nail polish and viewed under the microscope (IX81 
Olympus, Japan) at 1000x magnification using the Metamorph imaging 
software program. Lipopolysaccharides (LPS) (Sigma-Aldrich Chemical, St. 
Louis, USA) were added to the K562 cell culture (5 µg/ml) to serve as a 
positive control.  
For adherent cells (HUVEC), the cells were seeded on glass coverslips 
(Chance Propper, Liecester, UK) in a 24-well tissue culture plate. A cell 
suspension from a confluent monolayer in 75 cm
2
 tissue culture flask was 
prepared as described in Section 2.1.2. One ml of EBM-2 which contained 2 x 
10
5
 cells was added to each well containing a coverslip 24 hrs prior to 
treatment. The treatments were similar to the treatments described in Section 
2.8, except for the volume of the EBM-2 added is 700 μl instead of 200 μl. 
Three days post-treatment, the coverslips coated with HUVEC cells were 
fixed using 4% paraformaldehyde (Sigma-Aldrich Chemical, St.Louis, USA). 
VE-cadherin of the HUVEC cells was stained using BD Pharmingen mouse 
anti-human CD144 antibody at a dilution of 1:200. Fifty microliters of the 
diluted antibodies were spotted on a piece of parafilm (American National 
Can, New York, USA). The coverslips seeded with HUVEC were inverted 




incubated for an hour at 37 ºC in a 5 % CO2 humidified incubator (Thermo 
Scientific, Massachusetts, USA). After the incubation, the coverslips (Chance 
Propper, Liecester, UK) was washed thrice with PBS (Appendix 1a) by 
dipping the coverslips in PBS (Appendix 1a). The cells were then incubated 
with 50 μl of Anti-mouse IgG Dylight 594-conjugated (Thermo Scientific 
Pierce, Rockford, USA) at 1: 500 dilution in the same fashion as the primary 
antibody. After the incubation, the coverslips were washed thrice with PBS 
(Appendix 1a). Finally, DAPI staining was performed for 10 minutes at room 
temperature. Mounting medium (Life Technologies, California, USA) was 
then used to mount the coverslips on glass slides before viewing under the 
microscope (Olympus, Tokyo, Japan) at 1000x magnification using the 
Metamorph imaging software program. The antibodies used in this section are 













Table 2.1: List of antibodies used for immunofluorescence microscopy 
Antibody  Species  Dilution  Source 
Anti-TLR6 Rabbit 1: 200 Santa Cruz 
Biotechnology, 
Santa Cruz, USA 
Anti-TLR2 Mouse 1: 200 Santa Cruz 
Biotechnology, 




Mouse 1: 200 Biosciences, San 






























 2.3.3 Transmission electron microscopy  
 DV2-infected and mock-infected mouse peritoneal macrophages were 
prepared for transmission electron microscopy. Mouse peritoneal macrophages 
were harvested from wild type C57BL/6 and TLR6 C57BL/6 mouse as 




with DV2 at a M.O.I. of 10 in Falcon centrifugation tube. The cells were 
infected in the same fashion as described in section 2.2.6. The cells were 
harvested 2 days post-infection and washed twice with PBS (Appendix 1a). 
The cells were fixed in 2% paraformaldehyde (Sigma-Aldrich Chemical, 
St.Louis, USA) and 3% glutaraldehyde (Agar Scientific, Standsted, UK) in 
PBS (Appendix 1a). The cells were incubated at 4 ºC overnight. The cells 
were scraped off and transferred into an eppendorf tube. The cells were 
centrifuged at 3300 x g for 5mins. The cells were washed twice with PBS 
(Appendix 1a). The cells were then fixed again with 1% osmium tetraoxide 
(Ted Pella, Redding, CA, USA) with 0.1% potassium ferro-cyanide (Electron 
Microscopy Science, Hatfield, USA) in PBS (Appendix 1a) for 1 hr at room 
temperature. The fixing reagent was discarded and the cells were washed 
twice with PBS (Appendix 1a) and twice with water. The cells were then 
dehydrated in ascending graded series of ethanol (Merck, Darmstadt, 
Germany) at room temperature. The cells were resuspended in 25% ethanol 
and left for 15 mins. The cells were pelleted by centrifuging at 3300 x g for 5 
mins. The cell pellet was resuspended in 50 % ethanol for 15 mins. The cells 
were then pelleted and resuspended in 75 % ethanol at 4 ºC overnight. The 
cells were pelleted and resuspened in 90 % ethanol for 15 mins. Absolute 
ethanol was added to the cell pellet and left for 20 mins. This step was 
repeated for 2 times. Infiltration of cell pellets were performed using 
increasing ratio of London Resin White (LRW) (Electron Microscopy Science, 
Hatfield, USA) to absolute ethanol (7 parts ethanol : 3 parts LRW, 5 parts 
ethanol : 5 parts LRW, 3 parts ethanol : 7 parts LRW) for 30 mins each. 




removed and replaced with fresh LRW. The cells were then incubated 
overnight at 4 ºC. The absolute LRW was added to the cells and incubated at 
room temperature for an hour. This step was repeated for 2 times. During the 
last repeat, LRW was discarded and 100 μl of fresh LRW was added to the 
cells. The cells were transferred to size 3 BEEM capsules which were pre-
inserted, into size-0 gelatin capsules. LRW was topped up to the brim in 
BEEM capsules and gelatine capsules were capped. As LRW is sensitive to 
oxygen, the capsule were filled to the brim and tightly covered to prevent 
exposure to oxygen during polymerization. Gelatin capsules were inserted into 
2-ml eppendorf tubes and centrifuged at 2300 x g for 20 mins. The capsules 
were then placed in 60 ºC oven for at least 48 hrs to polymerize. After 
polymerization, the gelatine and BEEM capsules were cut and viewed under 
the transmission electron microscope (Philips, Amsterdam, Netherlands). 
 
2.4 PROTEIN EXPRESSION ANALYSIS 
 2.4.1 Cell lysate extraction 
Cells to be lysed were first washed twice with PBS. Following that, 
cell pellets were lysed using CelLytic
TM
 M cell lysis reagent (Sigma 
Diagnostics, St.Louis, USA) with EDTA-free protease inhibitor cocktail 
(Roche Applied Science, Upper Bavaria, Germany) for 10 mins on ice. The 






 2.4.2 Bradford assay 
Bradford assay was performed to quantify the amount of total protein 
in the cell lysate. Concentrated (5X) Bradford dye (Bio-Rad Laboratories, San 
Francisco, USA) was diluted to 1X Bradford dye using deionized water. Two 
hundreds μl of diluted Bradford dye was added into each well of a 96-well 
plate. BSA (Merck, Darmstadt, Germany) was used for the protein standard as 
only relative protein amounts were required rather than absolute 
quantification. Ten microliters of sample or standard was added to the diluted 
Bradford dye in the 96-well plate. The plate was incubated for 10 mins at 
room temperature before the absorbance was measured at a wavelength of 595 
nm using Infinite 200 PRO plate reader (Tecan, Mannedorf, Switzerland). The 
assay was performed in triplicate and a standard curve was generated from the 
the protein standard. The concentration of the sample was determined using 
the standard curve.  
 
 2.4.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
 Glass plates (Bio-Rad, San Francisco, USA) for casting sodium 
dodecyl sulfate (SDS) polyacrylamide gel was cleaned thoroughly and 
assembled. A 10% separation gel (Appendix 3a) was first casted between the 
two glass plates (Bio-Rad, San Francisco, USA) and allowed to solidify before 
adding the 5% stacking gel mixture (Appendix 3b) and comb between the 
glass plates. After polymerization, the comb was removed and assembled onto 
the electrophoresis module (Bio-Rad, San Francisco, USA). The 




running buffer (Appendix 3c) was added to the brim of the glass plates and to 
the level mark indicated on the tank. SDS-PAGE loading buffer (Appendix 
3d) was added to each sample and heated at 95 ºC for 2 mins in a 
thermocycler. Equal amount of the total protein from each sample and protein 
ladder (Fermentas, Burlington, Canada) were loaded into each well and 120V 
was applied to separate the protein according to their sizes.     
 
 2.4.4 Western blot 
 After the protein ladder was observed to be well-separated, the 
electrophoresis was stopped. The SDS-PAGE gel was removed from the glass 
plates and soaked in Towbin transfer buffer (Appendix 3e) for 15 mins. The 
proteins in the gel were transferred onto nitrocellulose membranes (Bio-Rad, 
San Francisco, USA) using the Trans-Blot SD semi-Dry Electrophoretic 
Transder Cell system (Bio-Rad, San Francisco, USA) at a constant voltage of 
20 V for 1 hr. The blot was blocked using 5% skim milk in TBST buffer 
(Appendix 3f) overnight at 4 ºC on a rocker shaker in cold room. After the 
overnight incubation, the blot was washed thrice with TBST buffer (Appendix 
3f).  Primary and secondary antibodies used for Western blot in this study are 
listed in Table 2.2. Primary antibody was diluted in 5% skim milk and added 
to the blot. The blot was incubated at room temperature on a rocker shaker for 
1.5 hr. The blot was washed thrice with TBST buffer (Appendix 3f). 
Secondary antibody staining of the blot was performed in the same fashion as 
the primary antibody. The blot was washed thrice with TBST buffer and one 




performed using enhanced chemiluminescence detection system with Pierce 
ECL Western Blotting Substrate (Thermofisher Scientific, Waltham, MA, 
USA). The chemiluminescent signal was then captured on CL-XPosure film 
(Thermofisher Scientific, Waltham, MA, USA). The intensity of the bands 
was quantified using GelQuant.NET software provided by 
biochemlabsolutions.com and the relative protein expression was normalized 
to actin loading control.  
 
Table 2.2: List of antibodies used for Western blot 
Antibody Species Dilution Source 
Anti-TLR6 Rabbit 1: 200 Santa Cruz 
Biotechnology, 
Santa Cruz, USA 
Anti-TLR2 Rabbit 1: 200 Abcam, 
Cambridge, UK 

















2.4.5 Flow Cytometric Analysis      
Cells which were mock-infected or infected with DV2 at an MOI of 10 




at 300 x g for 5 mins. The supernatant was then discarded and PBS (Appendix 
1a) was added to wash the cells. The cells were centrifuged again to remove 
the PBS (Appendix 1a). PBS (Appendix 1a) containing 5% BSA (Merck, 
Darmstadt, Germany) was used to resuspend the cells and incubated on ice for 
20 minutes. Primary antibody anti-TLR6 (Santa Cruz Biotechnology, Santa 
Cruz, USA) or anti-TLR2 (Santa Cruz Biotechnology, Santa Cruz, USA) was 
then added at a dilution of 1: 200 to the cell suspension and incubated on ice 
for 30 mins. The cells were then centrifuged and the supernatant was removed. 
PBS (Appendix 1a) was used to wash the cells before the cells were 
centrifuged again to remove the PBS (Appendix 1a). Following that, DyLight 
633/FITC-conjugated goat anti-rabbit or anti-mouse IgG secondary antibody 
(Thermo Scientific Pierce, Rockford, USA), was added at 1: 200 and 
incubated on ice for 30 mins. For the staining of two different antigens in the 
same sample, the above procedure of staining was repeated once more using 
primary antibodies derived from a different species and using secondary 
antibody with a different fluorochrome. For cells which were to be stained for 
CD14, anti-CD14 FITC-conguated, were added and stained in the same 
fashion as the primary antibody described above. This antibody was added last 
so that the secondary antibody detecting mouse IgG will not cross-react with 
it. The cells were then washed twice with PBS (Appendix 1a) before fixing 
using 4% paraformaldehyde at room temperature for 10 mins. After which the 
cells were washed and resuspended in 1 ml of PBS (Appendix 1a). The cells 
are then analyzed using CyAn™ ADP Analyzer (Beckman Coulter, 





 2.4.6 Enzyme-linked immunosorbent assay 
Quantification of human or mouse cytokines (IL-6 and TNF-α) was 
carried out using sandwich enzyme-linked immunosorbent assay (ELISA) 
which was performed in 96-well plate. ELISA for human or mouse IL-6 and 
TNF-α were performed using commercial kits (BD biosciences, San Jose, 
USA). Human cytokine samples were obtained from supernatant of 
experimental treated K562 cells or human PBMC. Mouse cytokine samples 
were obtained from blood of experimental treated mice. Blood of mouse were 
obtained via cardiac puncture using 27 G needle and syringe (BD biosciences, 
San Jose, USA).  One hundred μl of anti-IL-6 or anti-TNF-α antibody diluted 
1:250 with coating buffer were added into each well to coat the antibody onto 
the plate through an overnight incubation at 4°C. The plates were then washed 
three times using 1X wash buffer provided in the kit before blocking using 
200 μl of assay diluent (BD biosciences, San Jose, USA) per well at room 
temperature for one hr. The standards and the samples were added to wells. 
The volume added was 100 μl per well. The plate was incubated at room 
temperature for 2 hrs. The plate was then washed three times using wash 
buffer (BD biosciences, San Jose, USA). One hundred μl of anti-IL-6 or anti-
TNF-α biotinylated antibody and streptavidin-conjugated horseradish 
peroxidase diluted 1: 250 with assay diluent were added into each well and 
incubated at room temperature for an hour. The plate was then washed seven 
times, followed by adding 100 μl of tetramethyl benzidine substrate solution to 
each well. The plate was incubated till the substrate solution in the wells with 
the highest concentration of standard developed intense blue coloration. 50 μl 




Absorbance was measured on an absorbance reader (Tecan, Mannedorf, 
Switzerland) at wavelength of 450 nm with reference wavelength of 570 nm. 
The concentrations of the cytokine in experimental samples were determined 
from a standard curve with known concentrations of the respective cytokine. 
Samples are performed in triplicates. 
 
 2.4.7 Detection of DV NS1 protein secretion 
PBMC were seeded into each well of the 24-well plate with 1 ml of 
10% RPMI 1640 medium (Appendix 1b) as described in section 2.1.3. The 
PBMC within each well was mock-infected or infected with DV2 at an MOI 
of 10. Supernatant of triplicate wells of mock-infected and DV2-infected 
PBMC was harvested for dengue NS1 protein detection assay using the 
Platelia Dengue NS1 Antigen detection kit (Bio-Rad, San Francisco, USA). 
The relative amount of dengue NS1 protein was measured in optical density 
and was read using Tecan plate reader (Tecan, Mannedorf, Switzerland) at 
wavelength of 450 nm with reference wavelength of 620 nm. For the detection 
of dengue NS1 protein in mice, the sera were used instead. 
 
2.5  DNA PLASMID TRANSFECTION   
The expression of TLR6 in K562 cells was knocked down using 
plasmid expressing shRNA that targets TLR6 (psiRNA-hTLR6) (InvivoGen, 
San Diego, USA). The plasmids were transfected into K562 cells. psiRNA-
LucGL3 (InvivoGen, San Diego, USA) plasmid expressing shRNA with non-
targeting sequence was transfected into K562 cells to act as a non-targeting 
control. Transfection was performed using Lipofectamine
TM




Technologies, California, USA). Six hrs before transfection, K562 cells were 
plated 1 x 10
5
 cells in 0.5 ml of Opti-MEM I reduced serum medium (Life 
Technologies, California, USA) per well of a 24-well plate. For each well of 
cells to be transfected, Half a μg of DNA was diluted into 100 μl of Opti-
MEM I reduced serum medium (Life Technologies, California, USA). 0.5 μl 
of Plus
TM
 reagent was added directly to the diluted DNA and mixed gently. 
The mixture was incubated at room temperature for 10 mins. For each well of 
cells, 2 μl of LipofectamineTM LTX was added to the above diluted DNA 
solution and mixed gently. The mixture was incubated for 25 mins at room 
temperature to form DNA-Lipofectamine
TM
 LTX complexes. 100 μl of the 
DNA-Lipofectamine
TM
 LTX complexes was added directly to each well 
containing cells and mixed gently by rocking the plate back and forth. The 
plate was incubated at 37 ºC in a 5 % CO2 humidified incubator (Thermo 
Scientific, Massachusetts, USA) for 2 hrs before 0.5 ml of RPMI-1640 
(Appendix 1b) supplemented with 10% heat-inactivated fetal calf serum was 
added to each well. Three days post-transfection, stable cell clones of the cells 
expressing psiRNA-hTLR6 or psiRNA-LucGL3 were selected using Zeocin 
(Life Technologies, California, USA) at 200 µg/ml. Reporter plasmid (pNF-
κB/SEAP) (Imgenex, San Diego, USA) and plasmid expressing human TLR6 
and TLR2 genes (pDUO-hTLR6/TLR2) (InvivoGen, San Diego, USA) was 
transfected into HEK293 cells in the same fashion as mentioned above except 
that HEK293 cells were seeded 1 day before transfection in DMEM 
(Appendix 1e) supplemented with heat-inactivated 10% FCS (PAA, 
Piscataway, USA) and 0.5 ml of DMEM (Appendix 1e) supplemented with 




after transfection instead of RMPI-1640. Stable cell clones of the pNF-
κB/SEAP-transfected cells were obtained by selection using G418 (PAA, 
Piscataway, USA) at 500 µg/ml, while stable cell clones of the pDUO-
hTLR6/TLR2-transfected cells were obtained by selection using blasticidin 
(Life Technologies, California, USA) at 10 µg/ml.  
 
2.6 NFkB ACTIVATION REPORTER ASSAY 
Activation of NFκB was determined using a reporter plasmid (pNF-
κB/SEAP) (Imgenex, San Diego, USA) which expresses secreted alkaline 
phosphatase (SEAP) protein under the control of the NFκB promoter. These 
plasmids were transfected into HEK293 cells using Lipofectamine
TM
 LTX 
(Life Technologies, California, USA) in the same fashion as described in 
section 2.5. Stable cell clones of the transfected cells were obtained by 
selection using G418 (PAA, Piscataway, USA) at 500µg/ml. 2 x 10
5
 
transfected HEK293 cells were seeded into 24-well plate 1 day prior to 
treatment. The cells were then treated under various conditions [infected with 
DV2 at an M.O.I of 10, mock-infected, DV NS1 recombinant protein (1 
µg/ml), His-tag (1 μg/ml), LPS (5 µg/ml) or MALP-2 (50 ng/ml) (Imgenex, 
San Diego, USA) added into the culture medium]. Supernatant were harvested 
1 to 3 day post-treatment. The amount of SEAP in the supernatant was assayed 
according to manufacturer’s protocol. 10X dilution buffer was diluted to 1X 
with sterile autoclaved Ultrapure water (Millipore, Schwalbach, Germany). 
SEAP standards of concentrations (200 ng/ml, 100 ng/ml, 50 ng/ml, 25 ng/ml, 
12.5 ng/ml, 6.25 ng/ml, 3.125 ng/ml) were prepared by serial dilution using 




well of the round-bottom 96-well plate. Ten μl of Ultrapure water (Millipore, 
Schwalbach, Germany) was added to each well containing the sample or the 
standard. The plate was then sealed with plate sealer and incubated at 65ºC for 
30 mins to inactivate any endogenous alkaline phosphatase in the supernatant. 
The plate was then centrifuged briefly in a swing-out centrifuge (Beckman 
Coulter, California, USA). p-Nitrophenyl phosphate (PNPP) substrate was 
prepared by diluting 10X PNPP buffer with sterile autoclaved Ultrapure water 
(Millipore, Schwalbach, Germany) and dissolving 5 mg of PNPP substrate 
tablet in every 5 ml of 1X PNPP buffer. 100 μl of 1 mg/ml PNPP substrate 
solution was added to each well and incubated at room temperature for 2 hrs. 
SEAP catalyzes the hydrolysis of PNPP producing a yellow product that was 
read using absorbance reader (Tecan, Mannedorf, Switzerland) at 405 nm. The 
concentrations of SEAP in experimental samples were determined from a 
standard curve. Samples were performed in triplicates. 
 
2.7 EXPRESSION OF TLR6 AND TLR2 IN HEK293 CELLS 
TLR6 and TLR2 in HEK293 were expressed using a plasmid co-
expressing the human TLR6 and TLR2 genes (pDUO-hTLR6/TLR2) 
(InvivoGen, San Diego, USA) which was transfected into the NFκB-SEAP 
HEK293 cell clones obtained as described in section 2.6. Stable cell clones of 
the transfected cells were obtained by selection using both blasticidin (Life 
Technologies, California, USA) at 10 µg/ml and G418 (PAA, Piscataway, 
USA) at 500 µg/ml. The expression of TLR2 and TLR6 was confirmed with 
Western blot and flow cytometry after the transfected cells were stained for 




2.8 ASSESSMENT OF ENDOTHELIAL PERMEABILITY OF 
HUVEC ON TRANSWELL 
HUVEC cultured in EBM-2 medium were seeded onto 24-well 
Millicell ® hanging cell culture inserts (3.0 µm pore, 6.5 mm diameter) 
(Millipore, Schwalbach, Germany) at a density of 5 x 10
5
 cells per well and 
placed in wells of 24-well plate containing 1 ml of EBM-2 medium for 1 day 
to reach confluency. Prior to treatment, 0.5 ml of EBM-2 medium in the 
transwell was aspirated. Three hundred µl of the supernatant from the treated 
samples [mock-infected and DV2-infected psiRNA-LucGL3 and psiRNA-
hTLR6 with or without IL-6 neutralizing antibody (R & D Systems, 
Minneapolis, USA), NS1/His-tag-treated PBMC with isotype/blocking 
antibodies (as described in Section 2.10)], 2000 pg/ml of Human recombinant 
IL-6 (R & D Systems, Minneapolis, USA),  100 ng/ml of TNF-α (Millipore, 
Schwalbach, Germany) in 300 µl of RPMI-1640 (Appendix 1b) supplemented 
with 2 % FCS (PAA, Piscataway, USA) were added into the hanging cell 
culture inserts. Two hundreds µl of EBM-2 medium was also added into each 
of the hanging cell culture inserts. For treatment with IL-6 neutralizing 
antibody (R & D Systems, Minneapolis, USA), 3 µg/ml of IL-6 neutralizing 
antibody (R & D Systems, Minneapolis, USA) was incubated with 300 µl of 
the supernatant for an hour before adding the supernatant into the hanging cell 
culture inserts.  
The transendothelial electrical resistance (TEER) was measured with 
Millicell ® ERS-2 volt/ohm meter (Millipore, Schwalbach, Germany) at daily 
intervals for 3 days post-treatment. The shorter electrode of the ERS-2 




longer electrode was submerged in the lower chamber of the transwells. Care 
was taken to prevent the shorter electrode from touching the monolayer. The 
TEER of the monolayers were recorded when a stable reading was achieved. 
Triplicate measurements were taken for each transwell. Student’s t-test was 
used to compare the mean TEER readings. 
 
2.9 VIRAL RECOMBINANT PROTEIN 
Dengue viral recombinant proteins (Capsid, PrM, envelope, NS1, 
NS2a, NS2b, NS3, NS4a, NS4a, NS5) with 6x His-tag and protein tag (6x 
His-tag alone) at concentration of 1mg/ml were expressed using 
BaculoDirect
TM
 Baculovirus Expression System (Life Technologies, 
California, USA) and purified using high performance liquid chromatography. 
Commercially available recombinant NS1 protein with 6x His-tag (Abcam, 
Cambridge, UK) and 6x His-tag (Abcam, Cambridge, UK) were also used for 
this study.  
 
 
2.10 ANTIBODY BLOCKING TREATMENT 
 PBMC obtained as described in section 2.1.3 were incubated with 
TLR2 or TLR6 blocking antibodies (IgG1) (InvivoGen, San Diego, USA) at a 
concentration of 1000 ng/ml for 30 mins on ice before infection or mock-
infection as described in section 2.2.6 was performed. For PBMC to be 
blocked by both TLR2 and TLR6 blocking antibodies, 500 ng/ml of each 




Santa Cruz, USA) from unstimulated mice was used as isotype control at a 
concentration of 1000 ng/ml.  
 
2.11 DEVELOPMENT OF MURINE MODEL FOR DENGUE VIRUS 
INFECTION 
 2.11.1 Strains of mice 
C57BL/6 mice used in this study were obtained from InVivos and the 
former NUS CARE (NUS, Singapore). TLR6 knock-out C57BL/6 breeder 
mice were obtained from Oriental BioService, Kyoto, Japan and bred in NUS, 
Singapore. 
 
 2.11.2 Infection and mock-infection of mice 
One to two days old, 1 week-old, 2 week-old and 4 week-old C57BL/6 
mice were infected with 7.8 x 10
8 
PFU/ml or 5.4 x 10
11
 PFU/ml of 16681 DV2 
via intraperitoneal injection (IP) at a volume of 0.05ml/g. For intradermal 
injection, 50 μl of 16681 DV2 was injected in the back of 4 week-old mice at 
each of the four sites as indicated by the arrows (Figure 2.1). For mock-
infection, C6/36 culture supernatant of the same volume as the virus was 





Figure 2.1 Sites of intradermal injection in the back of mouse.  
50 μl of DV2 was injected into the back of the mouse at each of the four sites 




 2.11.3 Harvesting blood, peritoneal fluid and tissues of mice 
Mice were euthanized before blood was collected by cardiac puncture. 
The blood was left to clot at room temperature and centrifuged at 3300 x g for 
5 mins to obtain the serum. It was observed that some mice had a bulge at the 
site of injection on day 1 post-infection. Peritoneal fluid was extracted from 
the bulge using 27G needle and syringe for virus quantification as well. Brains 
of mice were harvested by removing the skin on top of the head and making 




harvested by making an incision at the abdomen. Hind limbs of mice were 
harvested by cutting the hind limbs of the mice at the pelvis joint. Brains, 
livers or hind limbs of mice were placed in hard tissue homogenizing tube 
containing ceramic beads (Precellys, Bertin, Germany). The weight of the 
tissues in each of the tubes was recorded and 0.5 ml of PBS (Appendix 1a) 
was added to each tubes. The tissues in the tubes were homogenized using a 
tissue homogenizer (Precellys, Bertin, Germany). The conditions used were 
6500 rpm for 10 secs with 3 repetitions and 5 secs rest in between. The tubes 
were then centrifuged at 3500 x g for 10 mins. The supernatant was collected 
in a new eppendorf tube and centrifuged at 10,000 x g for 10 mins. DV2 in the 
serum or peritoneal fluid or supernatant of homogenized tissues were 
determined using plaque assays as described in section 2.2.4. 1% 
penicillin/streptomycin, 1% amphotericin B (MP Biomedicals, California, 
USA) and 0.5% gentamycin (PAA, Piscataway, USA) were added to the 
overlay medium (Appendix 2b). As the volume of the serum or peritoneal 
fluid harvested from each of the pups may be less than 100 µl, there may not 
be neat sample and the calculation of PFU/g was adjusted according to the 
volume of sample used. IL-6 and TNF-α in the serum of treated mice were 
determined as described in section 2.4.6.  
 
 2.11.4 Stimulating production and harvesting of peritoneal 
macrophages 
4% thioglycollate medium (Biosciences, San Jose, USA) was prepared 




aluminium foil and stored at 4 ºC for 3 months before use. 4-week old mice 
were injected with 1 ml of 4% thioglycollate medium via intraperitoneal 
injection. Four days after injection, the mice were euthanized and the skin 
around the abdomen of the mice was removed to expose the intraperitoneal 
cavity. A blunt forceps were used to lift the membrane of the peritoneal away 
from the underlying organs and intestines. Using 18 G needle and 10 ml 
syringe, ice cold PBS (Appendix 1a) was injected into the intraperitoneal 
cavity without bursting the peritoneal membrane. Precaution was taken to 
avoid puncturing any organ or intestine. The abdomen of the mice was gently 
massaged before using 18 G needle and 10-ml syringe to withdraw the PBS 
(Appendix 1a) containing macrophages from the intraperitoneal cavity. A 
blunt forceps were used to hold the peritoneal membrane and a small incision 
was made. Pasteur pipette was used to suck any remaining PBS (Appendix 1a) 
from the intraperitoneal cavity. The macrophages in PBS (Appendix 1a) were 
collected in 15-ml Falcon centrifugation tube and centrifuge at 450 x g for 5 
mins at 4ºC. One ml of Red blood cell lysing buffer Hybri-Max
TM
 (Sigma-
Aldrich Diagnostics, St.Louis, USA) was added to the cell pellet and 
resuspended for 3 mins. Fourteen ml of PBS (Appendix 1a) was added and the 
tube was centrifuged at 450 x g for 5 mins at 4ºC. The cells were washed again 
with PBS (Appendix 1a) and counted using haemocytometer. The cells were 
cultured in RPMI-1640 (Appendix 1b) supplemented with 10% heat-
inactivated FCS (PAA, Piscataway, USA), 1% penicillin/streptomycin (Life 
Technologies, California, USA), 1% amphotericin B (MP Biomedicals, 





 2.11.5 Survival curve of mice after treatment 
 DV2-Infected or mock-infected wild type or TLR6
-/-
 C57BL/6 mice 
were monitored daily and observed for any abnormal signs which could be 
symptoms of infection for up to day 21 post-infection. 
 
2.12 STATISTICAL ANALYSIS 
The statistical comparisons were carried out using two tailed Student’s 
t-test for repeated measurements when applicable. The significance level was 
set at *: p < 0.05, **: p < 0.005, ***: p < 0.0001. Data were obtained from 
three independent experiments. Kruskal-Wallis test was used for non-































3.0 TLR6 of K562 cells is activated during dengue virus infection 
3.1 INTRODUCTION 
Dengue virus can infect various human cell types during an infection 
but the main cellular targets of infection by dengue virus are peripheral blood 
mononuclear cells, with monocytes and macrophages being preferentially 
infected (Kou et al, 2008; Wang et al, 2002b). Besides being the targets of 
infection, these cells being immune cells are likely to play important roles 
during dengue virus infection. The regulation of selected 84 immune genes in 
DV2-infected K562 cells compared to mock-infected K562 cells was 
investigated in our previous work using Superarray real-time PCR arrays 
(Supplementary Table 8.1). K562 cells are myelogenous leukemia cell line 
with monocytic properties (Klein et al, 1976). This cell line was chosen for its 
monocytic properties and it has been used widely for dengue virus infection 
studies (Jin et al, 2009; Kurane et al, 1990; Mazzon et al, 2009). The 84 
immune genes profiled in the PCR arrays are involved in immune cell 
activation and antimicrobial humoral response. The genes that were found to 
have more than two-fold change and significant p-value (< 0.05) evaluated by 
Student’s t-test are chemokine ligand 5, chemokine receptor 5, CD69 
molecule, CD80 molecule, interleukin 12 receptor, interleukin 1 receptor, 
interleukin 4, interleukin 6, protein tyrosine phosphatase receptor, toll-like 
receptor 6, tumor necrosis factor-alpha and tumor necrosis factor receptor. Up-
regulation of chemokine (C-C motif) ligand 5 (CCL5) in DV2-infected K562 
cells was previously reported by King and co-workers (2002) showing 
elevated CCL5 in dengue 2 virus-infected mast cells and monocytes. One 




4 after the onset of fever (Liu et al., 2002) also substantiated the up-regulation 
of CD69 in DV2-infected K562 cells. IL-6 production was also documented in 
in vitro models of DV infection (Lin et al, 2002; Reis et al, 2007a). Hence, the 
consistency of the data obtained from this study with previous published 
studies using other methods supported the reliability of this experimental 
approach.  
It was observed that some of the up-regulated genes (interleukin 6, 
TLR6 and TNF-α) are in the TLR6 pathway (Hochdorfer et al, 2011; Nakao et 
al, 2005; Shey et al, 2010). TLR6 has been known to function together with 
TLR2 in detecting diacylated lipoprotein (Nakao et al, 2005). So far, TLR6 
has not been reported to be involved in dengue virus infection but it has been 
reported to be involved in other viral infection (Chang et al, 2007; Murawski 
et al, 2009). TLR6 pathway activation is well-documented to play an 
important part in activating both the innate and adaptive immunity (Nakao et 
al, 2005; Takeda & Akira, 2004). These made TLR6 an interesting candidate 
gene to be further investigated. Hence, up-regulation of TLR6 was chosen for 
further validation.  
 
3.2 UP-REGULATION OF TLR6 IN DV2-INFECTED K562 CELLS 
3.2.1 Western blot analysis of TLR6 expression in DV2-infected K562 cell 
lysate.  
K562 cells were infected with DV2 at a M.O.I of 10 and the cell lysate 




protein expression (Sections 2.2.6 and 2.4.4). The band intensities of the 
mock-infected cells, UV-irradiated DV2-treated cells, DV2-infected and LPS-
treated K562 cells were normalized against actin that served as the loading 
control (Figure 3.1a). The relative density of the TLR6 bands was plotted on a 
graph (Figure 3.1b). There was increase in the expression of TLR6 in DV2-
infected K562 cells when compared to the mock-infected or UV-inactivated 
DV2-treated K562 cells. These results suggested that the surface proteins of 
DV2 (envelope or prM) were not responsible for inducing the up-regulation of 
TLR6 and active viral replication was required. LPS was used as a positive 
control as it has been reported by other studies that LPS was able to induce up-
regulation of TLR6 (Nhu et al, 2006; Olson & Miller, 2004; Sanlioglu et al, 


























































Figure 3.1 Western blot analyses of TLR6 protein expression in DV2-
infected K562 cells. 
Mock-infected, UV-DV2-treated, DV2-infected and LPS-treated K562 cells 
were lysed and equal total protein was loaded into SDS-PAGE gel. The 
presence of TLR6 protein in the cell lysate was detected using rabbit anti-
TLR6 antibody and goat anti-rabbit HRP conjugated antibody on the Western 
blot (a). Actin was also detected and was used as a loading control. The band 
intensity was measured using GelQuantNET software program. The intensities 
of the TLR6 bands were normalized against the intensity of the corresponding 




3.2.2 Immunofluorescence analyses of TLR6 expression on DV2-infected 
K562 cells. 
 To further confirm that K562 cells up-regulate TLR6 during dengue 
virus infection, immunofluorescence analyses were performed. K562 cells 
were either mock-infected or infected with DV2 at a M.O.I of 10 or LPS-
treated (as described in Section 2.2.6 and 2.3.2) were stained green using 
primary rabbit anti-TLR6 antibody and secondary goat anti-rabbit IgG 
conjugated with FITC (Table 2.1). DAPI was used to stain the nuclei. As seen 
in Figure 3.2, DV2-infected K562 cells and LPS-treated K562 cells were 
observed to have higher level of TLR6 expression (white arrows) indicated by 
more green spots being observed compared to the mock-infected. This 














a)                                                             b) 
   
c) 
 
Figure 3.2 Immunofluorescence images of DV2-infected, Mock-infected 
and LPS-treated K562 cells stained for TLR6 production. 
K562 cells were mock-infected (a), infected with DV2 at M.O.I. of 10 (b) or 
LPS-treated (c) (5 μg/ml) and stained for TLR6 at day 3 post-treatment. TLR6 
is stained green using primary rabbit anti-TLR6 antibody and secondary goat 
anti-rabbit IgG conjugated with FITC. Cell nuclei are stained blue with DAPI. 









3.3 DETECTION OF CYTOKINES IN DV2-INFECTED K562 CELLS 
3.3.1 The amount of IL-6 production by DV2-infected K562 cells was 
quantified by ELISA. 
 The activation of TLR6 pathway is documented to induce the 
production of IL-6 (Randhawa et al, 2011; Shey et al, 2010). Dengue virus-
infected patients’ sera have been found to contain high level of IL-6 (Hober et 
al, 1993; Pinto et al, 1999; Restrepo et al, 2008) and in vitro experiments 
using monocytic cell lines also showed up-regulation of IL-6 during dengue 
virus infection (Levy et al, 2010). Real-time PCR array performed previously 
also found up-regulation of IL-6 gene during dengue virus infection 
(Supplementary table 8.1). To determine the amount of IL-6 secreted into the 
extracellular milieu by K562 cells during dengue virus infection, ELISA was 
performed (Section 2.4.6). The cell culture supernatants were harvested from 
mock-infected and DV2-infected K562 cells as described in Section 2.2.6. IL-
6 expression was found to be up-regulated by K562 cells during DV2 infection 
(Figure 3.3). Student’s t-test was employed to compare the mean amount of 
IL-6 secreted into the supernatants of mock-infected and DV2-infected K562 
cells. The up-regulation of IL-6 expression by DV2-infected K562 cells was 
statistically significant from day 3 to day 6 post-infection when compared to 























Figure 3.3 Amount of IL-6 detected in K562 cell culture supernatants 
using ELISA. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected or DV2-infected K562 cells. Data represent 
mean ± SEM of three independent experiments. * denotes p-value < 0.05 for t-
tests comparing mean amount of IL-6 detected in culture supernatants of DV2-
infected K562 cells to that of the mock-infected K562 cells. 
 
3.3.2 The amount of TNF-α production by DV2-infected K562 cells was 
quantified by ELISA. 
Besides IL-6, TNF-α is another cytokine downstream of TLR6 
activation pathway (de Almeida et al, 2013; Jung et al, 2009). In our real time 
PCR array performed previously, TNF-α gene was also found to be up-
regulated 2.06-fold in K562 cells upon dengue virus infection when compared 
to mock-infected K562 cells (Supplementary Table 8.1). ELISA was 
performed to quantify the amount of TNF-α secreted into the extracellular 
milieu by K562 cells during dengue virus infection (Section 2.4.6). The cell 
culture supernatants were harvested from mock-infected and DV2-infected 
K562 cells as described in Section 2.2.6. Surprisingly, TNF-α expression was 




infected K562 cells (Figure 3.4). This unexpected result is discussed in the 
discussion section (Chapter 6). 



















Figure 3.4 Amount of TNF-α detected in the K562 cell culture 
supernatants using ELISA. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatant by mock-infected and DV2-infected K562 cells. Data represent 
mean ± SEM of three independent experiments. * denotes p-value < 0.05 for t-
tests comparing mean amount of TNF-α detected in culture supernatants of 
DV2-infected K562 cells to that of the mock-infected K562 cells. 
 
3.4 TLR6 IS INVOLVED IN THE IL-6 PRODUCTION BY K562 CELLS 
DURING DENGUE VIRUS INFECTION 
3.4.1 Knock-down of TLR6 in K562 cells using TLR6-silencing shRNA 
plasmid. 
Next, the contribution of IL-6 expression via TLR6 pathway activation 
during dengue infection was investigated. TLR6 was first knocked down in 
K562 cells with psiRNA-hTLR6 which produced TLR6-silencing short-
hairpin RNA (shRNA). The psiRNA-LucGL3 plasmid was used as non-




psiRNA-LucGL3 plasmid generates shRNA which targets the LucGL3 
reporter gene. The LucGL3 reporter gene is not found endogeneously in 
human cells. The transfection of the plasmids into K562 cells was described in 
Section 2.5. Both psiRNA-hTLR6 and psiRNA-LucGL3 plasmid backbones 
contain the GFPzeo reporter/resistance fusion gene which allows selection of 
stable cell lines. The shRNA plasmids allow long lasting knock-down of target 
genes and the expression of the plasmids by K562 cells after antibiotic 
selection can be monitored by the GFP expression. Untransfected K562 cells 
showed no GFP expression while psiRNA-LucGL3-transfected K562 cells and 
psiRNA-hTLR6-transfected K562 cells have GFP expression for most of the 
cells, indicated by the green fluorescence (Figure 3.5). This suggests that the 
transfected cells have successfully incorporated the shRNA plasmids and are 





















Figure 3.5 Immunofluorescence analyses of GFP expression by shRNA 
plasmid transfected K562 cells. 
 
Untransfected K562 cells (a), psiRNA-LucGL3-transfected K562 cells (b) and 
psiRNA-hTLR6-transfected K562 cells (c) were viewed under fluorescence 
microscope. Stable cell lines of K562 cells transfected with psiRNA-LucGL3 
or psiRNA-hTLR6 were obtained after antibiotic selection. Images which 
were taken in DIC and GFP channels were overlaid. Representative images are 
shown.    
 
3.4.2 Western blot analysis of TLR6 expression in TLR6 knock-down 
K562 cell lysate.  
The knock-down of TLR6 gene was validated using Western blot. 
Stable cell lines of K562 cells transfected with psiRNA-LucGL3 (non-
targeting control), psiRNA-hTLR6 plasmids and untransfected K562 cells 




2.4.4. TLR6 protein expression was knocked down in K562 cells transfected 
with psiRNA-hTLR6 as indicated by the lower intensity of TLR6 protein 
bands when compared to that of psiRNA-LucGL3-transfected K562 cells 
(Figure 3.6a). Using densitometric analysis, the TLR6 targeting shRNA 








































































Figure 3.6 Western blot analysis of TLR6 protein in K562 cells 
transfected with shRNA plasmid. 
 
Western blot was carried out to detect for TLR6 protein expression in 
untransfected K562 cells, psiRNA-LucGL3- (non-targeting control plasmid) 
and psiRNA-hTLR6-transfected K562 stable cell lines (a). Densitometric 





3.4.3 Flow cytometric analysis of TLR6 expression in TLR6 knock-down 
K562 cells 
In addition, flow cytometric analysis was carried out to confirm TLR6 
knock-down in K562 cells. Stable cell lines of K562 cells transfected with 
psiRNA-LucGL3 and psiRNA-hTLR6 plasmids were harvested and stained 
for TLR6 expression as described in Section 2.4.5. As the transfected cells 
have GFP expression, DyLight 633-conjugated secondary antibody was used 
instead of FITC. Higher level of TLR6 expression was noted in the K562 cells 
transfected with the non-targeting control plasmid upon flow cytometric 
analysis (Figure 3.7a). K562 cells transfected with the non-targeting control 
plasmid psiRNA-LucGL3 were shown to have higher fluorescence intensity 
by the rightward shift of the histogram compared to that of the psiRNA-
hTLR6-transfected K562 cells.  In addition, higher percentage of TLR6 
positive cells were detected in the psiRNA-LucGL3 (Figure 3.7b, c, f & g) 
population compared to the psiRNA-hTLR6 (Figure 3.7d, e, h & i) (Table 
3.1). When the gating was changed to select for higher TLR6 expressing cells 
the difference in population percentage becomes greater. This suggests that 
psiRNA-LucGL3 has more high TLR6 expressing cells compared to that of 
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Figure 3.7 Flow cytometric analysis of TLR6 knock-down in K562 cells. 
Flow cytometry (a) was performed on stable cell lines of K562 cells 
transfected with psiRNA-LucGL3 (b, c, f, g) and psiRNA-hTLR6 plasmids (d, 
e, h, i). The cells were stained for TLR6 and 30, 000 cells were analyzed for 
each sample. (f, g, h, i) used a higher TLR6 expression gating compared to (b, 
c, d, e). The population percentage is tabulated in the table below.  
 
Cells Population Percentage p-value 








Table 3.1 Flow cytometric analysis of TLR6 knock-down cells in K562 
cells 
The table shows the population percentage of the flow cytometric analysis in 
Figure 3.7. The population percentage is the percentage of cells in the gated 




3.4.4 The production of IL-6 in TLR6 knock-down K562 cells during 
dengue virus infection was quantified using ELISA. 
To investigate if TLR6 is activated and its contribution to IL-6 
expression during DV2-infection, supernatant from TLR6 knock-down K562 
cells and non-targeting control shRNA transfected K562 cells upon DV2 
infection or mock-infection were collected and the effect of TLR6 knock-
down on IL-6 production was determined using ELISA. The amount of IL-6 
secreted by the mock-infected TLR6 knock-down K562 cells was not 




with the control shRNA (Figure 3.8). However, upon dengue virus infection, 
IL-6 production by K526 cells transfected with psiRNA-hTLR6 was 
significantly lower than that of the K562 cells transfected with psiRNA-
LucGL3 from day 1 to day 5 post-infection (Figure 3.8). These results 
suggested that TLR6 was activated during dengue virus infection and the 
activation of TLR6 can contribute to IL-6 expression during dengue virus 
infection. 
 



















Figure 3.8 Amount of IL-6 detected in the TLR6 knockdown K562 cell 
culture supernatants quantified using ELISA. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected and DV2-infected psiRNA-LucGL3- and 
psiRNA-hTLR6-transfected K562 cells. Data represent mean ± SEM of three 
independent experiments. * denotes p-value < 0.05, ** denotes p-value < 
0.005 for t-tests comparing mean amount of IL-6 detected in culture 
supernatants of psiRNA-hTLR6-transfected K562 cells to that of the psiRNA-


























4.0 TLR6 AND TLR2 OF HUMAN PBMC ARE ACTIVATED BY 
DENGUE NS1 PROTEIN DURING DENGUE VIRUS INFECTION 
4.1 INTRODUCTION 
TLR6 up-regulation in K562 cells during dengue virus infection was 
validated in the previous chapter. TLR6 pathway activation and contribution 
to IL-6 expression during DV2 infection were observed in K562 cells. 
However, TNF-α expression and contribution through TLR6 pathway 
activation during DV2 infection could not be determined using K562 cells. 
The possible reason for that will be discussed in Chapter 6. This emphasizes 
the shortcoming of using the continuous cell line for our study on TLR6 
activation. 
Since PBMC represent a population consisting of various immune cells 
which are likely to play important role in the disease progression of dengue 
and are also targets of DV during an infection, PBMC will more closely 
represent a physiological system than established cell lines (Durbin et al, 
2008). PBMC will be used as the cell model to investigate TLR2 and TLR6 
involvement in dengue virus infection in this chapter. 
The activation of TLR2 and TLR6 by some viruses has only been 
discovered recently and not much is known about which component of the 
viruses is responsible for the activation (Chang et al, 2007; Murawski et al, 
2009). Chang and co-workers (2007) found that core protein and NS3 protein 
of hepatitis C virus are the viral proteins responsible for activation of TLR2 
and TLR6. We would also explore which viral protein(s) of dengue virus 




Increased endothelial permeability is one of the hallmarks of severe 
dengue diseases (Basu & Chaturvedi, 2008; Trung & Wills, 2010). It is known 
that inflammatory cytokines have an effect on the endothelial permeability 
(Friedl et al, 2002; Gurkan et al, 2011; Seynhaeve et al, 2006). Since 
activation of TLR2 and TLR6 increases inflammatory cytokines, it is likely 
that activation of TLR2 and TLR6 can have an effect on the endothelial 
permeability. In this chapter, the effect of activation of TLR2 and TLR6 on the 
endothelial permeability was also explored.  
 
4.2 HUMAN PBMC IS SUSCEPTIBLE TO DENGUE VIRUS 
INFECTION 
4.2.1 Production of progeny virus by PBMC during dengue virus 
infection was quantified using plaque assay. 
The up-regulation of TLR6 observed in DV2-infected K562 cells was 
investigated in DV2-infected PBMC. Blood from healthy donor was obtained 
for the extraction of PBMC as described in Section 2.1.3. First, the 
susceptibility of the PBMC to DV2 infection was determined using plaque 
assay (Figure 4.1). The virus titer peaked at day 2 post-infection (3.82 






























Figure 4.1 Virus growth curve in PBMC infected with DV2 at M.O.I. of 
10 was obtained using plaque assays. 
PBMC were infected with DV2 at M.O.I of 10 and plaque assays were 
performed to quantify the infectious virus yield from day 1 to 5 post-infection. 
Values plotted are mean ± SEM of three independent experiments performed 
in triplicate. 
 
4.2.2 IL-6 production by PBMC during dengue virus infection was 
quantified by ELISA. 
Next, ELISA was performed to determine the production of IL-6 in 
DV2-infected PBMC. ELISA was performed to quantify the amount of IL-6 
secreted into the extracellular milieu by PBMC cells during dengue virus 
infection (Section 2.4.6). The cell culture supernatants were harvested from 
mock-infected and DV2-infected PBMC as described in Section 2.2.6. DV2-
infected PBMC secreted significantly higher amount of IL-6 than mock-
























Figure 4.2 IL-6 detected in the cell culture supernatants of DV2-infected 
PBMC using ELISA. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected and DV2-infected PBMC. Data represent mean 
± SEM of three independent experiments. * denotes p-value < 0.05, ** 
denotes p-value < 0.005 for Student’s t-tests comparing mean amount of IL-6 
detected in culture supernatants of DV2-infected PBMC to that of the mock-
infected PBMC. 
 
4.2.3 TNF-α production by PBMC during dengue virus infection was 
quantified by ELISA. 
After investigating IL-6 production by PBMC during DV infection, 
TNF-α production by PBMC during DV infection was investigated. ELISA 
was performed to quantify the amount of TNF-α secreted into the extracellular 
milieu by PBMC during dengue virus infection (Section 2.4.6). The cell 
culture supernatants were harvested from mock-infected and DV2-infected 
PBMC as described in Section 2.2.6. DV2-infected PBMC secreted 
significantly higher amount of TNF-α compared to mock-infected PBMC 
starting from day 2 post-infection (257.9 pg/ml for the DV2-infected PBMC 




pg/ml to 91.2 pg/ml for the mock-infected PBMC). Unlike K562 cells, PBMC 
can up-regulate TNF-α upon dengue virus infection.  
 




















Figure 4.3 TNF-α detected in the cell culture supernatants of DV2-
infected PBMC using ELISA. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatants by mock-infected and DV2-infected PBMC. Data represent mean 
± SEM of three independent experiments. * denotes p-value < 0.05, ** 
denotes p-value < 0.005, *** denotes p-value < 0.0001 for Student’s t-tests 
comparing mean amount of TNF-α detected in culture supernatants of DV2-
infected PBMC to that of the mock-infected PBMC. 
 
4.3 TLR2/6 IS UPREGULATED IN HUMAN PBMC DURING DENGUE 
VIRUS INFECTION 
4.3.1 TLR6 expression on PBMC during dengue virus infection was 
analyzed using flow cytometry. 
TLR6 expression on PBMC upon dengue virus infection was 
investigated using flow cytometry. PBMC were stained with anti-TLR6 




described in Section 2.4.5. In addition, PBMC were also stained with anti-
CD14 FITC conjugated antibody to serve as a marker for human monocytes 
and macrophages (Jersmann, 2005; Ziegler-Heitbrock, 2007). 15, 000 CD14+ 
cells were analysed for TLR6 expression upon dengue virus infection. It was 
noticed that most of the TLR6 expressing cells are CD14+. Upon dengue virus 
infection, TLR6 was up-regulated at day 3 post-infection for CD14+ PBMC 
shown by the rightward shift of the histogram of DV2-infected PBMC (Figure 
4.4c). The rightward shift of the histogram indicated a proportion of cell 
population of DV2-infected CD14+ PBMC express higher amount of TLR6 
on the cell surface compared to the mock-infected. Scatterplots of mock-
infected (d, e, f) and DV2-infected PBMC cells (g, h, i) were shown. The 
percentage of cells in the region set is higher for DV2-infected PBMC 
compared to the mock-infected (Table 4.1). This suggests that DV2-infected 
PBMC has a higher proportion of CD14 + cells expressing TLR6 compared to 
the mock-infected. 
 
It was noticed that majority of the TLR6 expressing cells are CD14+ 
and almost all the CD14+ cells are expressing TLR6 (Table 4.3). The 
proportion of cells which are CD14+ and TLR6+ increased for both mock-
infected and DV2-infected PBMC but more so for the DV2-infected PBMC as 
day post-infection increases. The increase proportion of cells which are 
CD14+ for the mock-infected PBMC could be due to proliferation of the 
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Figure 4.4 TLR6 expression on DV2-infected PBMC was analyzed using 
Flow cytometry. 
Mock-infected (Red) and DV2-infected (Green) PBMC were harvested on day 
1 (a), day 2 (b) and day 3 (c) post-infection and stained for TLR6 and CD14. 
The histograms of mock-infected and DV2-infected PBMC were overlaid. 
PBMC were gated to exclude cell debris and to select for CD14+ cells. The 
fluorescence signals of DyLight 633 were detected using allophycocyanin 
channel. 15, 000 CD14+ PBMC were analyzed for each sample. Scatterplots 
of mock-infected (d, e, f) and DV2-infected PBMC cells (g, h, i) were also 
shown. 
 
Treatment Population Percentage p-value 






Table 4.1 Flow cytometric analysis of TLR6 expression of PBMC 
The table shows the population percentage of the flow cytometric analysis in 
Figure 4.4. The population percentage is the percentage of cells in the gated 
region. p-value is obtained using Student’s t-Test. 
 
4.3.2 TLR2 expression on PBMC during dengue virus infection was 
analyzed using flow cytometry. 
As TLR6 is known to heterodimerize with TLR2 for recognition of 
PAMPs, TLR2 expression on PBMC upon dengue virus infection was also 
investigated using flow cytometry (Farhat et al, 2008a; Triantafilou et al, 
2006). PBMC were stained with anti-TLR2 antibody and DyLight 633-
conjugated goat anti-mouse secondary antibody as described in Section 2.4.5. 
In addition, PBMC were also stained with anti-CD14 FITC conjugated 
antibody to serve as a marker for human monocytes and macrophages 




analysed for TLR2 expression upon dengue virus infection. Similar to TLR6, 
TLR2 was up-regulated upon dengue virus infection at day 3 post-infection for 
CD14+ PBMC. This was shown by the rightward shift of the histogram of 
DV2-infected PBMC (Figure 4.5c). The rightward shift of the histogram 
indicated a proportion of cell population of DV2-infected CD14+ PBMC 
expressed higher amount of TLR2 on the cell surface compared to the mock-
infected. Scatterplots of mock-infected (d, e, f) and DV2-infected PBMC cells 
(g, h) were shown. The percentage of cells in the region set is higher for DV2-
infected PBMC compared to the mock-infected (Table 4.2). This suggests that 
DV2-infected PBMC has a higher proportion of CD14 + cells expressing 
TLR2 compared to the mock-infected. 
Similar to TLR6 expressing cells, it was noticed that most of the TLR2 
expressing cells are CD14+ and almost all the CD14+ cells are expressing 
TLR2 (Table 4.4). Like what as observed for TLR6+ PBMC, the proportion of 
cells which are CD14+ and TLR2+ increased for both mock-infected and 
DV2-infected PBMC but more so for the DV2-infected PBMC as day post-
infection progresses. CD14+ monocytes expressing TLR2 were reported by 
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Figure 4.5 TLR2 expression on DV2-infected PBMC was analyzed using 
Flow cytometry. 
Mock-infected (Red) and DV2-infected (Green) PBMC were harvested on day 
1 (a), day 2 (b) and day 3 (c) post-infection and stained for TLR2 and CD14. 
The cells were gated to exclude cell debris and to select for CD14+ cells. The 
fluorescence signals of DyLight 633 were detected using allophycocyanin 
channel. 15, 000 cells were analyzed for each sample. Scatterplots of mock-
infected (d, e, f) and DV2-infected PBMC cells (g, h) were also shown. 
 
Treatment Population Percentage p-value 





Table 4.2 Flow cytometric analysis of TLR2 expression of PBMC 
The table shows the population percentage of the flow cytometric analysis in 
Figure 4.5. The population percentage is the percentage of cells in the gated 
region. p-value is obtained using Student’s t-Test. 
 
Treatment Mock-infected DV2-infected 
Receptor CD14+ TLR6+ CD14+ TLR6+ 
Day 1 51.23 99.84 53.23 99.77 
Day 2 51.37 99.88 58.26 99.91 
Day 3 53.21 99.94 59.24 99.95 
Table 4.3 Analysis of CD14+ and TLR6+ cells of DV2-infected PBMC in 
Figure 4.4. 
Under the CD14+ column is the percentage of TLR6+ cells that were CD14+. 
Under the TLR6+ column is the percentage of CD14+ cells that were TLR6+. 
 
Treatment Mock-infected DV2-infected 
Receptor CD14+ TLR2+ CD14+ TLR2+ 
Day 1 54.28 99.95 58.67 99.95 
Day 2 58.06 99.95 65.29 99.96 
Day 3 64.55 99.97 72.67 99.95 
Table 4.4 Analysis of CD14+ and TLR2+ cells of DV2-infected PBMC in 
Figure 4.5. 
Under the CD14+ column is the percentage of TLR2+ cells that were CD14+. 




4.3.3 Flow cytometric analysis of both TLR2/6 on PBMC during dengue 
virus infection. 
The expression of TLR6 and TLR2 on PBMC upon dengue virus 
infection was analyzed simultaneously using flow cytometry. TLR6 was 
stained with DyLight 633 conjugated secondary antibody while TLR2 was 
stained with FITC conjugated secondary antibody as described in Section 
2.4.5. It was observed that more cells were in region 2 for the DV2-infected 
PBMC (Figure 4.6b) compared to that of the mock-infected PBMC (Figure 
4.6a). The percentage of cells positive for TLR2 and TLR6 was 41.11 for 
DV2-infected PBMC while that of the mock-infected cells was 29.53 (Table 
4.5). It was also observed that the median fluorescence intensity of the TLR2 
and TLR6 were higher for the DV2-infected than the mock-infected (Table 
4.5). Comparing R1 and R4 of mock-infected and DV2-infected PBMC, DV2-
infected PBMC has lower total percentage of cells (7.11%) in these regions 
than mock-infected PBMC (13.45%). This could suggest that those cells 
which were initially only expressing either TLR2 or TLR6 started expressing 
both receptors upon DV2-infection. Comparing R1, R2 and R4 of mock-
infected and DV2-infected PBMC, DV2-infected PBMC has a higher 
percentage of cell population (48.21%) in these regions than the mock-
infected (42.98%). As R1, R2 and R4 contain cells which express TLR2 or 
TLR6 or both TLRs, the increase in total percentage of cells in these regions 
may suggest that during DV2 infection, cells which were initially not 
expressing these receptors started expressing them after DV2 infection. 
Together these data suggest that DV2 infection not only increases expression 




stimulated those cells which were not expressing TLR2 and TLR6 to express 
them, resulting in the overall increase in TLR2 and TLR6 expression seen in 





























Figure 4.6 Scatter plots of flow cytometric analysis of TLR2 (FITC) and 
TLR6 (APC) expression on PBMC.  
PBMC were mock-infected (a) and DV2-infected (b). The PBMC were 
harvested at day 3 post-infection and stained using rabbit anti-TLR6 antibody, 
goat anti-rabbit DyLight 633 (APC) antibody and mouse anti-TLR2 antibody 
conjugated with FITC. Region 1 (R1) contains cells which are negative for 
FITC but positive for APC. Region 2 (R2) contains cells which are positive for 
both FITC and APC. Region 3 (R3) contains cells which are negative for both 
FITC and APC. Region 4 (R4) contains cells which are positive for FITC but 
negative for APC. 30, 000 cells were analyzed. 
 
 
Table 4.5 Analysis of TLR2+ and TLR6+ cells of DV2-infected PBMC. 
Mock-infected (a) and DV2-infected (b) PBMC were harvested at day 3 post-
infection and stained using rabbit anti-TLR6 antibody, goat anti-rabbit 
DyLight 633 (APC) antibody and mouse anti-TLR2 antibody conjugated with 
FITC. 30, 000 cells were analyzed using flow cytometry. The number of cells 
in the different regions is expressed as percentage to the total number of cell 
analyzed. The median of the fluorescence of the cells in the different region is 
also given. Region 1 (R1) contains cells which are negative for FITC but 
positive for APC. Region 2 (R2) contains cells which are positive for both 
FITC and APC. Region 3 (R3) contains cells which are negative for both FITC 
and APC. Region 4 (R4) contains cells which are positive for FITC but 
negative for APC. Region 5 (R2 + R4) contains cells which express TLR2. 




4.4 TLR2/6 IS INVOLVED IN THE PRODUCTION OF IL-6 AND TNF-
α DURING DENGUE VIRUS INFECTION 
4.4.1 ELISA to quantify the amount of IL-6 production when TLR2/6 of 
PBMC is blocked during dengue virus infection. 
Primary cells like PBMC cannot be maintained in culture for long and 
thus transfection of shRNA plasmid into PBMC to get stable cell line with 
TLR2/6 knock-down is not feasible. Furthermore, PBMC have very low 
transfection efficiency, and therefore transient transfection also posed much 
problem (O'Neill et al, 2001). To investigate the effect of TLR2 and TLR6 
activation upon dengue virus infection, an alternate method of using blocking 
antibodies to interfere with TLR2 and TLR6 signalling was adopted (Section 
2.10). This approach has been successfully used by several research groups 
(Fong et al, 2010; Li et al, 2013; Meng et al, 2004).  
Prior to infection or treatment with stimulus, the PBMC were first 
blocked using TLR2/6 neutralizing antibodies. The supernatant of the treated 
PBMC were collected at day 2 post-treatment and IL-6 was quantified using 
ELISA as described in Section 2.4.6. MALP-2 is a specific agonist for TLR2/6 
(Takeuchi et al, 2001). Blocking of TLR2 and 6 can reduce the amount of IL-6 
produced by PBMC when stimulated by LPS (5 μg/ml) or MALP-2 (50 
ng/ml), compared to that of the isotype control (Figure 4.7). This suggested 
that TLR2/6 is the receptor activated by those ligands to result in the increase 
in IL-6. Blocking of TLR2 and TLR6 also reduced the amount of IL-6 




and TLR6 are activated during dengue virus infection and this activation led to 




























































Figure 4.7 Amount of IL-6 detected in the supernatant of PBMC culture 
when TLR2 and TLR6 were blocked. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected, DV2-infected, LPS-treated and MALP-2 
treated PBMC on day 2 post-treatment. Data represent mean ± SEM of three 
independent experiments. * denotes p-value < 0.05, ** denotes p-value < 
0.005, *** denotes p-value < 0.0001 for t-tests comparing mean amount of IL-
6 detected in culture supernatants of TLR2 and TLR6 blocked PBMC to that 
of the isotype control PBMC. 
 
4.4.2 ELISA to quantify the amount of TNF-α production when TLR2/6 
of PBMC is blocked during dengue virus infection. 
TLR2 and TLR6 of PBMC were blocked using TLR2/6 neutralizing 
antibodies before subjected to infection or treatment with stimulus. The 
supernatant of the treated PBMC were collected at day 2 post-treatment and 




TLR2 and 6 can reduce the amount of TNF-α produced by PBMC when 
stimulated by LPS (5μg/ml) or MALP-2 (50 ng/ml), compared to that of the 
isotype control (Figure 4.8). This suggested that TLR2/6 are the receptors 
activated by these ligands to result in the increase in TNF-α. Blocking of 
TLR2 and TLR6 also reduced the amount of IL-6 produced by PBMC during 
dengue virus infection, this suggested that TLR2 and TLR6 were activated 































































Figure 4.8 Amount of TNF-α detected in the supernatant of PBMC 
culture when TLR2 and TLR6 were blocked. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected, DV2-infected, LPS-treated and MALP-2-
treated PBMC on day 2 post-treatment. Data represent mean ± SEM of three 
independent experiments. * denotes p-value < 0.05, ** denotes p-value < 
0.005, *** denotes p-value < 0.0001 for t-tests comparing mean amount of 
TNF-α detected in culture supernatants of TLR2 and TLR6 blocked PBMC to 




4.5 DENGUE NS1 IS THE VIRAL PROTEIN THAT ACTIVATES 
TLR6/TLR2 
4.5.1 IL-6 production by PBMC after treatment with dengue viral protein 
was quantified by ELISA. 
ELISA was performed to determine which of the viral protein(s) can 
induce up-regulation of IL-6 in PBMC. The detection of up-regulation of IL-6 
by PBMC will indicate possible activation of receptor by the dengue viral 
proteins. ELISA was performed to quantify the amount of IL-6 secreted into 
the supernatant by PBMC after treatment with the individual dengue viral 
proteins on day 2 post-treatment. Day 2 post-treatment was chosen as the time 
point based on the ELISA results in Section 4.2.2 and 4.2.3. Both IL-6 and 
TNF-α were significantly up-regulated by DV2-infected PBMC on day 2 post-
infection. Among the dengue viral proteins, DV NS1 protein is the only viral 
protein which stimulated high amount of IL-6 expression (5864 pg/ml) (Figure 
4.9). IL-6 expression was slightly down-regulated by dengue envelope protein 
(296 pg/ml) and NS3 protein (297 pg/ml) compared to His-tag-treated PBMC 
(346 pg/ml). The IL-6 level of His-tag-treated PBMC were comparable to that 
of the untreated, suggesting that His-tag did not trigger IL-6 production and 
the IL-6 detected in the culture supernatant of the His-tag-treated PBMC was 
due to basal expression. The IL-6 level of UV-inactivated DV2-treated PBMC 
was also comparable to the untreated. This suggested that non-replicative virus 
cannot induce IL-6 expression. The positive control, LPS was found to 
stimulate IL-6 production by PBMC in a dose-dependent manner (3518 pg/ml, 

























































































Figure 4.9 IL-6 detected in the PBMC culture supernatants after 
stimulation by dengue viral protein.  
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by PBMC treated with dengue viral proteins treated (capsid, 
envelope, premembrane, NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5, each 
50 μg/ml), His-tag-treated PBMC, untreated PBMC, UV-inactivated DV2-
treated PBMC (10 virus particles per cell), LPS-treated PBMC (5 μg/ml, 10 
μg/ml, 50 μg/ml) on day 2 post-treatment. Data represent mean ± SEM of 
three independent experiments. * denotes p-value < 0.05, ** denotes p-value < 
0.005, *** denotes p-value < 0.0001 for Student’s t-tests comparing mean 
amount of IL-6 detected in culture supernatants of viral protein-treated PBMC 
to that of the His-tag-treated PBMC. Student’s t-tests were also used to 
compare the mean amount of IL-6 detected in culture supernatants of LPS-
treated PBMC to that of the untreated PBMC, the mean amount of IL-6 
detected in the culture supernatants of His-tag-treated PBMC to that of the 
untreated PBMC, the mean amount of IL-6 detected in the culture supernatants 







4.5.2 TNF-α production by PBMC after treatment with dengue viral 
protein was quantified by ELISA. 
ELISA was also performed to determine which of the viral protein can 
induce up-regulation of TNF-α by PBMC. The detection of up-regulation of 
TNF-α by PBMC will indicate possible activation of receptor by the dengue 
viral proteins. ELISA was performed to quantify the amount of TNF-α 
secreted into the supernatant by PBMC after treatment with the individual 
dengue viral proteins. Among the dengue viral proteins, DV NS1 protein is the 
only viral protein which stimulated high amount of TNF-α expression (293 
pg/ml) (Figure 4.10) compared to that of the His-tag-treated PBMC (30 
pg/ml). The TNF-α level of His-tag-treated PBMC were comparable to that of 
the untreated, suggesting that His-tag did not trigger TNF-α production and 
the TNF-α detected in the culture supernatant of the His-tag-treated PBMC 
was due to basal expression. The TNF-α level of UV-inactivated DV2-treated 
PBMC was also comparable to the untreated. This suggests that non-
replicative virus cannot induce TNF-α expression. The positive control, LPS 
was found to stimulate TNF-α production by PBMC in a dose-dependent 



























































































Figure 4.10 TNF-α detected in the PBMC culture supernatants after 
stimulation by dengue viral protein. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatant by PBMC treated with dengue viral proteins (capsid, envelope, 
premembrane, NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5, each 50μg/ml), 
His-tag-treated PBMC, untreated PBMC, UV-inactivated DV2-treated PBMC 
(10 virus particles per cell), LPS-treated PBMC (5 μg/ml, 10 μg/ml, 50 μg/ml) 
on day 2 post-treatment. Data represent mean ± SEM of three independent 
experiments. * denotes p-value < 0.05, ** denotes p-value < 0.005, *** 
denotes p-value < 0.0001 for t-tests comparing mean amount of TNF-α 
detected in culture supernatants of viral protein-treated PBMC to that of the 
His-tag-treated PBMC. Student’s t-tests were also used to compare the mean 
amount of TNF-α detected in culture supernatants of LPS-treated PBMC to 
that of the untreated PBMC, the mean amount of TNF-α detected in the 
culture supernatants of His-tag-treated PBMC to that of the untreated PBMC, 
the mean amount of TNF-α detected in the culture supernatants of UV-








4.5.3 IL-6 production by PBMC after treatment with DV NS1 protein was 
quantified by ELISA.  
Next, the amount of IL-6 produced by DV NS1 protein-treated PBMC 
was quantified for four days post-treatment. Lower amount of DV NS1 protein 
was used for the stimulation (1 μg/ml). ELISA was performed to quantify the 
amount of IL-6 in the supernatants of DV NS1-treated PBMC on day 1 to day 
4 post-treatment as described in Section 2.4.6. DV NS1 protein-treated PBMC 
produced significantly higher amount of IL-6 compared to that of the His-tag-
treated PBMC (Control) from day 1 post-treatment (Figure 4.11). The up-
regulation is faster than that of the DV2-infected PBMC which only produced 
significantly higher IL-6 from day 2 post-treatment (Figure 4.2). The delay 
could be due to time taken for DV NS1 protein synthesis. The IL-6 produced 



























Figure 4.11 IL-6 detected in the PBMC culture supernatants after 
stimulation by DV NS1 protein. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by DV NS1 protein-treated PBMC (1 μg/ml) on day 1 to day 4 
post-treatment. Data represent mean ± SEM of three independent experiments. 
* denotes p-value < 0.05, ** denotes p-value < 0.005 for t-tests comparing 
mean amount of IL-6 detected in culture supernatants of DV NS1 protein-
treated PBMC to that of the His-tag-treated PBMC (control).  
 
4.5.4 TNF-α production by PBMC after treatment with DV NS1 protein 
was quantified by ELISA.  
Next, the amount of TNF-α produced by DV NS1 protein-treated 
PBMC was quantified for four days post-treatment. ELISA was performed to 
quantify the amount of TNF-α in the supernatants of DV NS1 protein-treated 
PBMC on day 1 to day 4 post-treatment as described in Section 2.4.6. DV 
NS1 protein-treated PBMC produced significantly higher amount of TNF-α 
compared to that of the His-tag-treated PBMC (Control) from day 1 post-
treatment (Figure 4.12). The amount of TNF-α produced by DV NS1 protein-
treated PBMC peaked at day 1 post-treatment (226 pg/ml). The amount of 




differences in the TNF-α level between different samples. These unusual 
phenomenal could be due to the PBMC starting to undergo cell death after 4 
days in culture. 



















Figure 4.12 TNF-α detected in the PBMC culture supernatants after 
stimulation by DV NS1 protein. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatant by DV NS1 protein-treated PBMC (1 μg/ml) on day 1 to day 4 
post-treatment. Data represent mean ± SEM of three independent experiments. 
* denotes p-value < 0.05, ** denotes p-value < 0.005 for t-tests comparing 
mean amount of TNF-α detected in culture supernatants of DV NS1 protein-
treated PBMC to that of the His-tag-treated PBMC (control).  
 
4.5.5 ELISA to quantify IL-6 production when TLR2/6 of PBMC is 
blocked prior to DV NS1 protein treatment  
To determine if the IL-6 production by PBMC upon DV NS1 protein 
stimulation is through TLR2 and TLR6, TLR2 and TLR6 neutralizing 
antibodies were used described in Section 2.10. TLR2 and TLR6 of PBMC 
were blocked prior to addition of DV NS1 protein into the PBMC culture (1 




treatment and IL-6 was quantified using ELISA as described in Section 2.4.6. 
Day 1 was chosen as the time point as IL-6 was found to be significantly up-
regulated on day 1 post-treatment in Figure 4.11. The IL-6 amount secreted by 
His-tag-treated PBMC was not affected by the neutralizing antibodies as 
shown by the comparable levels of IL-6 detected in the supernatants of His-
tag-treated PBMC with prior treatment of isotype and neutralizing antibodies 
(Figure 4.13). Thus, TLR2 and TLR6 were not involved in the IL-6 secretion 
by the His-tag-treated PBMC. The IL-6 detected in the supernatant of His-tag 
treated PBMC was most probably basal level expression. With both TLR2 and 
TLR6 blocked, IL-6 secreted by DV NS1 protein-treated PBMC was 
significantly reduced compared to that of the isotype control. With only TLR6 
blocked, IL-6 secreted by DV NS1 protein-treated PBMC was comparable to 
that of both TLR2 and TLR6 blocked. Therefore, DV NS1 protein stimulation 
of TLR2 and TLR6 is dependent on both receptors working together, the 
stimulation is inhibited when one of the receptors is blocked. With only TLR2 
blocked, IL-6 secreted by DV NS1 protein-treated PBMC was significantly 
reduced and surprisingly lower than that of the His-tag-treated PBMC. The 
TLR2 neutralizing antibody may have some effect on the basal IL-6 
expression of PBMC but the reason as to why IL-6 expression of the His-tag-
treated PBMC was not affected in this case was unexpected. TLR2 
neutralizing antibody was found to be more effective than TLR6 neutralizing 
antibody. The expected level of IL-6 for DV NS1 protein-treated PBMC with 
both TLR2 and TLR6 blocked was in between the level of IL-6 for those with 
TLR2 blocked only and those with TLR6 blocked only. This is because 




amount of TLR2 neutralizing antibody and half the amount of TLR6 
neutralizing antibody, so that the total amount of antibodies added for all 
treatment including the isotype control were the same. The unexpected result 
could be due to some of the TLR2 antibody cross-reacting with the TLR6 
antibody and affected the effectiveness of the neutralizing antibody. In 
summary, PBMC which were treated with TLR2/6 neutralizing antibodies 
secreted less IL-6 compared to the isotype control. Together, these data imply 




























































Figure 4.13 Amount of IL-6 detected in the supernatant of DV NS1 
protein-treated PBMC culture when TLR2 and TLR6 were blocked. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by DV NS1 protein-treated PBMC (1 μg/ml) on day 1 post-
treatment. TLR2 and TLR6 of the PBMC were blocked prior to the treatment. 
Data represent mean ± SEM of three independent experiments. * denotes p-
value < 0.05, ** denotes p-value < 0.005 for t-tests comparing mean amount 
of IL-6 detected in culture supernatants of DV NS1 protein-treated PBMC 
isotype control to that of DV NS1 protein-treated TLR2/6 blocked PBMC. 
 
4.5.6 ELISA to quantify TNF-α production when TLR2/6 of PBMC is 
blocked prior to DV NS1 protein treatment.  
To determine if the TNF-α production by PBMC upon DV NS1 protein 
stimulation is through TLR2 and TLR6, TLR2 and TLR6 neutralizing 
antibodies were used as described in Section 2.10. TLR2 and TLR6 of PBMC 
were blocked prior to addition of DV NS1 protein into the PBMC culture (1 




treatment and TNF-α was quantified using ELISA as described in Section 
2.4.6. Day 1 was chosen as the time point as TNF-α was found to be 
significantly up-regulated on day 1 post-treatment in Figure 4.12. Similar to 
what was observed for IL-6, the TNF-α amount secreted by His-tag-treated 
PBMC in general, was not affected by the neutralizing antibodies (Figure 
4.14). Thus, TLR2 and TLR6 were not involved in the TNF-α secretion by the 
His-tag-treated PBMC. The TNF-α detected in the supernatant of His-tag 
treated PBMC was most probably basal level expression. With both TLR2 and 
TLR6 blocked, TNF-α secreted by DV NS1 protein-treated PBMC was 
significantly reduced compared to that of the isotype control. With only TLR6 
blocked, TNF-α secreted by DV NS1-treated PBMC was comparable to that of 
both TLR2 and TLR6 blocked. With only TLR2 blocked, TNF-α secreted by 
DV NS1 protein-treated PBMC was significantly reduced. Unlike what was 
observed for IL-6, with only TLR2 neutralizing antibody, the basal TNF-α 
expression of His-tag-treated PBMC was affected, as shown by the lower 
TNF-α level of the TLR2 blocked His-tag-treated PBMC compared to that of 
the isotype control His-tag-treated PBMC. Similar to what was observed for 
the IL-6, when both TLR6 and TLR2 blocking antibodies were added, the 
reduction of TNF-α secretion was less than adding TLR6 or TLR2 blocking 
antibody separately. In summary, PBMC which were treated with TLR2/6 
neutralizing antibodies secreted less TNF-α compared to the isotype control. 



























































Figure 4.14 Amount of TNF-α detected in the supernatant of DV NS1-
protein treated PBMC culture when TLR2 and TLR6 were blocked. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatant by DV NS1 protein-treated PBMC (1 μg/ml) on day 1 post-
treatment. TLR2 and TLR6 of the PBMC were blocked prior to the treatment. 
Data represent mean ± SEM of three independent experiments. * denotes p-
value < 0.05, ** denotes p-value < 0.005 for t-tests comparing mean amount 
of TNF-α detected in culture supernatants of DV NS1 protein-treated PBMC 
isotype control to that of DV NS1 protein-treated TLR2/6 blocked PBMC. 
 
4.5.7 Western blot analysis of TLR2 and TLR6 expression of HEK293 
cells. 
In the TLR2/6 signalling pathway, NFκB is an important transcription 
factor that is involved in the expression of cytokines like IL-6 and TNF-α 
(Blackwell & Christman, 1997; Brandt et al, 2013; Libermann & Baltimore, 
1990). A reporter assay for screening TLR agonists and antagonists using NF-
κB response element was developed and used by many research groups (Clark 




secreted alkaline phosphatase (SEAP) reporter whose expression is under 
control of an NF-κB response element. HEK293 cell line which naturally does 
not possess many of the TLR was also used for the reporter assay. HEK293 
cells has good transfection efficiency to allow expression of desired TLR and 
the SEAP reporter plasmid for investigating specific TLR ligand. According to 
literature search, HEK 293 cells were found to express low level of 
endogenous TLR6 but not TLR2 (Bowdish et al, 2009; Farhat et al, 2008b). 
To further confirm DV NS1 protein as the agonist of TLR2 and TLR6, the 
SEAP reporter assay was used as described in Section 2.6. The SEAP reporter 
plasmid, TLR2/6 expression plasmid or TLR6 silencing plasmid was 
transfected into HEK 293 cell line as described in Section 2.5 and 2.7. The 
expression of TLR2 and TLR6 in the untransfected and transfected HEK 293 
cell line was determined using Western blot analysis (Figure 4.15). TLR2 was 
not expressed endogenously in HEK293 as TLR2 bands were only detected in 
HEK 293 cells which has been transfected with TLR2/6 expressing plasmid 
(Figure 4.15a). The relative density of the TLR2 bands was plotted on a graph 
(Figure 4.15b). TLR6 bands were detected in HEK 293 cells and those 
transfected with TLR2/6 expressing plasmid had higher expression indicated 
by the darker bands (Figure 4.15c). HEK 293 cells transfected with TLR6 
silencing plasmid expressed lower amount of TLR6, approximately 55% 






















































































































































































Figure 4.15 Western blot analyses of TLR2 and TLR6 protein expression 
in untransfected and transfected HEK 293 cells. 
Untransfected HEK 293 cells and HEK 293 cells transfected with SEAP 
reporter plasmid, pDUO-hTLR6/TLR2 plasmid, psiRNA-LucGL3 plasmid 
and psiRNA-hTLR6 plasmid were lysed and equal total protein was loaded 
into SDS-PAGE gel. The presence of TLR2 protein in the cell lysate was 
detected using rabbit anti-TLR2 antibody and goat anti-rabbit HRP conjugated 
antibody on the Western blot (a). Actin was used as loading control. The band 
intensity was measured using GelQuantNET software program. The intensities 
of the TLR2 bands were normalized against the intensity of the corresponding 
actin bands and were plotted in the graph (b). The presence of TLR6 protein in 
the cell lysate was detected using rabbit anti-TLR6 antibody and goat anti-
rabbit HRP conjugated antibody on the Western blot (c). The intensities of the 
TLR6 bands were normalized against the intensity of the corresponding actin 
bands and were plotted in the graph (d). The expression of TLR6 by NFκB & 
psi-LucGL3 was compared against NFκB & psi-hTLR6 (e). 
 
4.5.8 NK-κB is activated by DV NS1 protein in the presence of TLR2 and 
TLR6. 
After verifying the expression of TLR2 and TLR6 in the transfected 
HEK 293 cells, SEAP reporter assay was used to determine if DV NS1 protein 
is activating TLR2 and TLR6 as described in Section 2.6. A commercially 
available full length DV NS1 recombinant protein was also used in addition to 
the DV NS1 protein obtained from the Baculovirus expression system. LPS 
and MALP-2 were used as positive control. For HEK 293 cells transfected 
with only SEAP reporter plasmid, the SEAP secretion by HEK 293 cells 
treated with DV NS1 protein and the positive controls were not significantly 
different from the negative controls (untreated and His-tag-treated HEK 293 
cells) (Figure 4.16a). This suggests that DV NS1 protein, LPS and MALP-2 
cannot stimulate NFκB activation in the absence of TLR2. DV2-infected HEK 




suggests that DV2-infection can trigger NFκB activation through pathway 
independent of TLR2. For HEK 293 cells transfected with both SEAP reporter 
plasmid and TLR2/6 expression plasmids, the SEAP secretion by HEK 293 
cells treated with DV NS1 protein and the positive controls were significantly 
different from the negative controls from day 1 post-treatment (Figure 4.16b). 
This agrees with the results in Section 4.5.3 and 4.5.4 where IL-6 and TNF-α 
were significantly increased on day 1 post-treatment in DV NS1 protein-
treated PBMC. The result suggests that activation of NFκB by DV NS1 
protein is dependent on both TLR2 and TLR6. This agrees with the results in 
Section 4.5.5 and 4.5.6. DV2-infected HEK 293 cells secreted significantly 
more SEAP compared to the mock-infected HEK 293 cells from day 2 post-
infection. This agrees with the results in Section 4.2.2 and 4.2.3 where IL-6 
and TNF-α of DV2-infected PBMC increased significantly at day 2 post-
infection. It was noticed that the SEAP expression of the HEK 293 cells was 
increased with the expression of TLR2 and TLR6 when comparing the 
negative controls of Figure 4.16a and Figure 4.16b. To determine if the NFκB 
activation observed in Figure 4.16a could be due to the effect of TLR6 alone, 
HEK 293 cells were transfected with both SEAP reporter plasmid and TLR6 
silencing plasmid. The SEAP secretion by DV2-infected HEK 293 cells 
transfected with non-targeting control was not significantly different from 
DV2-infected HEK 293 cells transfected with TLR6 silencing plasmid (Figure 
4.16c). The NFκB activation detected in DV2-infected HEK293 cell in the 
absence of TLR2 and with TLR6 knock-down was due to activation of other 
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Figure 4.16 NFκB activation by DV NS1 protein was assayed using SEAP 
reporter assay. 
HEK 293 cells transfected with SEAP reporter plasmid (a), HEK 293 cells 
transfected with both SEAP reporter plasmid and pDUO-hTLR6/TLR2 
plasmid (b) and HEK 293 cells transfected with both SEAP reporter plasmid 
and psiRNA-LucGL3 or psiRNA-hTLR6 (c) were treated with His-tag (1 
μg/ml), DV NS1 recombinant protein (1 μg/ml), LPS (5 μg/ml), MALP-2 (50 
ng/ml), mock-infected or DV2-infected (M.O.I of 10). The supernatants of the 
HEK 293 cell cultures were harvested at day 1 to day 3 post-treatment. The 
SEAP in the supernatants were quantified using SEAP reporter assay kit. Data 
represent mean ± SEM of three independent experiments. * denotes p-value < 
0.05, ** denotes p-value < 0.005, *** denotes p-value < 0.0001 for t-tests 
comparing mean amount of SEAP detected in culture supernatants of DV NS1 
protein-treated HEK 293 cells to that of His-tag-treated HEK 293 cells, mock-
infected HEK 293 cells to that of DV2-infected HEK 293 cells, LPS-treated 
HEK 293 cells to that of untreated and MALP-2 HEK 293 cells to that of 
untreated. 
 
4.5.9 DV NS1 protein is secreted by DV2-infected PBMC. 
DV NS1 protein has been identified to be the viral protein that 
activates TLR2 and TLR6. As both TLR2 and TLR6 are cell surface receptors, 
DV NS1 protein secretion by DV2-infected PBMC will provide a mean for 




secretion by DV2-infected PBMC was assessed using Bio-Rad Platelia 
Dengue NS1 Antigen detection kit. 
When the assay was first attempted, neat supernatant from mock-
infected and DV2-infected PBMC were used, the optical density obtained for 
the DV2-infected PBMC samples were all close to detection limit and no trend 
was observed from day 0 to day 6 post-infection. This was most likely due to 
the sensitivity of the assay and the amount of DV NS1 protein in DV2-
infected PBMC supernatant was too high for the assay. However, the readings 
of the mock-infected samples remained low, suggesting the specificity of the 
assay. In the second attempt, each sample was diluted 10x to prevent 
saturation of DV NS1 protein in the assay. After dilution, a trend for the DV 
NS1 protein secretion by DV2-infected PBMC samples across the 6 days of 
infection was observed (Figure 4.17). Samples harvested at day 0 post-
infection was used to assess the amount of DV NS1 protein left over in the 
PBMC culture after infection. The relative OD for day 0 is significantly higher 
for DV2-infected PBMC than mock-infected PBMC, suggesting that low 
amount of DV NS1 protein remained in the culture of DV2-infected PBMC 
after infection despite PBS washes. The secretion of DV NS1 protein into 
supernatants increases from day 2 post-infection and peaked at day 5 post-





























Figure 4.17 DV NS1 protein secretion into supernatants of DV2-infected 
PBMC culture. 
Supernatants of mock-infected and DV2-infected PBMC cultures were 
harvested at day 0 to day 6 post-infection. The amount of DV NS1 protein in 
the culture was assayed using Bio-Rad Platelia Dengue NS1 Antigen detection 
kit. Relative OD was obtained from the assay. Data represent mean ± SEM of 
three independent experiments. * denotes p-value < 0.05, ** denotes p-value < 
0.005, *** denotes p-value < 0.0001 for t-tests comparing mean relative OD 
detected in culture supernatants of DV2-infected PBMC to that of the mock-
infected PBMC.   
 
4.6 DV NS1 PROTEIN UPREGULATES TLR2/6 OF PBMC DURING 
DENGUE VIRUS INFECTION 
4.6.1 Western blot analysis of TLR6 expression after treatment with DV 
NS1 protein. 
DV2-infection was found to up-regulated TLR6 in PBMC (Section 
4.3). To determine if this up-regulation is due to DV NS1 protein, Western 
blot analysis was used as described in Section 2.4.4. PBMC were treated with 
His-tag (1 μg/ml), DV NS1 protein (1 μg/ml), LPS (5 μg/ml), mock-infected 
or DV2-infected (M.O.I of 10). TLR6 bands of DV2-infected, DV NS1 




infected and His-tag-treated PBMC (Figure 4.18a). The relative density of the 
TLR6 bands normalized against the actin bands was plotted on a graph (4.18b) 






























































Figure 4.18 Western blot analyses of TLR6 protein expression in DV NS1 
protein-treated PBMC. 
Mock-infected, His-tag-treated, DV2-infected, DV NS1 protein-treated, LPS-
treated PBMC were lysed and equal total protein was loaded into SDS-PAGE 
gel. The presence of TLR6 protein in the cell lysate was detected using rabbit 
anti-TLR6 antibody and goat anti-rabbit HRP conjugated antibody on the 
Western blot (a). Actin was used as loading control. The band intensity was 
measured using GelQuantNET software program. The intensities of the TLR6 
bands were normalized against the intensity of the corresponding actin bands 






4.6.2 Western blot analysis of TLR2 expression after treatment with DV 
NS1 protein. 
DV2-infection was found to up-regulate TLR2 in PBMC (Section 4.3). 
To determine if this up-regulation is due to DV NS1 protein, Western blot 
analysis was used as described in Section 2.4.4. PBMC were treated with His-
tag (1 μg/ml), DV NS1 protein (1 μg/ml), LPS (5 μg/ml), mock-infected or 
DV2-infected. TLR2 bands of DV2-infected, DV NS1 protein-treated and 
LPS-treated PBMC were darker than those of mock-infected and His-tag-
treated PBMC (Figure 4.19a). The relative density of the TLR2 bands 
normalized against the actin bands was plotted on a graph (4.19b) The result 

























































Figure 4.19 Western blot analyses of TLR2 protein expression in DV NS1 
protein-treated PBMC. 
Mock-infected, His-tag-treated, DV2-infected, DV NS1 protein-treated, LPS-
treated PBMC were lysed and equal total protein was loaded into SDS-PAGE 
gel. The presence of TLR2 protein in the cell lysate was detected using rabbit 
anti-TLR2 antibody and goat anti-rabbit HRP conjugated antibody on the 
Western blot (a). Actin was used as loading control. The band intensity was 
measured using GelQuantNET software program. The intensities of the TLR2 
bands were normalized against the intensity of the corresponding actin bands 





4.6.3 TLR6 and TLR2 expression on PBMC during dengue virus infection 
were analyzed using immunofluorescence analyses. 
TLR6 and TLR2 expression on PBMC were further investigated using 
immunofluorescence analyses. Mock-infected and DV2-infected PBMC were 
harvested at day 3 post-infection and stained for TLR6/TLR2 and CD14. The 
staining of untreated PBMC (Figure 4.20a & f) were comparable to that of the 
mock-infected (Figure 4.20b & g) and His-tag-treated PBMC (Figure 4.20d & 
i). Similar to the results obtained in flow cytometric analyses, TLR6/TLR2 
was up-regulated in DV2-infected PBMC (Figure 4.20c & h), indicated by the 
denser red spots compared to the mock-infected PBMC (Figure 4.20b & g). 
TLR6/TLR2 was also up-regulated in DV NS1 protein-treated PBMC (Figure 
4.20e & j) compared to the His-tag-treated PBMC (Figure 4.20 d & i).  
Colocalization of both TLR2 and TLR6 with CD14 were observed for 
untreated, mock-infected, DV2-infected, His-tag-treated and DV NS1 protein-
treated PBMC. Hence, the colocalization of the receptors could be 
independent of infection or DV NS1 protein stimulation. Similar result was 










a)                       b)                      c)                      d)                      e) 
 
f)                        g)                      h)                      i)                       j)          
 
Figure 4.20 Immunofluorescence images of untreated, mock-infected, 
DV2-infected, His-tag-treated and DV NS1 protein-treated PBMC. 
PBMC were untreated (a & f), mock-infected (b & g), DV2-infected (c & h), 
His-tag-treated (d & i) and DV NS1 protein-treated (e & j). The PBMC were 
harvested at day 3 post-treatment. TLR6 is stained red using primary rabbit 
anti-TLR6 antibody and secondary goat anti-rabbit DyLight 633 antibody (a to 
e). TLR2 is stained red using primary mouse anti-TLR2 antibody and 
secondary goat anti-mouse DyLight 633 (f to j). CD14 is stained green using 
anti-CD14 antibody conjugated with FITC (a to j). Cell nuclei are stained blue 
with DAPI. Representative images from triplicate experiments are shown.  
 
4.7 ENDOTHELIAL PERMEABILITY IN HUVEC IS REDUCED 
WHEN TLR6 IS KNOCKED DOWN/BLOCKED DURING DENGUE 
VIRUS INFECTION 
4.7.1 Transendothelial electrical resistance measurement of HUVEC 
seeded on transwells. 
Increased endothelial leakage is one of the symptoms of patient 
suffering from the more severe forms of dengue. Since IL-6 has been 




we investigate whether TLR6 activation affects endothelial permeability in 
human primary endothelial cell, HUVEC (Desai et al, 2002; Maruo et al, 
1992). Endothelial integrity of HUVEC was determined by measuring 
transendothelial electrical resistance (TEER). An increase in endothelial 
permeability is due to loss of cell-cell adhesion resulting in gaps between 
cells. The formation of these gaps in the HUVEC monolayer lowers TEER. 
HUVEC which were treated with TNF-α or IL-6 have much lower TEER 
when compared to untreated HUVEC as early as day 1 post-treatment (Figure 
4.21a). Interestingly, adding of IL-6 neutralizing antibody to the IL-6 treated 
supernatant can completely eliminate the effect of IL-6 on HUVEC 
endothelial integrity. Supernatant of DV2-infected psiRNA-LucGL3 cells 
induced endothelial permeability as indicated by the significantly lower TEER 
when compared to mock-infected psiRNA-LucGL3 (Figure 4.21b). Unlike 
what was observed in Figure 4.21a, IL-6 neutralizing antibody treatment 
increased the integrity of the HUVEC monolayer but not to the same level as 
that of the mock-infected psiRNA-LucGL3 treated with isotype control 
antibody. This suggests that there could be other secretory products in the 
supernatant other than IL-6 that contributed to higher endothelial permeability. 
In Figure 4.21c, the treatment with IL-6 neutralizing antibody on the 
supernatant of DV2-infected psiRNA-hTLR6 increased the integrity of the 
HUVEC monolayer as compared to that treated with supernatant of the DV2-
infected with isotype control antibody. It was noticed that the increase in 
endothelial permeability was minimal for the HUVEC monolayer treated with 
supernatant of DV2-infected psiRNA-hTLR6 and IL-6 neutralizing antibody 




psiRNA-LucGL3 and IL-6 neutralizing antibody. This is probably due to 
DV2-infected psiRNA-hTLR6 expressed less IL-6 when compared to DV2-
infected psiRNA-LucGL3. Comparing Figure 4.21b and Figure 4.21c, 
supernatant of DV2-infected psiRNA-LucGL3 cells induced greater 
endothelial permeability in HUVEC than the supernatant of DV2-infected 
psiRNA-hTLR6 cells. This was indicated by the lower TEER value of the 
HUVEC monolayer treated with supernatant of DV2-infected psiRNA-
LucGL3 as compared to that of DV2-infected psiRNA-hTLR6. In summary, 
the effect of the secretory products of DV2-infected K562 on the HUVEC 
endothelial permeability is reduced when TLR6 is knocked down. Thus, TLR6 
activation resulted in production of secretory products which can increase 
HUVEC endothelial permeability.  
 Supernatants of DV NS1 protein-treated PBMC and His-tag-treated 
PBMC with or without TLR2/6 blocking antibody treatment were harvested 
and added to HUVEC monolayer. His-tag-treated PBMC with or without 
TLR2/6 blocking antibody treatment did not significantly decrease TEER of 
HUVEC compared to the untreated HUVEC, suggesting that His-tag did not 
trigger PBMC to secrete any products which can affect the endothelial 
integrity of HUVEC (Figure 4.21d). Supernatant of DV NS1 protein-treated 
PBMC significantly decreases TEER of HUVEC compared to that of the His-
tag-treated PBMC control from day 1 post-treatment (Figure 4.21e). When 
TLR2/6 blocking antibodies were added to PBMC prior to DV NS1 protein-
treatment, the effect of the supernatant on the HUVEC endothelial 
permeability was reduced, indicated by the smaller reduction in TEER 




suggesting that the secretory products in the supernatant of DV NS1 protein-
treated PBMC was affected by DV NS1 protein activation of TLR2 and TLR6. 
Like what was observed in Figure 4.14 and Figure 4.15, TLR2 blocking 
antibody was more effective, resulting in smaller reduction of TEER. In 
summary, DV NS1 protein activation of TLR2 and TLR6 stimulated secretory 
products by PBMC and these secretory products can affect endothelial 
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Figure 4.21 Effect of TLR2 and TLR6 activation on endothelial 
permeability. 
HUVEC monolayer was treated with IL-6 neutralizing antibody (3 μg/ml), IL-
6 recombinant protein (2000 pg/ml), isotype (iso) control antibody (3μg/ml) 
and IL-6 neutralizing antibody (ab), TNF-α (100 ng/ml) (a). HUVEC 
monolayer was treated with supernatants of mock-infected or DV2-infected 
psiRNA-LucGL3 K562 cells with IL-6 neutralizing antibody treatment or with 
isotype control antibody treatment (b). HUVEC monolayer was treated with 
supernatants of mock-infected or DV2-infected psiRNA-hTLR6 K562 cells 
with IL-6 neutralizing antibody treatment or with isotype control antibody 
treatment (c). HUVEC monolayer was treated with supernatants of His-tag-
treated PBMC with TLR2/6 blocking antibodies or isotype control antibody 
(d). HUVEC monolayer was treated with supernatants of DV NS1 protein-
treated PBMC with TLR2/6 blocking antibodies or isotype control antibody. 
The transendothelial electrical resistance of the HUVEC monolayers on 
transwells  was measured from day 0 to day 3 post-treatment. Data represent 
mean ± S.D. of three independent experiments performed in triplicate. * 
denotes p-value < 0.05, ** denotes p-value < 0.005, *** denotes p-value < 
0.0001 for Student’s t-tests comparing the mean TEER reading of the various 
treatments to the control [untreated for (a), mock-infected psiRNA-LucGL3 + 
iso for (b), mock-infected psiRNA-hTLR6 + iso for (c), untreated for (d) and 
His-tag iso for (e)]. 
 
4.7.2 Immunofluorescence analyses of VE-cadherin in treated HUVEC. 
Furthermore, the effect of TLR6 activation on expression VE-cadherin 
was determined. VE-cadherin is a cell adhesion molecule that plays a critical 
role in maintaining the integrity of endothelial cells (Hordijk et al, 1999). Loss 
of VE-cadherin leads to loss of cell-cell adhesion and results in increased 
endothelial permeability. TNF-α was found to have an effect on VE-cadherin 
expression by down-regulating VE-cadherin gene expression on the 
transcriptional level (Hofmann et al, 2002). The VE-cadherin staining pattern 
of untreated HUVEC consisted of a continuous lining of cell borders with 
strong fluorescence (Figure 4.22a). Like what was observed for Figure 4.22a, 
HUVEC monolayer treated with IL-6 neutralizing antibody exhibited strong 




led to marked decrease in staining and discontinuous lining of VE-cadherin 
(Figure 4.22c). It was also noticed that HUVEC treated with TNF-α were 
more sparsely arranged. This could be due to the tremendous loss of VE-
cadherin which greatly reduced cell-cell adhesion. Treatment with IL-6 also 
led to decrease in staining and disjointed lining of VE-cadherin (Figure 4.22d). 
The effect of IL-6 on the expression of VE-cadherin in HUVEC was 
suppressed when IL-6 neutralizing antibody was added to the IL-6 
recombinant protein prior to adding into HUVEC culture (Figure 4.22e). 
HUVEC treated with mock-infected psiRNA-LucGL3 supernatant (Figure 
4.22f) or treated with mock-infected psiRNA-hTLR6 supernatant (Figure 
4.22g) exhibited similar staining pattern as untreated HUVEC indicating that 
supernatant of mock-infected psiRNA-LucGL3 and psiRNA-hTLR6 do not 
affect VE-cadherin expression. In contrast, HUVEC treated with DV2-infected 
psiRNA-LucGL3 supernatant (Figure 4.22h) resembled that of HUVEC 
treated with TNF-α or IL-6. Hence, DV2-infected psiRNA-LucGL3 
supernatant contains proinflammatory factors like IL-6 which can induce the 
down-regulation of VE-cadherin expression. HUVEC treated with DV2-
infected psiRNA-hTLR6 supernatant showed down-regulation of VE-cadherin 
as shown in Figure 4.22i but not as extensive as HUVEC treated with DV2-
infected psiRNA-LucGL3 supernatant. This suggested knock-down of TLR6 
may reduce the amount of proinflammatory factors produced which could 
have affected VE-cadherin expression between the cell junctions of HUVEC. 
When IL-6 neutralizing antibody was added into the supernatant of mock-
infected psiRNA-LucGL3 supernatant and psiRNA-hTLR6 supernatant 




to that of Figure 4.22f and Figure 4.22g. When IL-6 neutralizing antibody was 
added into the supernatant of DV2-infected psiRNA-LucGL3 supernatant and 
psiRNA-hTLR6 supernatant (Figure 4.22l and Figure 4.22m), the VE-cadherin 
expression was higher than that of Figure 4.22h and Figure 4.22i. This 
suggests that IL-6 was one of the proinflammatory factors that caused the 
down-regulation of VE-cadherin observed in Figure 4.22h and Figure 4.22i.  
 In addition, when supernatant of PBMC treated with His-tag was 
added to the HUVEC monolayer, the VE-cadherin expression is comparable to 
the untreated (Figure 4.22n). When supernatant of PBMC treated with DV 
NS1 protein was added to the HUVEC monolayer, the VE-cadherin 
expression decreased and became discontinuous (Figure 4.22o). This result 
suggests that stimulation of PBMC by DV NS1 protein can increase 
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Figure 4.22 VE-cadherin expression on HUVEC on day 3 post-treatment 
Untreated HUVEC (a), HUVEC treated with IL-6 neutralizing antibody (b), 
HUVEC treated with TNF-α (100 ng/ml) (c), HUVEC treated with IL-6 (2000 
pg/ml) (d), HUVEC treated with IL-6 recombinant protein and IL-6 
neutralizing antibody (e), HUVEC treated with 300 µl of supernatant of mock-
infected psiRNA-LucGL3 (f), HUVEC treated with 300 µl of supernatant of 
mock-infected psiRNA-hTLR6 (g), HUVEC treated with 300 µl of 
supernatant of DV2-infected psiRNA-LucGL3 (h), HUVEC treated with 300 
µl of supernatant of DV2-infected psiRNA-hTLR6 (i), HUVEC treated with 
300 µl of supernatant of mock-infected psiRNA-LucGL3 and IL-6 
neutralizing antibody (j),  HUVEC treated with 300 µl of supernatant of mock-
infected psiRNA-hTLR6 and IL-6 neutralizing antibody (k), HUVEC treated 
with 300 µl of supernatant of DV2-infected psiRNA-LucGL3 and IL-6 
neutralizing antibody (l),  HUVEC treated with 300 µl of supernatant of DV2-
infected psiRNA-hTLR6 and IL-6 neutralizing antibody (m), HUVEC treated 
with 300 μl of supernatant of His-tag-treated PBMC (n) and HUVEC treated 
with 300 μl of supernatant of DV NS1 protein-treated PBMC (o). VE-cadherin 
was stained red and the nuclei of cells were stained blue with DAPI. 






































5.0 TLR6 KNOCKOUT INCREASED SURVIVAL RATE OF MICE 
DURING DENGUE VIRUS INFECTION 
5.1 INTRODUCTION 
In the previous chapters, TLR2 and TLR6 were found to be activated 
by PBMC during dengue virus infection. DV NS1 protein was found to be the 
viral protein which activates TLR2 and TLR6. This activation increased 
expression of IL-6 and TNF-α which are proinflammatory cytokines. The 
expression of proinflammatory cytokines during dengue virus infection has 
been implicated in the immunopathogenesis of the disease. TLR2 and TLR6 
activation was also shown to be able to affect endothelial permeability of 
HUVEC. Thus, this activation could be contributing to the increased 
endothelial permeability observed in patients. Cytokines are known to play 
important role in combating against infection (Cooper et al, 2011). However, 
cytokines are double-edged swords, they have also been known to be the cause 
of certain diseases (Feldmann, 2008; Tisoncik et al, 2012). Hence, the 
activation of TLR2 and TLR6 could be beneficial or detrimental to the host. 
To assess this role, the use of cell model is not sufficient, an animal model is 
needed. One of the most established animal models for dengue research is 
AG129 mice (Johnson & Roehrig, 1999; Julander et al, 2011; Martinez-
Gutierrez et al, 2014; Tan et al, 2010). However, the only strain of TLR6 
knockout (TLR6
-/-
) mice which is available to us is C57BL/6 mice. It has been 
reported that C57BL/6 strain of immunocompetent mice can develop 
hemorrhage, high virus titers, macrophage infiltration and TNF-α production 




5.2 MURINE MODEL FOR DENGUE VIRUS INFECTION 
5.2.1 Plaque assay to quantify the virus titer in 4 week-old DV2-infected 
wild-type C57BL/6 mice.  
Following the animal model developed by Chen and co-workers 
(2007a), C57BL/6 mice at 4 week-old were injected with 1.56 x 10
8 
PFU of 
the same DV2 strain 16681 via intradermal injection as described in Section 
2.11.2. The blood of the mice was harvested as described in Section 2.11.3. 
The viremia of the mice was determined using plaque assay. Virus was not 
detected in the serum of any of the mice on day 1 to 5 and day 21 post-
infection, suggesting that the mice were resistant to the infection (Table 5.1). 
No virus titer was detected even at day 1 post-infection, indicating that the 
innate immune responses of the mice can quickly and efficiently clear the 
virus injected into the mice.  
High doses of DV2 virus has been shown to increase susceptibility of 
mice to DV2 infection (Raut et al, 1996). Hence, C57BL/6 mice at 4 week-old 
were injected with higher amount of virus (1.08 x 10
11 
PFU of DV2 strain 
16681) via intradermal injection. However, no virus was detected both in the 
sera and livers of the mice (Table 5.2). As intraperitoneal injection can inject a 
larger volume of virus into mice, it was explored as an alternate route to infect 
the mice. C57BL/6 mice were injected with 5.4 x 10
11 
PFU of DV2 strain 
16681 via intraperitoneal injection. Very low virus titers (3.333 PFU/ml) were 
detected in the sera of two mice at day 1 and day 3 post-infection (Table 5.3). 
Sera of mock-infected C57BL/6 mice were also titered using plaque assay to 




result of the injected DV2 and not due to any inherent microbes that could be 
present in the mice (Table 5.4). No virus was detected in the sera of mock-
infected C57BL/6 mice, indicating that the virus detected in the sera of DV2-







Serum: PFU/ml       
1 Serum 6 0, 0, 0, 0, 0, 0 
2 Serum 6 0, 0, 0, 0, 0, 0 
3 Serum 6 0, 0, 0, 0, 0, 0 
4 Serum 6 0, 0, 0, 0, 0, 0 
5 Serum 6 0, 0, 0, 0, 0, 0 
21 Serum 6 0, 0, 0, 0, 0, 0 
Table 5.1 Virus titer in 4-week old mice after intradermal infection of 
DV2.  
Wild-type C57BL/6 mice were injected with 1.56 x 10
8
 PFU of DV2 strain 
16681 via intradermal route at 4 points on the back of the mouse. Blood of 
mouse was harvested at day 1, 2, 3, 4, 5 and 21 post-infection via cardiac 
puncture. Sera of the mice were obtained after centrifugation of the clotted 























Serum: PFU/ml       
 Liver: PFU/g 
1 Serum 6 0, 0, 0, 0, 0, 0 
2 Serum 6 0, 0, 0, 0, 0, 0 
3 Serum 6 0, 0, 0, 0, 0, 0 
4 Serum 6 0, 0, 0, 0, 0, 0 
5 Serum 6 0, 0, 0, 0, 0, 0 
21 Serum 6 0, 0, 0, 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.2 Virus titer in 4-week old mice after intradermal infection of 
DV2.  
Wild-type C57BL/6 mice were injected with 1.08 x 10
11
 PFU of DV2 strain 
16681 via intradermal route at 4 points on the back of the mouse. Blood of 
mouse was harvested at day 1, 2, 3, 4, 5 and 21 post-infection via cardiac 
puncture. Sera of the mice were obtained after centrifugation of the clotted 
blood. Livers of the mice were also harvested and homogenized. The virus 







Serum: PFU/ml           
Liver: PFU/g 
1 Serum 6 0, 0, 0, 0, 0, 3.333 
2 Serum 6 0, 0, 0, 0, 0, 0 
3 Serum 6 0, 0, 0, 0, 0, 3.333 
4 Serum 6 0, 0, 0, 0, 0, 0 
5 Serum 6 0, 0, 0, 0, 0, 0 
21 Serum 6 0, 0, 0, 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.3 Virus titer in 4-week old mice after intraperitoneal injection of 
DV2.  
Wild-type C57BL/6 mice were injected with 5.4 x 10
11
 PFU of DV2 strain 
16681 via intraperitoneal injection. Blood of mice was harvested at day 1, 2, 3, 
4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were obtained 
after centrifugation of the clotted blood. Livers of the mice were also 
harvested and homogenized. The virus titers in the sera and livers of the mice 










Serum: PFU/ml       
1 Serum 3 0, 0, 0 
2 Serum 3 0, 0, 0 
3 Serum 3 0, 0, 0 
4 Serum 3 0, 0, 0 
5 Serum 3 0, 0, 0 
21 Serum 3 0, 0, 0 
Table 5.4 Virus titer of dengue virus in 4-week old mice after 
intraperitoneal injection of C6/36 cell culture supernatant.  
Wild-type C57BL/6 mice were injected with ~1 ml of C6/36 cell culture 
supernatant via intraperitoneal injection. Blood of mice was harvested at day 
1, 2, 3, 4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were 
obtained after centrifugation of the clotted blood. The virus titers in the sera of 
the mice were quantified using plaque assays. 
 
5.2.2 Visual assessment of subcutaneous tissue, abdomen and intestine of 
4 week-old mice. 
Hemorrhage is a clinical manifestation of the more severe dengue 
disease (Krishnamurti et al, 2001). Immunocompetent C57BL/6 mice which 
received intradermal inoculations of DV2 were reported to develop 
hemorrhage, high virus titers, macrophage infiltration and TNF-α production 
(Chen et al, 2007a) (Figure 5.1). Following their murine model and using the 
same DV2 strain, hemorrhage was not observed in our 4 week-old DV2-
infected mice (Figure 5.2). In addition, intraperitoneal injection was used as an 








a)                                                            b) 
 
c)                                                            d) 
 
Figure 5.1 Intradermal inoculation of DV induces hemorrhage in 
immunocompetent mice. Figures adapted from (Chen et al, 2007a). 
C57BL/6 mice were injected intradermally with 3 X 10
9
 PFU of viable DV at 
four different sites in the back as indicated by arrows. Subcutaneous tissue (a), 
abdomen (b), and intestine (c) were exposed at day 3 after inoculation. 
C57BL/6 mice were also injected intradermermally with lower amount of 
viable DV (8 x 10
7
 PFU) and the subcutaneous tissue was exposed at day 3 of 












Figure 5.2 Hemorrhagic symptoms in 4-week old mice which were 
infected with DV2 via intradermal injection were visually assessed. 
C57BL/6 mice were injected intradermally with ~1.08 X 10
11
 PFU of viable 
DV at four different sites in the back. Subcutaneous tissue (a), abdomen (b), 
and intestine (c) were exposed at day 3 after inoculation. Representative 















Figure 5.3 Hemorrhagic symptoms in 4-week old mice which were 
infected with DV2 via intraperitoneal injection were visually assessed. 
C57BL/6 mice were injected intraperitoneally with ~5.4 X 10
11
 PFU of DV2. 
Subcutaneous tissue (a), abdomen (b), and intestine (c) were exposed at day 3 










5.2.3 Plaque assay to quantify the virus titer in 2 week-old DV2 infected 
wild-type mice 
It has been documented that younger mice with less developed immune 
system are more susceptible to infection (Elahi et al, 2013; Procario et al, 
2012). Younger mice at 2 week-old old were intraperitoneally injected with 
~2.7 x 10
11
 PFU of DV2 strain 16681. Lower amount of virus was used due to 
the smaller injection volume allowed in the smaller mice. Intraperitoneal route 
of delivery was chosen as virus was detected using that route in the 4 week-old 
mice (Section 5.2.1). Viruses were detected in two of the infected mice at day 
1 post-infection (Table 5.5). The virus titers obtained were higher than that of 
the 4 week-old, suggesting that the younger mice may be more susceptible. No 


















Serum: PFU/ml           
Liver: PFU/g 
1 Serum 6 0, 0, 0, 0, 13.333, 43.333 
2 Serum 6 0, 0, 0, 0, 0, 0 
3 Serum 6 0, 0, 0, 0, 0, 0 
4 Serum 6 0, 0, 0, 0, 0, 0 
5 Serum 6 0, 0, 0, 0, 0, 0 
21 Serum 6 0, 0, 0, 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.5 Virus titer in 2-week old mice after intraperitoneal injection of 
DV2.  
Wild-type C57BL/6 mice were injected with 2.7 x 10
11
 PFU of DV2 strain 
16681 via intraperitoneal injection. Blood of mice was harvested at day 1, 2, 3, 
4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were obtained 
after centrifugation of the clotted blood. Livers of the mice were also 
harvested and homogenized. The virus titers in the sera and livers of the mice 








Serum: PFU/ml       
1 Serum 3 0, 0, 0 
2 Serum 3 0, 0, 0 
3 Serum 3 0, 0, 0 
4 Serum 3 0, 0, 0 
5 Serum 3 0, 0, 0 
21 Serum 3 0, 0, 0 
Table 5.6 Virus titer of dengue virus in 2-week old mice after 
intraperitoneal injection of C6/36 cell culture supernatant.  
Wild-type C57BL/6 mice were injected with ~0.5 ml of C6/36 cell culture 
supernatant via intraperitoneal injection. Blood of mice was harvested at day 
1, 2, 3, 4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were 
obtained after centrifugation of the clotted blood. The virus titers in the sera of 






5.2.4 Visual assessment of subcutaneous tissue, abdomen and intestine of 
2 week-old wild-type mice 
Although the plaque assay results suggested increased susceptibility in 
the 2 week-old mice, no hemorrhages was observed in the DV2-infected 2 























Figure 5.4 Hemorrhagic symptoms in 2-week old mice which were 
infected with DV2 via intraperitoneal injection were visually assessed. 
C57BL/6 mice were injected intraperitoneally with ~2.7 X 10
11
 PFU of DV2. 
Subcutaneous tissue (a), abdomen (b), and intestine (c) were exposed at day 3 







5.2.5 Plaque assay to quantify the virus titer in 1 week-old DV2 infected 
wild-type mice. 
Many of the DV2-infected 2 week-old mice still did not gain viremia. 
Therefore, younger mice of 1 week-old were infected with ~1 x 10
11
 PFU of 
DV2 strain 16681 via intraperitoneal injection as described in Section 2.11.2. 





 PFU/ml) were detected in the sera of two out of the six infected 
mice on day 1 post-infection (Table 5.7). Sera of mock-infected mice were not 
detected to have any virus (Table 5.8). The virus titers of the infected 1 week-
old mice were higher than that of the 2 week-old mice, suggesting increased 
susceptibility of the 1 week-old mice to DV2 compared to the 2 week-old 






Serum: PFU/ml           
 Liver: PFU/g 
1 Serum 6 0, 0, 0, 0, 3.87 x 10
2
, 2.87 x 10
2
 
2 Serum 6 0, 0, 0, 0, 0, 0 
3 Serum 6 0, 0, 0, 0, 0, 0 
4 Serum 6 0, 0, 0, 0, 0, 0 
5 Serum 6 0, 0, 0, 0, 0, 0 
21 Serum 6 0, 0, 0, 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.7 Virus titer in 1-week old mice after intraperitoneal injection of 
DV2.  
Wild-type C57BL/6 mice were injected with ~1 x 10
11
 PFU of DV2 strain 
16681 via intraperitoneal injection. Blood of mice was harvested at day 1, 2, 3, 
4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were obtained 
after centrifugation of the clotted blood. Livers of the mice were also 
harvested and homogenized. The virus titers in the sera and livers of the mice 










Serum: PFU/ml       
1 Serum 3 0, 0, 0 
2 Serum 3 0, 0, 0 
3 Serum 3 0, 0, 0 
4 Serum 3 0, 0, 0 
5 Serum 3 0, 0, 0 
21 Serum 3 0, 0, 0 
Table 5.8 Virus titer of dengue virus in 1-week old mice after 
intraperitoneal injection of C6/36 cell culture supernatant.  
Wild-type C57BL/6 mice were injected with ~0.2 ml of C6/36 cell culture 
supernatant via intraperitoneal injection. Blood of mice was harvested at day 
1, 2, 3, 4, 5 and 21 post-infection via cardiac puncture. Sera of the mice were 
obtained after centrifugation of the clotted blood. The virus titers in the sera of 
the mice were quantified using plaque assays. 
 
5.2.6 Visual assessment of subcutaneous tissue, abdomen and intestine of 
1 week-old wild-type mice 
Although higher virus titers were detected in the 1 week-old wild-type 
mice compared to that of the 2 week-old wild-type mice, similar to what was 
observed for DV2-infected 2 week-old wild-type mice, no hemorrhagic 
symptoms was observed in all the 36 DV2-infected wild-type 1 week-old mice 














Figure 5.5 Hemorrhagic symptoms in 1-week old mice which were 
infected with DV2 via intraperitoneal injection were visually assessed. 
C57BL/6 mice were injected intraperitoneally with ~1 X 10
11
 PFU of DV2. 
Subcutaneous tissue (a), abdomen (b), and intestine (c) were exposed at day 3 













The plaque assay results of the 1 week-old mice were still not 
consistent and great variability was observed. The higher virus titer detected in 
the sera of the 1 week-old mouse compared with that of the 2 week-old, 
suggests that the younger the mice, the more susceptible they are to DV2. 
Thus, younger mice which were 1-2 day-old were injected with 2.7 x 10
10 
PFU 
of DV2 and quantified for virus titer in the sera and livers as described in 
Section 2.11.3. The virus titers obtained from the 1-2 day-old pups at day 1 
and day 2 post-infection were more consistent (Figure 5.6a). DV2 were 
detected in all the DV2-infected pups from day 1 to day 2 post-infection. The 
average virus titer detected in the sera of the DV2-infected wild-type mice on 
day 1 was 1.51 x 10
5
 PFU/ml while that on day 2 was 9.17 x 10
2 
PFU/ml and 
that on day 3 was 1.81 x 10
2
 PFU/ml. This suggests that the pups were 
susceptible to dengue virus infection. With the more consistent detection of 
virus titers in the wild-type infected mouse population, 1-2 day-old TLR6
-/-
 
mice were also infected in the same way as the wild-type. Virus in the sera of 
TLR6
-/-
 mice were also quantified (Figure 5.6b). The average virus titer 
detected in the sera of the DV2-infected TLR6
-/-
 mice was 2.73 x 10
6
 PFU/ml 
while that on the day 2 was 2.40 x 10
3
 PFU/ml and that on day 3 was 2.54 x 
10
1
 PFU/ml. Comparing the virus titers obtained in the sera of infected wild-
type and TLR6
-/-
 mice, virus titers were not statistically significantly different. 
This suggests similar susceptibility of wild-type and TLR6
-/-
 mice to DV2. 
Viremia persisted in both wild-type and TLR6
-/-
 mice till day 3. By day 4 post-






 mice whose serum detected presence of DV2 on day 5 post-infection. 
Virus titers in the livers of wild-type and TLR6
-/-
 mice were also quantified 
using plaque assay (Figure 5.7a & b). Unlike what was observed for the sera, 
DV2 persisted longer in the liver of infected wild-type mice compared to the 
infected TLR6
-/-
 mice from day 2 to 5. No virus was detected from day 2 to 
day 4 for the DV2-infected TLR6
-/-
 mice. The sera and livers of both the wild-
type and TLR6
-/-
 mock-infected mice were detected to be absent of DV2 












































































Figure 5.6 Virus titer of DV2 in sera of 1-2-day old mice after 
intraperitoneal injection of DV2 virus.  
Wild-type (a) and TLR6
-/-
 (b) C57BL/6 mice were injected with 0.05 ml of 
DV2 via intraperitoneal injection. The blood was harvested at day 1, 2, 3, 4, 5 
and 21 post-infection via cardiac puncture. Sera of the mice were obtained 
after centrifugation of the clotted blood. The virus in the sera was quantified 
by plaque assays. Virus titers of 0 PFU/ml were set to 0 Log10 PFU/ml to be 
reflected on the log scale graph. No actual virus titer of 0 Log10 PFU/ml was 
obtained from any of the samples. Each sample group is in triplicates. Using 
Kruskal-Wallis test, virus titers in sera of DV2-infected and mock-infected 
wild-type mice were found to be significantly different. Using Kruskal-Wallis 
test, virus titers in sera of DV2-infected and mock-infected TLR6
-/-
 mice were 
also found to be significantly different. Using Kruskal-Wallis test, virus titers 
in the sera of DV2-infected wild-type and TLR6
-/-
















































































Figure 5.7 Virus titer of DV2 in livers of 1-2-day old mice after 
intraperitoneal injection of DV2 virus.  
Wild-type (a) and TLR6
-/-
 (b) C57BL/6 mice were injected with 0.05 ml of 
DV2 via intraperitoneal injection. The livers were harvested at day 1, 2, 3, 4, 5 
and 21 post-infection via cardiac puncture. The livers were homogenized as 
described in Section 2.11.3. The virus in the livers was quantified by plaque 
assays. Virus titers of 0 PFU/ml were set to 0 Log10 PFU/ml to be reflected on 
the log scale graph. No actual virus titer of 0 Log10 PFU/ml was obtained from 
any of the samples. Livers of mock-infected C57BL/6 mice were also 
quantified and all did not produce any plaque (data not shown on graph). Each 
sample group is in triplicates. Using Kruskal-Wallis test, virus titers in the 
liver of DV2-infected wild-type and TLR6
-/-
























Serum: PFU/ml            
Liver: PFU/g 
1 Serum 3 0, 0, 0 
2 Serum 3 0, 0, 0 
3 Serum 3 0, 0, 0 
4 Serum 3 0, 0, 0 
5 Serum 3 0, 0, 0  
21 Serum 3 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.9 DV2 titer in wild-type 1-2 day-old mice after intraperitoneal 
injection of C6/36 cell culture supernatant.  
Wild-type C57BL/6 mice were injected with 50 μl of C6/36 cell culture 
supernatant via intraperitoneal injection (Mock-infected). Blood of mice was 
harvested at day 1, 2, 3, 4, 5 and 21 post-infection via cardiac puncture. Sera 
of the mice were obtained after centrifugation of the clotted blood. Livers of 
the mice were also harvested and homogenized. The virus titers in the sera and 







Serum: PFU/ml           
 Liver: PFU/g 
1 Serum 3 0, 0, 0 
2 Serum 3 0, 0, 0 
3 Serum 3 0, 0, 0 
4 Serum 3 0, 0, 0 
5 Serum 3 0, 0, 0  
21 Serum 3 0, 0, 0 
1 Liver 3 0, 0, 0 
2 Liver 3 0, 0, 0 
3 Liver 3 0, 0, 0 
4 Liver 3 0, 0, 0 
5 Liver 3 0, 0, 0  
21 Liver 3 0, 0, 0 
Table 5.10 DV2 titer in TLR6
-/-
 1-2 day-old mice after intraperitoneal 
injection of C6/36 cell culture supernatant.  
TLR6
-/-
 C57BL/6 mice were injected with 50 μl of C6/36 cell culture 
supernatant via intraperitoneal injection (Mock-infected). Blood of mice was 
harvested at day 1, 2, 3, 4, 5 and 21 post-infection via cardiac puncture. Sera 
of the mice were obtained after centrifugation of the clotted blood. Livers of 
the mice were also harvested and homogenized. The virus titers in the sera and 




5.2.8 Visual assessment of subcutaneous tissue, abdomen and intestine of 
1-2 day-old wild-type mice. 
Subcutaneous tissue, abdomen and intestine of DV2-infected 1-2 day-
old wild-type and TLR6
-/-
 mice were examined for signs of hemorrhages. 
Despite the virus titers observed in the sera and tissues of wild-type and TLR6 
-/-
 mice, almost all mice did not exhibit any signs of hemorrhages (Figure 5.8). 
Out of the 36 mice, only 1 TLR6
-/-
 was found to show signs of hemorrhages at 
day 2 post-infection (Figure 5.8 d). The mouse did not succumb to the 
infection and the hemorrhagic symptom disappeared two days after the onset 















a)                                                         b) 
 
c)                                                         d) 
 
Figure 5.8 Hemorrhagic symptoms in 1-2 day-old mice which were 
infected with DV2 via intraperitoneal injection were visually assessed. 
C57BL/6 mice were injected intraperitoneally with ~2.7 X 10
10
 PFU of DV2. 
Subcutaneous tissue (a), abdomen (b), and intestine (c) were exposed at day 3 
after inoculation. Representative images are shown. One TLR6
-/-
 DV2-








5.2.9 Symptoms developed in mice during dengue virus infection. 
The mice infected at 4 week-old, 2 week-old and 1 week-old did not 
show any symptoms throughout the 21 days of monitoring. However, mice 
infected at 1-2 day-old developed some symptoms like enlarged belly, lower 
limb paralysis, moribundity and death. 
Some of the 1-2 day-old mice infected via intraperitoneal injection 
developed bulging bellies at day 1 post-infection (Figure 5.9b). A pup of the 
same age without bulging belly was shown as a comparison (Figure 5.9a). The 
rate of incidence of this symptom is about 1 in 20 of the DV2-infected mice. 
Some of the mice which developed this symptom were observed to be dead at 
day 2 post-infection while others recovered from it. 
Fluid accumulation in visceral organs was reported to be a 
characteristic feature of the endothelial permeability syndrome induced by 
DV2 (Figure 5.10) (Balsitis et al, 2010; Shresta et al, 2006). One mouse 
infected at 1-2 day-old was observed to show similar feature at day 21 post-
infection (Figure 5.11). However, only one mouse was observed, suggesting 
the rarity of this symptom in our model. 
 Hindlimb paralysis was also observed in DV2-infected mice (video in 
CD). Symptoms of paralysis of extremities which has been observed in some 
dengue patients were also observed in our mice model (video in CD). 
However, such occurrences were rare. From the observations of the mice on a 
daily basis, the occurrence of paralysis was observed on day 10-14 post-
infection. When the virus titers of these mice which displayed lower limb 




were localized in the brain rather than the limb, liver or the serum (Table 
5.11). This suggested that DV2 persisted in the brain of these mice and 
affected the central nervous system, leading to the paralysis. Three of the mice 
which were showing symptoms of limb paralysis were not sacrificed for tissue 
samples or serum samples but left to observe the progression of the infection. 
The mice did not succumb to the infection, instead the mice recovered from 
the paralysis after two days from the observation of the paralysis. High virus 
titers were found in the homogenized brains of the mice which displayed 
symptoms of paralysis, much higher than the asymptomatic mice. One of the 
mice was found to have only one limb paralyzed (video in CD), the virus titer 
in each of the limb were titered separately to determine if there will be a 
difference in the two limbs. The virus titers were found to be approximately 
the same, this suggested that the paralysis was not due to the presence of the 
virus in the limbs (Table 5.11). Moreover, some of the mice which exhibited 
limb paralysis were not detected with DV in the limb, further substantiating 
that paralysis was not due to DV in the limbs (Table 5.11). 
 Some of the DV2-infected mice were found to succumb to the 
infection. No viable virus was detected in the tissues of the dead mice which 
could be due to decomposition. Blood of the dead mice could not be harvested 
due to the clotting of the blood. Only three moribund mice were found 
throughout the study, suggesting the short window between moribundity and 
death. High virus titers were detected in the brain, liver and limbs of the 
moribund mice. However, no virus was detected in the sera of the moribund 




and high amount of IL-6 was detected (2690.5 pg/ml). Due to the limited 
amount of sera, TNF-α amount was not assayed. 
. 




Figure 5.9 Observation of enlarged belly in DV2-infected mice.  
Enlarged belly is a symptom observed in some of the mice infected with DV2 
via intraperitoneal injection at day 1 post-infection (b). An image of DV2-
infected mouse without bulging belly was shown for comparison (a). A mouse 





Figure 5.10 Lethal enhancement of dengue disease by anti-DV sera. 
Figures adapted from (Balsitis et al, 2010) 
Mice were administered 100 μl naϊve mouse serum (NMS) or anti-DV1 serum 
(α-DV1), challenged iv with the indicated dose of DV2 strain D2S10 24 hours 
later. Vascular leak-associated fluid accumulation was observed in visceral 


















a)                                                             b) 
 
Figure 5.11 Abnormal observation of enlarged organ in wild-type DV2-
infected mice at day 21 post-infection. 
A swollen organ was observed during the process of harvesting liver for 
plaque assay in a wild-type DV2-infected mouse at day 21 post-infection (a). 
The mouse was infected at the age of 1-2 day-old. It was the only mouse 
observed to have this abnormality throughout the entire study. Another DV2-






















Serum/Fluid: PFU/ml       
Liver/Brain/Limb: PFU/g 
Death WT Brain 4 0 
Death WT Brain 4 0 
Death WT Liver 4 0 
Death WT Limb 4 0 
Death WT Peritoneal fluid 1 1.11 x 10
4 
Moribundity WT Brain 6 3.07 x 10
5 
Moribundity WT Liver 6 6.31 x 10
3 
Moribundity WT Limb 6 2.01 x 10
5 
Moribundity WT Serum 5 0 
Moribundity WT Serum 5 0 
Hindlimb paralysis WT Brain 10 2.76 x 10
4 
Hindlimb paralysis WT Brain 11 5.24 x 10
5 
Hindlimb paralysis WT Brain 14 8.16 x 10
5 
Hindlimb paralysis WT Liver 14 0 
Hindlimb paralysis WT Liver 11 0 
Hindlimb paralysis WT Liver 10 0 
Hindlimb paralysis WT Limb 14 9.49 x 10
1 
Hindlimb paralysis WT Limb 11 1.38 x 10
3 
Hindlimb paralysis WT Limb 
(unparalyzed) 
11 4.01 x 10
3 
Hindlimb paralysis WT Serum 12 0 
Hindlimb paralysis WT Serum 12 0 
Hindlimb paralysis KO Brain 13 7.10 x 10
5 
Hindlimb paralysis KO Liver 13 0 
Hindlimb paralysis  KO Limb 13 0 
Hindlimb paralysis KO Serum 13 0 
Hindlimb paralysis 
& Recovered 
KO Liver 14 0 
Hindlimb paralysis 
& Recovered 




KO Limb 14 0 
Hindlimb paralysis 
& Swollen intestine 
WT Intestine 14 4.27 x 10
2 
 
Bulging belly WT Liver 3 0 
Bulging belly WT Serum 1 1.36 x 10
5 
Bulging belly WT Serum 1 3.00 x 10
5 
Bulging belly WT Peritoneal fluid 1 1.13 x 10
6 
Bulging belly WT Peritoneal fluid 1 1.27 x 10
6 
Bulging belly KO Brain 2 0 
Bulging belly & 
Death 
KO Peritoneal fluid 2 3.50 x 10
3 
Bulging belly & 
Death 
KO Liver 2 0 
Bulging belly & 
Death 







Table 5.11 Virus titer of DV2 in symptomatic mice. 
Mice which were observed to have developed certain symptoms of infection 
were noted. Besides harvesting serum, brain, liver and limb of the 
symptomatic mice, abnormal tissue (intestine) or peritoneal fluid discovered 
during the harvesting were also harvested to be quantified for DV2 virus titer. 
 
5.2.10 Plaque assay to quantify the virus titer in the limb of 1-2 day-old 
DV2-infected wild-type and TLR6
-/-
 mice. 
As paraplegia was observed in the DV2-infected mice, hindlimbs of 
the asymptomatic mice were also harvested and quantify for DV2 titer using 
plaque assay. Lower virus titers were detected in the limbs of DV2-infected 
TLR6
-/-
 mice compared to that of the wild-type on day 4 and 5 post-infection 
(Figure 5.12a & b). And no virus was detected in the limbs of DV2-infected 
TLR6 
-/-
 mice on day 2, 3 and 21 post-infection while virus titers were 
detected in that of the wild-type. This result may suggest that DV2-infected 
TLR6
-/-
 mice can clear the virus in the limb more efficiently than DV2-















































































Figure 5.12 DV2 Titer in limbs of 1-2-day old mice after intraperitoneal 
injection of DV2 virus.  
Wild-type (a) and TLR6
-/-
 (b) C57BL/6 mice were injected with 0.05 ml of 
DV2 via intraperitoneal injection. The hindlimbs of mice were harvested at 
day 1, 2, 3, 4, 5 and 21 post-infection. The hindlimbs were homogenized as 
described in Section 2.11.3. The virus in the limb was quantified by plaque 
assay. Virus titers of 0 PFU/ml were set to 0 Log10 PFU/ml to be reflected on 
the log scale graph. No actual virus titer of 0 Log10 PFU/ml was obtained from 
any of the samples. Hindlimbs of mock-infected C57BL/6 mice were also 
quantified and all did not produce any plaque (data not shown on graph). Each 
sample group is in triplicates. Using Kruskal-Wallis test, virus titers in the 
limbs of DV2-infected wild-type and TLR6
-/-








Virus Titer           
 Limb: PFU/g 
1 Wild-type 3 0, 0, 0 
2 Wild-type 3 0, 0, 0 
3 Wild-type 3 0, 0, 0 
4 Wild-type 3 0, 0, 0 
5 Wild-type 3 0, 0, 0  
21 Wild-type 3 0, 0, 0 
1 TLR6 KO 3 0, 0, 0 
2 TLR6 KO 3 0, 0, 0 
3 TLR6 KO 3 0, 0, 0 
4 TLR6 KO 3 0, 0, 0 
5 TLR6 KO 3 0, 0, 0  
21 TLR6 KO 3 0, 0, 0 
Table 5.12 DV2 titer in 1-2 day-old mice after intraperitoneal injection of 
C6/36 cell culture supernatant.  
Wild-type and TLR6 
-/-
 C57BL/6 mice were injected with 0.05 ml of C6/36 
supernatant via intraperitoneal injection. The hindlimbs of mice were 
harvested at day 1, 2, 3, 4, 5 and 21 post-infection. The hindlimbs were 
homogenized as described in 2.11.3.  
 
5.2.11 Plaque assay to quantify the virus titer in the brain of 1-2 day-old 
DV2-infected wild-type and TLR6
-/-
 mice. 
Paralysis of the limb could be due to presence of virus in the central 
nervous system (Johnson & Roehrig, 1999). In view of that, the brains of 
DV2-infected wild-type and TLR6
-/-




gain entry into the brain and persisted there in both the wild-type and TLR6
-/-
 
mice (Figure 5.13a & b). DV2 was able to replicate in the brain of TLR6
-/-
 
mice from day 1 post-infection, much faster than that of the wild-type mice. 
Compromised immune response due to the knockout of TLR6 could be the 
reason for the observation. DV2 was only detected from day 3 post-infection 
in the wild-type mice. DV2 can still be detected at the endpoint of the 
experiment in both wild-type and TLR6
-/-
 mice. In summary, when the mice 
were infected via the intraperitoneal injection of DV2, the virus gets into the 
bloodstream of the mice and spread to other organs and tissue like liver and 
limbs. DV2 managed to gain entry into the brain of some of the mice and 
persisted there. DV2 in the bloodstream were the first to be cleared, followed 
by other organs and tissues. Clearing of DV2 in the brain seemed to be the 
most inefficient. DV2 can persist in the brain longer than in the liver and limb, 
shown by high DV2 titer in some of the infected mice at the endpoint of the 
study. It was noticed that virus titers in brains of asymptomatic mice were 
much lower than that of the mice which displayed symptoms of paralysis 
(Table 5.11). This suggests that paraplegia could be due to the effect of high 
DV2 titer in the brain. No virus was detected in the brain of the mock-infected 










































































Figure 5.13 DV2 Titer in brains of 1-2-day old mice after intraperitoneal 
injection of DV2 virus.  
Wild-type (a) and TLR6
-/-
 (b) C57BL/6 mice were injected with 2.7 x 10
10
 
PFU of DV2 via intraperitoneal injection. The brains of mice were harvested 
at day 1, 2, 3, 4, 5 and 21 post-infection. The brains were homogenized as 
described in Section 2.11.3. The virus in the brains was quantified by plaque 
assay. Virus titers of 0 PFU/ml were set to 0 Log10 PFU/ml to be reflected on 
the log scale graph. No actual virus titer of 0 Log10 PFU/ml was obtained from 
any of the samples. Brains of mock-infected C57BL/6 mice were also 
quantified and all did not produce any plaque (data not shown on graph). Each 
sample group is in triplicates. Using Kruskal-Wallis test, virus titers in the 
brains of DV2-infected wild-type and TLR6
-/-







Virus Titer           
 Brain: PFU/g 
1 Wild-type 3 0, 0, 0 
2 Wild-type 3 0, 0, 0 
3 Wild-type 3 0, 0, 0 
4 Wild-type 3 0, 0, 0 
5 Wild-type 3 0, 0, 0  
21 Wild-type 3 0, 0, 0 
1 TLR6 KO 3 0, 0, 0 
2 TLR6 KO 3 0, 0, 0 
3 TLR6 KO 3 0, 0, 0 
4 TLR6 KO 3 0, 0, 0 
5 TLR6 KO 3 0, 0, 0  
21 TLR6 KO 3 0, 0, 0 
Table 5.13 DV2 titer in 1-2 day-old mice after intraperitoneal injection of 
C6/36 cell culture supernatant.  
Wild-type and TLR6
-/-
 C57BL/6 mice were injected with 0.05 ml of C6/36 cell 
culture supernatant via intraperitoneal injection. The brains of mice were 
harvested at day 1, 2, 3, 4, 5 and 21 post-infection. The brains were 
homogenized as described in Section 2.11.3.  
 
5.3 IL-6 AND TNF-α ARE UP-REGULATED DURING DENGUE 
VIRUS INFECTION. 
5.3.1 ELISA to quantify IL-6 level in sera of DV2-infected mice. 
It has been shown using the PBMC cell model that DV2 infection up-




investigated using ELISA as described in Section 2.4.6. It was noticed that not 
all the mice up-regulated IL-6 expression upon dengue virus infection (Figure 
5.14a & b). Some of the mice, both DV2-infected wild-type and TLR6
-/-
, 
remained unresponsive to the infection. The amount of IL-6 in the sera of 
those mice was comparable to that of the mock-infected mice. Among those 
that responded, DV2-infected wild-type mice secreted higher amount of IL-6 
compared to that of the DV2-infected TLR6
-/-
 mice, indicating that TLR6 
activation contributes to the IL-6 expression during dengue virus infection. 
This observation is similar to what was seen in the PBMC cell model. In 
addition, it was noticed that IL-6 up-regulation in the sera of DV2-infected 
TLR6
-/-
 mice subsided by day 5 post-infection while that of responsive wild-
type mice remained up-regulated. In general, there was an increasing trend 
observed in the IL-6 expression of those responsive DV2-infected wild-type 


























































Figure 5.14 The amount of IL-6 in the sera of DV2-infected mice was 
detected using ELISA. 
ELISA was performed to quantify the amount of IL-6 in the sera of wild-type 
(a) and TLR6
-/-
(b) mice infected with 2.7 x 10
10
 PFU of DV2 at 1-2 day-old 
via intraperitoneal injection. There were 24 mice in each time point (12 DV2-
infected and 12 Mock-infected, 12 mice were wild-type mice and 12 mice 
were TLR6
-/-
 mice). Blood of mice was harvested at day 1, 3, 5 and 21 post-
infection in triplicates via cardiac puncture. Blood of mock-infected mice was 
also harvested. Sera of the mice were obtained after centrifugation of the 
clotted blood. Using Kruskal-Wallis test, the amount of IL-6 detected in the 
sera of DV2-infected wild-type and TLR6
-/-
 mice was significantly different 
among the respondents. 
 
 
5.3.2 ELISA to quantify TNF-α level in sera of DV2-infected mice 
The amount of TNF-α in the sera of DV2-infected mice was also 
determined using ELISA as described in Section 2.4.6. TNF-α expression in 
sera of DV2-infected mice was similar to IL-6 expression (Figure 5.15a & b). 
Among those that responded, DV2-infected wild-type mice secreted higher 
amount of TNF-α compared to that of the DV2-infected TLR6-/- mice, 
indicating that TLR6 activation contributes to the TNF-α expression during 
dengue virus infection. However, only two wild-type mice were found to have 
up-regulated TNF-α on day 5 post-infection compared to three for that of the 
IL-6. This is not surprising as the mice sera used for TNF-α detection and IL-6 
detection are independent samples, harvested from different mice due to the 












































Figure 5.15 The amount of TNF-α in the sera of DV2-infected mice was 
detected using ELISA 
ELISA was performed to quantify the amount of TNF-α in the sera of wild-
type (a) and TLR6
-/-
 (b) mice infected with 2.7 x 10
10
 PFU of DV2 at 1-2 day-
old via intraperitoneal injection. There were 24 mice in each time point (12 
DV2-infected and 12 Mock-infected, 12 mice were wild-type mice and 12 
mice were TLR6
-/-
 mice). Blood of mice was harvested at day 1, 3, 5 and 21 
post-infection in triplicates via cardiac puncture. Blood of mock-infected mice 
was also harvested. Sera of the mice were obtained after centrifugation of the 
clotted blood. Using Kruskal-Wallis test, the amount of TNF-α detected in the 
sera of DV2-infected wild-type and TLR6
-/-
 mice was significantly different 




5.4 DV NS1 PROTEIN IS DETECTED IN THE SERA OF DV2-
INFECTED MICE 
5.4.1 ELISA to quantify DV NS1 protein level in sera of DV2-infected 
mice 
DV NS1 protein was found to be the viral protein responsible for 
activating TLR2 and TLR6 using the PBMC cell model. In addition, PBMC 
were able to secrete DV NS1 protein upon DV2 infection. As DV NS1 protein 
could be the viral protein responsible for the IL-6 and TNF-α up-regulation in 
the mice as well, the presence of DV NS1 protein in the sera of mice after 
intraperitoneal injection of DV2 was determined using Bio-Rad Platelia 
Dengue NS1 Antigen detection kit as described in Section 2.4.7. 
DV NS1 protein persisted in the sera of mice after injection of DV2 for 
both wild-type and TLR6
-/-
 mice (Figure 5.16a & b). In general for both wild-
type and TLR6
-/-
 mice, the DV NS1 protein level starts to decrease from day 4 
post-infection and on day 5, DV NS1 protein level in one of the WT mouse 
serum fell close to the relative OD of the mock-infected. The amount of DV 
NS1 protein in the sera of the DV2-infected wild-type and TLR6
-/-
 mice was 
comparable. This could be due to the comparable virus titers in the DV2-
infected wild-type and TLR6
-/-
 mice, suggesting comparable replication level 





















































































Figure 5.16 DV NS1 protein level in sera of DV2-infected mice were 
quantified using Dengue NS1 antigen detection kit. 
Wild-type and TLR6
-/-
 mice at 1-2 day-old were infected with 2.7 x 10
10
 PFU 
of DV2 strain 16681. Blood of mice was harvested at day 1, 2, 3, 4, 5 and 21 
post-infection via cardiac puncture. Sera of the mice were obtained after 
centrifugation of the clotted blood. DV NS1 protein in the sera of the mice 
was assayed using Bio-rad Platelia Dengue NS1 Antigen detection kit as 
described in Section 2.4.7. Using Kruskal-Wallis test, DV NS1 protein level in 
the sera of mock-infected and DV2-infected wild-type mice were significantly 
different. Using Kruskal-Wallis test, DV NS1 protein level in the sera of 
mock-infected and DV2-infected TLR6
-/-
 mice were significantly different. 
Using Kruskal-Wallis test, DV NS1 protein level in the sera of DV2-infected 
wild-type and TLR6
-/-
 mice were not significantly different. 
 
 
5.5 MURINE MACROPHAGES ARE SUSCEPTIBLE TO DENGUE 
VIRUS INFECTION 
5.5.1 Plaque assay to quantify progeny virus production in wild-type and 
TLR6
-/-
 murine macrophages 
Monocytes of mouse are present in low amount in the blood and due to 
the low volume of blood which can be harvested from each mouse, the number 
of mice required to get enough cells to assay for virus replication in murine 
cells would be huge (Petkova et al, 2008). Hence, an alternative is required.   
Mouse peritoneal cavity is an easily accessible site for the harvesting 
of moderate numbers of resident macrophages (Zhang et al, 2008). However, 
the number of macrophages present in the peritoneum under non-elicited 
condition is insufficient for extensive studies. Macrophage yield was increased 
by injecting thioglycollate broth into the peritoneal cavity prior to cell harvest. 
Thioglycollate broth increases macrophage yield by inceasing monocyte 




Susceptibility of murine peritoneal macrophages was determined using 
plaque assay as described in Section 2.2.4. Comparable virus titers were 
detected for DV2-infected wild-type and TLR6
-/-
 mice for day 1 to 5 post-
infection, suggesting that the knockout of TLR6 did not affect the 
susceptibility of the macrophages to DV2 infection (Figure 5.17).  
 





























Figure 5.17 Virus growth curve in wild-type and TLR6
-/-
 mouse peritoneal 
macrophages infected with DV2 at M.O.I. of 10 was obtained using 
plaque assays. 
Murine peritoneal macrophages were harvested from 4 week-old wild-type 
and TLR6
-/-
 mice as described in Section 2.11.4. Wild-type and TLR6
-/-
 mouse 
peritoneal macrophages were infected with DV2 at M.O.I of 10 and plaque 
assays were performed to quantify the infectious virus yield from day 1 to 5 
post-infection. Supernatants of mock-infected murine peritoneal macrophages 
were also quantified by plaque assay. Values plotted are mean ± SEM of three 
independent experiments performed in triplicate. Mean virus titers of 0 
PFU/ml were set to 0 Log10 PFU/ml to be reflected on the log scale graph. No 







5.5.2 Transmission electron microscopy to visualize DV2-infected murine 
peritoneal macrophages at ultrastructural level. 
As virus titer obtained from the DV2-infected wild-type and TLR6
-/-
 
macrophages were quite low and can be confounded by residual viruses, the 
replication of DV2 in the murine peritoneal macrophages were further verified 
using transmission electron microscopy. Replication complexes were found in 
the DV2-infected murine peritoneal macrophages and electron dense particles 
resembling dengue viruses were found in close proximity to the replication 
complexes (Figure 5.18a). Size of dengue virus is approximately 40-60 nm 
and the electron dense core of the virus is about 30 nm (B.D. Lindenbach, 
2007; Kuhn et al, 2002). The size of the electron dense particle observed fits 
the size of DV electron dense core. No similar structures were seen in the 




















Figure 5.18 Ultrastructural analysis of DV2-infected murine peritoneal 
macrophages 
Murine peritoneal macrophages were infected with DV2 and harvested at day 
2 post-infection for ultrastructural analysis using electron microscope. 
Membranous structures and replication complexes (RC) (arrows) induced by 
DV in murine peritoneal macrophages can be observed (a). DV2 particles 
(arrowheads) can also be observed in close proximity with the replication 
complexes. Mock-infected murine peritoneal macrophages did not show 
structures resembling replication complexes and DV (b). Rough endoplasmic 
reticula (ER) were visible in the mock-infected murine peritoneal 
macrophages. 
 
5.6 TLR6 IS INVOLVED IN THE UP-REGULATION OF CYTOKINES 
BY MURINE PERITONEAL MACROPHAGES DURING DENGUE 
VIRUS INFECTION 
5.6.1 ELISA to quantify IL-6 level in supernatant of DV2-infected and DV 
NS1 protein-treated wild-type/TLR6
-/-
 murine peritoneal macrophages. 
DV NS1 protein was found to activate TLR6 and TLR2 of human PBMC, 
leading to up-regulation of IL-6 and TNF-α expression. The effect of DV NS1 
protein on IL-6 expression of murine peritoneal macrophages was 
investigated. Similar to what was observed for PBMC cell model, without the 
activation of TLR6, DV2-infected murine peritoneal macrophages secreted 
significantly lesser amount of IL-6 (Figure 5.19). The amount of IL-6 
produced by DV NS1 protein-treated wild-type murine peritoneal 
macrophages was significantly much more than DV NS1 protein-treated 
TLR6
-/-
 murine peritoneal macrophages. The level of IL-6 produced by DV 
NS1 protein-treated TLR6
-/-
 murine peritoneal macrophages was comparable 
to that produced by the mock-infected TLR6
-/-
 murine peritoneal 




production of IL-6 by murine peritoneal macrophages. The amount of IL-6 
produced by DV2-infected TLR6
-/-
 murine peritoneal macrophages was higher 
than that of the mock-infected, suggesting that the stimulation by DV NS1 
protein only contributed partially to the amount of IL-6 detected in the DV2 
infection. In addition, the effect of MALP-2 on the secretion of IL-6 by the 



















































Figure 5.19 Amount of IL-6 detected in the supernatant of DV NS1 
protein-treated murine peritoneal macrophage culture. 
ELISA was performed to quantify the amount of IL-6 secreted into the 
supernatant by mock-infected, DV2-infected, His-tag-treated, DV NS1 
protein-treated and MALP-2-treated wild-type or TLR6
-/-
 murine peritoneal 
macrophages (1 μg/ml) on day 2 post-treatment. Data represent mean ± SEM 
of three independent experiments. * denotes p-value < 0.05, ** denotes p-
value < 0.005, *** denotes p-value < 0.0001 for t-tests comparing mean 
amount of IL-6 detected in culture supernatants of wild-type murine peritoneal 
macrophages to that of TLR6
-/-






5.6.2 ELISA to quantify TNF-α level in supernatant of DV2-infected and 
DV NS1 protein-treated wild-type/TLR6
-/-
 murine peritoneal 
macrophages. 
The effect of DV NS1 protein on TNF-α expression of murine 
peritoneal macrophages was also investigated. Similar to IL-6 expression, 
without the activation of TLR6, DV2-infected murine peritoneal macrophages 
secreted significantly lesser amount of TNF-α (Figure 5.20). However, the 
amount of TNF-α secreted by the DV2-infected TLR6-/- murine peritoneal 
macrophages was still higher than the mock-infected TLR6
-/-
 murine 
peritoneal macrophages, indicating that TLR6 activation during dengue virus 
infection did not contribute to all the TNF-α expression, only partially. On the 
contrary, stimulation of TLR6 on murine peritoneal macrophages by DV NS1 
protein contributed to most of the TNF-α detected as DV NS1 protein-treated 
TLR6
-/-
 murine peritoneal macrophages produced IL-6 which was comparable 
to the amount produced by the His-tag-treated TLR6
-/-



























































Figure 5.20 Amount of TNF-α detected in the supernatant of DV NS1 
protein-treated murine peritoneal macrophage culture. 
ELISA was performed to quantify the amount of TNF-α secreted into the 
supernatant by mock-infected, DV2-infected, His-tag-treated, DV NS1 
protein-treated and MALP-2-treated wild-type or TLR6
-/-
 murine peritoneal 
macrophages (1 μg/ml) on day 2 post-treatment. Data represent mean ± SEM 
of three independent experiments. * denotes p-value < 0.05, ** denotes p-
value < 0.005, *** denotes p-value < 0.0001 for t-tests comparing mean 
amount of TNF-α detected in culture supernatants of wild-type murine 
peritoneal macrophages to that of TLR6
-/-
 murine peritoneal macrophages for 
the various treatments. 
 
5.7 SURVIVAL RATE OF DV2-INFECTED TLR6
-/-
 MICE IS HIGHER 
THAN DV2-INFECTED WILD-TYPE MICE  
5.7.1 Survival curve of DV2-infected wild-type and TLR6
-/-
 mice. 
In order to determine if TLR6 activation during dengue virus infection 
contributes to the pathogenesis of the disease, 184 wild-type and 203 TLR6
-/-
 
mice were injected with 2.7 x 10
10
 PFU of DV2 at day 1-2 day-old as 
described in Section 2.11.2. The survival rate of the DV2-infected wild-type 




type mice were found dead on day 1 post-infection, three were found dead on 
day 2 post-infection, three were found dead on day 3 post-infection, ten were 
found dead on day 4 post-infection, nine were found dead on day 5 post-
infection, seven were found dead on day 6 post-infection, one was found dead 
on day 13 post-infection and two were found dead at end point of the study. 
The survival rate of the TLR6
-/-
 DV2-infected mice is 83.0% at the end point 
of the study. Fifteen of the DV2-infected TLR6
-/-
 mice were found dead on 
day 1 post-infection, four were found dead on day 2 post-infection, eight were 
found dead on day 3 post-infection, one was found dead on day 1 post-
infection and one was found dead on day 17 post-infection. Knockout of 
TLR6 increased the survival rate of the mice at the end point of the study by 
21.6%, suggesting that activation of TLR6 may contribute to the pathogenesis 
of the disease, leading to fatality observed in the DV2-infected mouse 
population. Using Log-rank test, DV2-infected wild-type mice survival curve 
was found to be statistically different from DV2-infected TLR6
-/-
 mice. Thus 
knockout of TLR6 significantly changed the survival of the DV2-infected 
mice. A mock-infected wild-type mouse was found dead on day 3 post-
infection and one mock-infected TLR6
-/-
 mouse was found dead on day 1 post-
infection. The cause of death could be congenital disorder or complications 
































Figure 5.21 The survival rate of the DV2-infected mice was determined. 
Wild-type (184 mice) and TLR6
-/-
 (203) mice were infected with 2.7 x 10
10
 
PFU of DV2 strain 16681 at 1-2 day-old via intraperitoneal injection. Mock-
infected wild-type (140 mice) and TLR6
-/-
 (146) mice were injected with 50 μl 
of C6/36 cell culture supernatant. The survival of the mice was monitored 
from day 1 to day 21 on a daily basis. Kaplan-Meier survival curves were 
shown. Log-rank test was performed to determine if there was significant 
difference in survivability between DV2-infected wild-type and TLR6 KO 




























6.0 DISCUSSION & FUTURE WORK 
In the recent years, it has become evident that PRRs play a major role 
in infectious and even in non-infectious diseases (Iwasaki & Medzhitov, 2004; 
Kaisho & Akira, 2006). One family of PRRs, the TLR family has emerged as 
a key component of the innate immune system and it can activate signals 
which are crucial for the initiation of adaptive immune responses (Iwasaki & 
Medzhitov, 2004). Studies in recent years have shown the presence of mRNA 
and protein expression of TLRs in various immune and non-immune cells 
(Nagai et al, 2006; Okamoto et al, 2009; Zarember & Godowski, 2002). 
Human PBMC were found to express the whole range of human TLRs (TLR1-
10) (Siednienko & Miggin, 2009). The expression of TLRs has been found to 
increase following inflammations and exposure to pathogens or specific 
ligands (Komatsuda et al, 2008; Liu et al, 2001; Salomao et al, 2009; Tanabe 
et al, 2003).  In our study, TLR6 was found to be up-regulated in K562 cells 
upon DV infection. This up-regulation suggested the possible involvement of 
TLR6 in dengue virus infection.  
The up-regulation of TLR6 was observed for K562 cells incubated 
with infectious DV2 but not for K562 cells incubated with UV-inactivated 
DV2. UV radiation inactivates viruses through chemical modification of the 
viral genetic material, DNA and RNA (Lytle & Sagripanti, 2005). The 
modification of DNA and RNA by UV radiation hinders DNA and RNA 
polymerases which are essential for virus replication (McGregor, 1999). 
Hence, replication of the DV2 is required for the up-regulation of TLR6 in 
K562 cells.  In addition, it could also suggest that the surface proteins of DV2, 




for the up-regulation. However, there are some evidences that UV radiation 
has an effect on the structure of protein, thus the second point needs to be 
further affirmed (Pattison & Davies, 2006).  
 LPS was documented to increase expression of TLR6 and thus it was 
used as a positive control in our studies (Nhu et al, 2006; Sanlioglu et al, 
2001; Zarember & Godowski, 2002). Reports of LPS stimulating TLR2 were 
made previously but were dismissed later when tested with highly-purified 
LPS. TLR2 and TLR1/6 are usually not activated by most LPS, with only a 
few true exceptions (Girard et al, 2003; Que-Gewirth et al, 2004; Yokota et al, 
2007). The presence of lipoprotein in phenol-extracted LPS led to the 
stimulation of TLR2 and TLR6 (Hirschfeld et al, 2000; Lee et al, 2002). Since 
phenol-extracted LPS can also activate TLR2 and TLR6 due to the lipoprotein 
present, it was also used as an alternate positive control for activation of TLR2 
and TLR6. K562 cells which were treated with high concentration of LPS 
were found to up-regulate TLR6 expression. This could be due to the presence 
of lipoprotein in the phenol-extracted LPS or due to the activation of trans-
acting factors, IRF-1 and IRF-2 by the LPS or a combination of both (Nhu et 
al, 2006). 
Upon recognition of PAMPs by TLRs, a number of different signalling 
pathways are triggered (Mogensen, 2009). Signal transduction by TLRs is 
mediated by five adaptor proteins: MyD88, MAL, TRIF, TRAM and SARM 
(Figure 6.1) (O'Neill & Bowie, 2007). TLR-induced responses are mediated 
by three major signalling pathways: NFκB, mitogen-activated protein kinase 
and IFN regulatory factor pathways (Akira & Takeda, 2004; Akira et al, 2006; 




induces proinflammatory response (Kawai & Akira, 2007). IFN regulatory 
factors, as the name suggests, are required for the production of IFN. Inactive 
NFκB is sequestered in the cytoplasm by inhibitor protein known as IκB 
protein (Kawai & Akira, 2007). IκB protein becomes phosphorylated when 
TLR is stimulated, resulting in its degradation by proteasome (Kawai & Akira, 
2007). Unsequestered NFκB moves into the nucleus and induces expression of 
proinflammatory cytokines (Hayden et al, 2006). Activation of TLR6 recruits 
MyD88 and Mal, leading to activation of NFκB and expression of 
proinflammatory cytokines like IL-6 and TNF-α  (Mogensen, 2009). IL-6 up-
regulation was detected in DV2-infected K562, suggesting that DV2 not only 










Figure 6.1: TLRs and their adaptor molecules. Figure from (Mogensen, 
2009). 
MyD88 and Mal are utilized by TLR1/2 and TLR2/6. Four adaptor molecules, 
MyD88, Mal, TRIF and TRAM are involved in TLR4 signaling while only 
TRIF is utilized by TLR3. MyD88 are utilized by TLR5, TLR7, TLR8 and 
TLR9. SARM negatively regulates TRIF-dependent signalling of TLR3 and 
TLR4. In general, proinflammatory cytokines are induced by MyD88-




RNA interference was used to verify if TLR6 was activated during 
dengue virus infection. shRNA was used instead of siRNA as one drawback 
that the latter has is its effect is only transient in mammalian cells (Hannon, 
2002). Mammalian cells do not have the mechanisms to amplify the silencing 
effects observed in worms and plants (Hannon, 2002). On the contrary, gene 
of shRNA can be incorporated into the genome of a mammalian cell using a 
plasmid and induce stable suppression of target gene (Hannon, 2002). This 
allowed the monitoring of the effect of stable TLR6 suppression on IL-6 




regulation of IL-6 during DV infection, suggesting that IL-6 up-regulation was 
contributed by TLR6 activation. Reduction in the expression of TLR6, 
reduced the amount of IL-6 secreted by DV2-infected K562 while the amount 
of IL-6 secreted by the mock-infected K562 were not affected by the 
knockdown of TLR6 (Figure 3.8). The knockdown of TLR6 did not 
completely eliminate the up-regulation. This could be due to two reasons. 
First, the shRNA that targets TLR6 did not completely inhibit TLR6 protein 
expression. A faint band of TLR6 protein was still detected (Figure 3.6). 
Silencing of gene using RNA interference is known to be just partial inhibition 
of gene (Luo & Chang, 2004). Depletion of a target protein using RNA 
interference is never complete (Campeau & Gobeil, 2011). As the expression 
of TLR6 was only reduced, DV2 can still activate the remaining TLR6, 
leading to only reduction in expression of IL-6 and not the complete 
abrogation of IL-6 expression induced by DV infection. Alternatively, it could 
be due to the activation of other PRRs beside TLR6 during DV infection. 
TLR3 was reported to be activated by DV as well (Tsai et al, 2009). Silencing 
of TLR3 in U937 cells was found to significantly reduce DV-induced IL-8 
production and expression of TLR3 in HEK293 cells induced IL-8 secretion 
after DV infection (Tsai et al, 2009). Although the authors measured IL-8 
instead of IL-6 as an indication of TLR3 activation, IL-6 was also reported to 
be secreted upon activation of TLR3 (Jack et al, 2005; Villacres et al, 2008). 
In addition, expression of TLR3 was detected in K562 cells (Okamoto et al, 
2009). Thus, the activation of TLR3 may also contribute to the IL-6 up-




TLR3 is stimulated by double-stranded RNA (Alexopoulou et al, 
2001). shRNA has to be processed to siRNA by Tat-RNA-binding 
protein/PKR activating protein/Dicer complex in the cells  before RNA 
interference can take place (Rao et al, 2009). siRNA is a form of double-
stranded RNA. TLR3 activation by siRNA and shRNA has been documented 
(Cho et al, 2009; Kariko et al, 2004). The control cells (psiLucGL3-
transfected K562 cells) expressed shRNA but the shRNA does not target any 
endogenous gene in the mammalian cell. As the IL-6 expression of the DV2-
infected TLR6 knockdown K562 cells were compared against that of the 
DV2-infected control cells which also expressed shRNA, any up-regulation of 
the IL-6 due to TLR3 activation would be taken into account. In addition, the 
IL-6 expression by the mock-infected TLR6 knockdown and control K562 
were not high and was comparable to the untransfected K562 cells and thus, 
contribution of IL-6 by activation of TLR3 if any was minimal (Figure 3.3 & 
3.8).  
With the detection of IL-6, the presence of TNF-α presence in the 
supernatant of DV2-infected K562 cells was also assayed. Surprisingly TNF-α 
up-regulation was not detected in DV2-infected K562 cells. It was found 
through literature search that K562 cells have impaired TNF-α expression 
(Sullivan et al, 2007). Upon LPS or PMA stimulation, K562 cells do not 
produce TNF-α. DNA of K562 cells are methylated or partially methylated at 
the TNF-α locus (Beutler & Brown, 1991; Sullivan et al, 2007). DNA 
methylation is one epigenetic mechanism to regulate gene expression 
(Robertson, 2005). DNA methylation prevents transcription and expression of 




K562 cells (Sullivan et al, 2007). Inability of K562 cells to express TNF-α 
suggests that the cell line may not be so suitable for this study and was 
replaced by human PBMC for most of the subsequent experiments.  
Human blood consists of a number of different types of immune cells. 
In our study, Ficoll paque was used to remove erythrocytes from blood cell 
population by density gradient centrifugation. Ficoll paque is composed of 
high molecular weight sucrose polymers and has a density of 1.077g/ml 
(Grisendi et al, 2010). Ficoll paque separates the blood into fractions 
according to the cell density upon centrifugation (Ab Kadir et al, 2012). 
PBMC are comprised of the monocytes, T cells, B cells, natural killer cells 
and dendritic cells. These cells are less dense than Ficoll paque and will be 
found at the upper interface of the Ficoll layer. Erythrocytes, neutrophils and 
eosinophils whose densities are greater than 1.077g/ml will be mostly 
excluded after PBMC isolation. Density of basophils varies around 1.077g/ml 
and thus may be found in the isolated PBMC. The frequencies of the various 
cell populations in PBMC were found to vary among individuals (Eady et al, 
2005). In that particular study which consists of 10 female and 8 male 
volunteers aged between 20 to 43 year-old, the cell populations of the PBMC 
preparations are: 59.4 ± 7.5% T cells, 21.2 ± 6.3% monocytes, 12.3 ± 6.3% 
natural killer cells, 5.3 ± 2.0% B cells and 0.1% ± 0.2% granulocytes (Eady et 
al, 2005). These immune cells play pivotal roles during an infection. 
Among the PBMC, monocytes have been implicated in both the 
protection and immunopathogenesis of dengue (Wong et al, 2012). Depletion 
of monocytes and macrophages in mice using clodronate-loaded liposomes 




of monocytes and macrophages in DV control during an infection (Fink et al, 
2009). Ironically, monocytes were found to be the cells among PBMC that 
supported DV infection and the cells responsible for ADE of DV infection 
(Blackley et al, 2007; Hotta et al, 1984). In our study, PBMC culture was also 
found to be permissive to DV2 infection and virus titer peaked at day 2 post-
infection (Figure 4.1). This is consistent with the result obtained by another 
group. The group reported the growth curve of DV2 in monocytes to peak at 
day 2 post-infection (Al-Alimi et al, 2014). Although other cell types in the 
PBMC like T cells and B cells were found to be less susceptible to DV 
infection, they are likely to play important roles during DV infection (Blackley 
et al, 2007). There are evidences that cell-cell cross-talk between various 
immune cells in PBMC affect cytokine production during an infection (Eberl 
et al, 2009; He et al, 2014b). Hence, PBMC culture would be a more 
representative and physiological model of infection than using monocytes 
alone.  
Upon dengue virus infection, PBMC secretes both IL-6 and TNF-α 
(Figure 4.2 & 4.3). This is consistent with what was observed in the sera of 
dengue patients. Dengue patients’ sera have been found to contain high level 
of IL-6 (Hober et al, 1993; Pinto et al, 1999; Restrepo et al, 2008) and in vitro 
experiments using monocytic cell lines also showed up-regulation of IL-6 
during dengue virus infection (Levy et al). Similarly, TNF-α level was also 
increased in the sera of dengue patients (Hober et al, 1993; Pinto et al, 1999; 
Restrepo et al, 2008). In addition, production of IL-6 and TNF-α by PBMC 
from different donors were reported to vary slightly after stimulation 




when PBMC from different donors were used. As the coefficients of variation 
for IL-6 and TNF-α were less than one, the variance should be low. 
Similar to monocytes, IL-6 and TNF-α are implicated in both the 
protection and immunopathogenesis of dengue virus infection (Fernandez-
Mestre et al, 2004; Lei et al, 2001). Upon sensing the presence of foreign 
microbes through recognition of PAMPs, biological mediators like IL-6 and 
TNF-α are released. Although these mediators initiate and regulate the 
inflammatory response and adaptive immune response to eliminate foreign 
microbes, they have also been found to be involved in lethal manifestations 
like septic shock syndrome, vascular leakage and cachexia, resulting from 
disease, infection or injury (Iwasaki & Medzhitov, 2010; Kawai & Akira, 
2011; Tracey & Cerami, 1994). This provided evidence that the manifestation 
of illness could also be caused by the host own immune system, not 
necessarily by exogenous pathogens.  
 Similar to the observation in K562 cells, PBMC can up-regulate TLR6 
during DV infection. TLR6 was found to be up-regulated on day 3 post-
infection (Figure 4.4). TLR6 requires heterodimerization with TLR2 to 
recognize ligand and trigger cytokine production (Farhat et al, 2008a; Ozinsky 
et al, 2000; Triantafilou et al, 2006). In addition, TLR2/6 heterodimers have 
been successfully crystallized (Kang et al, 2009). As TLR2 is partner of 
TLR6, its expression by PBMC during dengue virus infection was also 
investigated. Like what was observed for TLR6, TLR2 was found to be up-
regulated by PBMC on day 3 post-infection (Figure 4.5). This result was 
supported by the findings by another research group. CD14+ monocytes 




TLR2 was also up-regulated by PBMC during in vitro DV2 infection 
(Azeredo et al, 2010). In addition, they also found that UV-inactivated DV2 
did not increase TLR2 expression, suggesting that virus replication is required 
for the up-regulation of TLR2 (Azeredo et al, 2010). This observation is 
similar to what we observed for TLR6 expression of K562 cells. From our 
flow cytometric data, it was observed that PBMC increased their TLR2 and 
TLR6 expression during DV infection. From the data (Table 4.3), the up-
regulation of TLR2/6 was contributed in 3 ways. Firstly, those cells which are 
not expressing both TLR2 and TLR6 began to express them after DV 
infection. The proportion of cells in the R3 (TLR2- & TLR6-) decreased from 
57.03% to 51.78% during DV infection. However, this decrease in percentage 
could also be due to the specific expansion of cells which are expressing 
TLR6 and TLR2 during DV infection. Secondly, those cells which are 
expressing only either TLR2 or TLR6 began to express both of them. The 
proportion of cells in the R1 (Only TLR6+) and R4 (Only TLR2+) regions 
decreased from 5.76% to 1.44% and 7.69% to 5.66% respectively. The 
proportion of cells in the R2 (Both TLR2+ & TLR6+) region increased from 
29.53% to 41.11% during DV infection. Lastly, the cells which are already 
expressing the two TLRs, began to increase the expression of both TLRs, 
resulting in more of these receptors on the surface of these cells. The median 
FITC fluorescence intensity of the R2 region increased from 27.74 to 46.00, 
suggesting more TLR2 expression by the cells which were expressing both 
TLR2 and TLR6. The median APC fluorescence intensity of the R2 region 
increased from 28.76 to 35.72, suggesting more TLR6 expression by the cells 




The mechanism of TLR2 regulation has not been fully elucidated 
(Chamorro et al, 2009; Johnson & Tapping, 2007; Shuto et al, 2002; Wang et 
al, 2002a). It was reported that chromatin remodelling involving DNase I and 
restriction enzyme occurs at TLR2 promoter region following infection (Wang 
et al, 2002a). This remodelling of chromatin increases accessibility of 
transcription factors resulting in greater transcription of TLR2 (Wang et al, 
2002a).  In addition, two pathways were found to be important for TLR2 
regulation. IKKβ-IκBα-dependent NFκB pathway activation and MKK3/6-
p38α/β pathway inhibition are essential for TLR2 expression (Shuto et al, 
2002). One study supported the involvement of NFκB in TLR2 expression. 
PDTC, a pharmacologic inhibitor of NFκB was shown to prevent the up-
regulation of TLR2 by TLR2 and TLR4 agonist (Johnson & Tapping, 2007). 
On the other hand, the up-regulation of TLR6 is not well-studied and remained 
unclear.     
Besides TLR2 and TLR6, another receptor, CD14 was up-regulated on 
the PBMC upon DV infection. CD14 was found to be up-regulated on the 
TLR2 and TLR6 positive PBMC on day 1 to day 3 post-infection. CD14 is a 
receptor that functions in LPS recognition and it is widely used as a 
differentiation marker for human monocytes and macrophages (Ziegler-
Heitbrock & Ulevitch, 1993). On day 1 post-infection, the proportion of 
TLR6+ PBMC that was CD14+ is 51.23% for the mock-infected PBMC and 
53.23% for the DV2-infected PBMC. On day 3 post-infection, the proportion 
of TLR6+ PBMC that was CD14+ is 53.21% for the mock-infected PBMC 
and 59.24% for the DV2-infected PBMC. On day 1 post-infection, the 




PBMC and 58.67% for the DV2-infected PBMC. On day 3 post-infection, the 
proportion of TLR2+ PBMC that was CD14+ is 64.55% for the mock-infected 
PBMC and 72.67% for the DV2-infected PBMC. The CD14 expression was 
increased for both mock-infected and DV2-infected TLR6+ and TLR2+ 
PBMC but the up-regulation of CD14 is higher for the DV2-infected PBMC. 
The increase in CD14 observed in mock-infected and DV2-infected PBMC 
could be due to minimal cell proliferation of the CD14+, TLR6+, TLR2+ 
PBMC. The higher CD14+ increase observed in DV2-infected PBMC could 
be attributed to increased proliferation due to TLR ligation. It has been shown 
that TLR ligation can trigger cell proliferation of hematopoietic stem cells 
(Nagai et al, 2006). This can be verified in the future using cell proliferation 
assay. Cytokines produced during an infection were also proposed to be 
responsible for the increase in CD14+ monocytes (Ziegler-Heitbrock, 2007).  
The increase in CD14+ cells during DV infection were also observed by other 
groups. CD14+ monocytes expressing TLR2 were increased in peripheral 
blood from dengue patients (Azeredo et al, 2010). Higher CD14+ cells in the 
PBMC were also observed in DHF patients compared with DF patients which 
may have implications for ADE and the immunopathogenesis of DHF (Durbin 
et al, 2008). As CD14+ cells in the PBMC are mainly monocytes, the increase 
in CD14+ cells could suggest the specific expansion of this cell type during 
DV infection. It was also noted that those CD14+ cells were almost 100% 
positive for both TLR2 and TLR6. 
The use of PBMC as a cell model is not without its shortcoming too. 
PBMC being primary cells have very low transfection efficiency. Thus, the 




method was used to interfere with TLR2 and TLR6 signaling of PBMC. 
Neutralizing antibodies which block TLR2 and TLR6 signaling were used 
instead in this study. This method has been adopted by many research groups 
which were working on TLRs in human or animal cell models, indicating the 
feasibility and effectiveness of the method (Fong et al, 2010; Li et al, 2013; 
Meng et al, 2004). The effectiveness of the TLR2 and TLR6 neutralizing 
antibodies used in our study were also tested using TLR2 and TLR6 specific 
ligand, MALP-2. Treatment of TLR2 and TLR6 neutralizing antibodies prior 
to MALP-2 stimulation reduced the IL-6 and TNF-α production to almost the 
same level as the mock-infected PBMC, suggesting that the neutralizing 
antibodies were highly effective. Similarly, the treatment of TLR2 and TLR6 
neutralizing antibodies prior to DV infection, reduced the IL-6 and TNF-α 
production but the reduction was not as great as compared to that of the 
MALP-2 stimulated control (Figure 4.7). This could suggest that the IL-6 
production during DV infection was only partially contributed by TLR2 and 
TLR6 activation.  
After affirmation of the activation of TLR2 and TLR6 during DV 
infection, the dengue viral protein responsible for the activation was 
investigated. The 10 dengue viral proteins were separately added to PBMC 
culture and the IL-6 and TNF-α expression by the treated PBMC culture were 
quantified. Among the 10 dengue viral proteins, only DV NS1 protein up-
regulated IL-6 expression by the PBMC while dengue envelope protein and 
dengue NS3 protein induced slight down-regulation of IL-6 expression (Figure 
4.9). Similar results were obtained for TNF-α detection, only DV NS1 protein 




down-regulation was observed. In addition, UV-inactivated DV2 failed to 
induce IL-6 and TNF-α expression by the PBMC, suggesting that DV 
replication is required for the induction. In addition, a dose-dependent effect 
of DV NS1 protein on the amount of IL-6 and TNF-α secreted by PBMC was 
observed. When the amount of DV NS1 protein added to the PBMC reduced 
from 50 μg/ml to 1 μg/ml, the magnitude of IL-6 and TNF-α induced also 
decreased but more so for the IL-6 expression (Figure 4.9 & Figure 4.11). 1 
μg/ml of dengue NS1 protein is a concentration within the range which can be 
detected in the sera of dengue patients (several nanograms per millilitre to 
several micrograms per millilitre) (Alcon et al, 2002). 
The induction of IL-6 and TNF-α by DV NS1 protein was further 
verified to be through TLR2 and TLR6. Neutralizing antibodies of TLR2 and 
TLR6 reduced IL-6 and TNF-α production by PBMC after stimulation with 
DV NS1 protein. DV NS1 protein also stimulated up-regulation of TLR2 and 
TLR6 of PBMC when added to the PBMC culture. Thus, DV NS1 protein 
could be the protein produced during DV infection that led to the increased in 
TLR2 and TLR6. This explained why DV replication was required for the 
stimulation of TLR2 and TLR6 up-regulation and activation. DV NS1 protein 
was documented to be secreted by infected cells and the presence of DV NS1 
protein was detected in the sera of patients (Gutsche et al, 2011; Libraty et al, 
2002; Somnuke et al, 2011). Moreover, the amount of DV NS1 protein in the 
sera of patients was found to correlate with the severity of the dengue disease 
(Libraty et al, 2002). This correlation suggested that DV NS1 protein plays an 
important role in the pathogenesis of dengue disease. From the SEAP reporter 




addition of DV NS1 protein directly to the HEK cell culture induced activation 
of NFκB on day 1 post-infection. The delay in the activation of NFκB could 
be due to the time taken for the DV infection to produce DV NS1 protein. This 
was supported by the data obtained from the DV NS1 protein detection in the 
supernatant of DV2-infected PBMC. DV NS1 protein secreted by DV2-
infected PBMC increased on day 2 post-infection. The secreted DV NS1 
protein can interact with TLR2 and TLR6 found on the surface of PBMC.  
Activation of TLR2 and TLR6 by DV NS1 protein up-regulates IL-6 
and TNF-α production. Since both cytokines were implicated in increasing the 
endothelial permeability of cells, this activation is likely to have an effect on 
the endothelial permeability as well (Abe et al, 1990; Ali et al, 1999). 
Vascular leakage is the manifestation of the more severe forms of dengue 
infection, DHF and DSS. (Trung & Wills, 2010). There are evidences to 
support that physiologic dysfunction in DHF and DSS is related to biological 
mediators that are capable of inducing severe disease without much structural 
injury (Bhamarapravati, 1989). Patients who recover from the critical stage of 
DHF or DSS do so very quickly without any sequelae (Bhamarapravati, 1989). 
No severe pathologic manifestation in major organs and no evidence of 
secondary microbial infection was found in most of the expired patients 
(Bhamarapravati, 1989). The absence of secondary infection implies no 
immunosuppression was induced during dengue infection. Increase in 
endothelial permeability is proposed to be the major cause of vascular leakage 
seen in dengue patients (Carr et al, 2003). Although the endothelial cells were 
shown to be susceptible to DV infection in vitro, the endothelium of DHF 




(Andrews et al, 1978; Carr et al, 2003; Sahaphong et al, 1980). The alterations 
in endothelial cell permeability were proposed to be induced by biological 
mediators produced by other cell types during DV infection and not due to 
direct viral replication or cytolysis of the endothelial cells (Carr et al, 2003). 
Our results corroborated their hypothesis. Using HUVEC endothelial cell 
permeability model, it was found that TLR2 and TLR6 activation by DV NS1 
protein increased endothelial permeability (Figure 4.21). IL-6 and TNF-α have 
also been shown to induce endothelial permeability in our study. The effect of 
TLR2 and TLR6 activation on the permeability of HUVEC was due to the 
production of biological mediators like IL-6. In addition, IL-6 and TNF-α have 
been shown to down-regulate VE-cadherin at the cell to cell junction 
(Kayakabe et al, 2012; Menon et al, 2006). Our results also supported their 
findings (Figure 4.22). Hence, production of IL-6 and TNF-α by TLR2 and 
TLR6 activation down-regulates VE-cadherin at the cell to cell junction, 
leading to increased endothelial permeability. 
As mentioned previously, the roles of monocytes, IL-6 and TNF-α 
during DV infection have conflicting reports as to whether they are beneficial 
or detrimental to the hosts. Since TLR2 and TLR6 are in close association 
with monocytes, IL-6 and TNF-α, the activation of TLR2 and TLR6 by DV 
protein could be beneficial or detrimental to the hosts and required further 
investigation. To understand the impact of TLR2 and TLR6 activation on the 
host during dengue virus infection, the use of cell-based model is inadequate. 
The symptoms of DV infection cannot be demonstrated using in vitro cell-




In this study, we have developed a murine model for dengue virus 
infection using 1-2 day old C57BL/6 mouse. 1 week-old, 2 week-old and 4 
week-old C57BL/6 mice were found to be resistant to DV infection (Table 5.1, 
5.2, 5.3, 5.5 & 5.7). This suggests the age of the mice at the point of DV 
infection is an important factor for the susceptibility of the mice to DV 
infection. It was shown that the younger the mice, the more susceptible they 
are to DV infection. This result is supported by the findings of other groups. 
The observation of higher susceptibility of younger mice to infection was 
ascribed to the immaturity of the neonatal immune cells, minimal T helper 1 
function and immune deficiencies among T cells, B cells and antigen-
presenting cells in neonates (Adkins et al, 2004; Elahi et al, 2013; Procario et 
al, 2012; Zaghouani et al, 2009). 
Besides the age of the mice, the amount of DV used for the infection 
was also observed to be important. When 4-week old mice were injected with 
higher amount of DV, viremia was detected in two of the mice. This could be 
due to the high amount of DV introduced into the mice that overwhelmed the 
immune system, allowing the successful replication of DV.  
Although consistent viremia was detected in the mice infected at 1-2 
day old for both wild-type and TLR6
-/-
 mice, the virus titers were observed to 
decrease as the day of infection progressed. This suggests that the DV2-
infected mice were able to mount an effective immune response to fight the 
infection. The fast clearance of DV may suggest that the innate immunity is 
sufficient for the clearing. Published studies have demonstrated that innate 
immunity was sufficient to clear DV infection using human cell-engrafted scid 




virus titers in the livers of the DV2-infected mice for both wild-type and 
TLR6
-/-
 mice. However, the virus titers of the livers were not as consistent 
compared to that of the sera, only a few of the livers of DV2-infected mice 
were detected to contain infectious virus (Figure 5.7). An important point to be 
taken into consideration is that the DV detected in the liver could be 
contributed partially by the virus found in the blood. However, the blood 
contamination has been minimized as the blood of the pups was harvested 
before the harvest of the liver. Hence, the liver should contain very minimum 
amount of blood when harvested. The observation that virus was detected in 
all the serum samples but not in all the liver samples of infected pups at day 1 
and day 2 post-infection showed that the above mentioned contamination was 
kept to a minimal.      
It has been reported that C57BL/6 strain of immunocompetent mice 
can develop hemorrhage, high virus titers, macrophage infiltration and TNF-α 
production upon DV2 intradermal inoculations (Chen et al, 2007a). Despite 
following the murine model developed by Chen and co-workers (2007a), none 
of our 4-week old DV2-infected mice developed hemorrhage. DV2 strain 
16681 of two different amounts (1.56 x 10
8 
PFU and 1.08 x 10
11 
PFU) was 
used for the intradermal infection of our mice. C57BL/6 mice were injected 
with 3 x 10
9 
PFU, 8 x 10
7 
PFU and 4 x 10
7
 PFU of DV2 strain 16681 by Chen 
and co-workers (Chen et al, 2007a). The mice injected with the various 
amount of DV2 were capable of showing hemorrhagic symptoms. Of the two 
infective doses of DV which we had used for injection of the mice, the lower 
amount was comparable to the amount of the DV2 used by Chen and co-




not due to differences in amount of virus used. The discrepancies could be 
attributed to differences in genetic background of the strain of mice or genetic 
difference in the DV2 16681 strain. The genetic difference could be 
introduced by mutation during passaging of the virus.   
No symptoms of DV infection was observed for our 4 week-old, 2 
week-old and 1 week-old DV2-infected mice. However, some clinical 
symptoms and signs of infection were observed in our 1-2 day-old suckling 
murine model. The symptoms include enlarged belly, lower limb paralysis and 
moribundity. Some of the DV2-infected mice even succumbed to the infection 
and fatality was observed. Enlarged belly was observed in some of the DV2-
infected mice. It was noticed that the enlargement was due to accumulation of 
fluid at the site of injection, peritoneal cavity. High virus titers were detected 
from the fluid harvested from the enlarged belly. This acculmulation of fluid 
could be due to inflammation, resulting in increased vascular permeability 
(Wiig, 2011). Fluid accumulation in the visceral organs was reported to be a 
characteristic feature of increased vascular permeability induced by DV 
(Balsitis et al, 2010; Shresta et al, 2006). However, fluid accumulation in the 
visceral organs was not common in our murine model, only one such possible 
case was noted during our study. Fluid accumulation in the peritoneal cavity 
was more common in our murine model. Signs of fluid accumulation could 
suggest dysfunction of vascular integrity.  
One clinical sign observed in dengue patients and our murine model is 
paralysis of extremities (Garcia-Rivera & Rigau-Perez, 2002). The occurrence 
of paralysis was observed to be between day 10 to day 14 of infection (Table 




observed in other murine model of DV infection and the time of development 
was similar to our murine model (Huang et al, 2000; Shresta et al, 2004). 
AG129 mice were reported to develop paralysis within 7 to 14 days post-
infection (Shresta et al, 2004). The development of paralysis was faster than 
the wild-type counterpart of the mice and thus the authors attributed the 
difference to the AG129’s deficiency in IFN receptors.  
Since paralysis of the hindlimbs was observed, hindlimbs of mice both 
symptomatic and asymptomatic were harvested for virus quantification via 
plaque assays. DV was detected in the limbs of both DV2-infected wild-type 
and TLR6
-/-
 mice. One of the mice showed paralysis in only one of its limbs. 
The virus titer in the paralyzed limb (1.4 x 10
3
 PFU/g) was comparable to that 
of the normal limb (4.0 x 10
3
 PFU/g), suggesting that paralysis was not due to 
virus replication in the limb. Moreover, no virus was detected in the limbs for 
one of the paralyzed mice, further affirming this point.   
It was reported that the paralysis was due to virus replication in the 
central nervous system (Shresta et al, 2004). Hence, the brains of the mice 
were harvested for quantification of virus. Among the asymptomatic mice, 
virus was detected in the brain as early as day 1 post-infection for the DV2-
infected TLR6
-/-
 mice and the virus persisted in the brains of the mice till the 
endpoint of the experiment. This suggests that virus clearance is least efficient 
in the brain of the mice. Similar trend was observed for AG129 murine model 
(Shresta et al, 2004). AG129 mice harboured DV in the extraneural tissues and 
neural tissues at day 3 post-infection, with higher viral titers in the extraneutral 
sites than the neural sites. By day 7 post-infection, virus was only detected in 




was noticed that the viral loads in the brain of the asymptomatic mice (< 10
4
 
PFU/g) were much lower than that of the mice displaying hindlimb paralysis 
(2.8 x 10
4
 PFU/g, 5.2 x 10
5 
PFU/g, 8.2 x 10
5
 PFU/g, 7.1 x 10
5 
PFU/g) (Table 
5.10). Hence, extensive replication of DV in the brain of the mice can result in 
the paralysis observed in the mice. Similarly, AG129 mice with paralysis were 
reported to carry high viral loads in the brain (Shresta et al, 2004). The viral 




 PFU/g (Table 
5.10).  
Mice which were not sacrificed but were monitored for disease 
progression, recovered two days after the onset of paralysis. The brain, liver 
and limb of one of the mice were harvested and quantified for virus. No virus 
was detected in the liver and limbs of the recovered mouse while virus was 
still detected in the brain. The viral load (2.1 x 10
4
 PFU/g) was still higher 
than the asymptomatic mice but lower than that of the symptomatic mice 
(Table 5.10 & Figure 5.13). This suggests that viral load in the brain of the 
mice can be controlled by the mouse immune system even though the clearing 
of the virus in the brain was not as efficient compared to the sera, liver and 
limb. The microglial cells are the main cell type of the innate immune system 
in the brain (Rivest, 2009). The microgial cells also express TLRs and produce 
pro-inflammatory mediators in response to TLR ligands (Rivest, 2003; Rivest, 
2006). Human microgial cells express high levels of TLR2 and TLR3, 
moderate levels of TLR4, TLR5, TLR6, TLR7 and TLR8 but low level of 
TLR9 (Bsibsi et al, 2002). Mouse microgial cells express similar TLRs except 
for TLR5 (McKimmie & Fazakerley, 2005). As there is no lymphatic system 




antigen-presenting cells, the immune responses in the brain are limited 
(Rivest, 2009). This may explain why the virus can persist in the brain for a 
long time in contrast to other organs and sera. As mentioned for the virus 
detected in the livers, DV detected in the brain could also be contributed 
partially by the virus found in the blood. However, this type of contamination 
has been minimized as the blood of the pups was harvested before the harvest 
of the brain. The observation that virus was detected in all the serum samples 
but not in all the brain samples of infected pups at day 1 and day 2 post-
infection showed that the above mentioned contamination was kept to a 
minimal.  
As human IL-6 and TNF-α were detected in our human cell-based 
model upon DV infection, murine IL-6 and TNF-α were assayed for in the 
sera of the DV2-infected mice. Unlike what was observed for the cell-based 
model, IL-6 and TNF-α were only detected to be up-regulated in the sera of 
some of the DV2-infected mice. For both wild-type and TLR6
-/-
 mice, the 
level of IL-6 and TNF-α detected in some of the DV2-infected mice were 
comparable to that of the mock-infected mice. This suggests only some of the 
DV2-infected mice responded to the DV-infection by up-regulation of IL-6 
and TNF-α. This high variability of hyporesponsiveness of young mice to 
stimulation was also documented by other research groups (Adkins et al, 
2004; Elahi et al, 2013; Zaghouani et al, 2009). Among the responsive mice, 
the IL-6 and TNF-α of the DV2-infected wild-type mice were higher than the 
DV2-infected TLR6
-/-
 mice and the up-regulation lasted for a longer time. 




activation contributed to IL-6 and TNF-α production in mice during DV 
infection.  
As there was high variability in the IL-6 and TNF-α result obtained 
from the sera of mice, murine peritoneal macrophages from 4-week old wild-
type and TLR6
-/-
 C57BL/6 mice were used to further verify the involvement of 
TLR6 in IL-6 and TNF-α expression during DV infection. Murine peritoneal 
macrophages were widely used to elucidate TLR ligands and TLR6 ligands 
were among those tested (Chang et al, 2007; Murawski et al, 2009; Sharma et 
al, 2005; Takeuchi et al, 2001). MALP-2 was also used to further confirm the 
functionality of TLR6 of the wild-type and TLR6
-/-
 murine peritoneal 
macrophages. Wild-type murine peritoneal macrophages up-regulated both IL-
6 and TNF-α upon stimulation by MALP-2 while TLR6-/- murine peritoneal 
macrophages were non-responsive. During DV infection, TLR6
-/-
 murine 
peritoneal macrophages produced significantly less IL-6 and TNF-α compared 
to that of the wild-type murine peritoneal macrophages. This corroborates the 
result obtained from the sera of the mice. Knockout of TLR6 did not 
completely abrogate IL-6 and TNF-α up-regulation during DV infection, 
suggesting TLR6 activation only partially contributed to the IL-6 and TNF-α 
detected during DV infection. The redundancy of pathogen sensing pathways 
was documented (Court et al, 2010). One pathogen can be recognized by 
multiple PRRs and the signalling pathways activated downstream of TLRs 
have redundancy (Savva & Roger, 2013). The synergistic effect of activating 
more than one PRR has also been reported. Synergy between TLR2 and TLR4 
can potentiate the up-regulation of cytokine production (Dennehy et al, 2008). 






 mice did not have significant difference in virus detected in the sera of 
the mice. Knockout of TLR6 did not prevent the activation of macrophages. 
The macrophages can still sense the presence of pathogen through other PRRs 
and gets activated to produce IL-6 and TNF-α. This also explains why virus 
replication in murine peritoneal macrophages was not affected by the absence 
of TLR6 as shown by in vitro DV infection of murine peritoneal macrophages 
(Figure 5.17). Similar to our human PBMC model, DV NS1 protein stimulated 
the production of IL-6 and TNF-α by wild-type murine peritoneal 
macrophages. TLR6
-/-
 murine peritoneal macrophages were unresponsive to 
DV NS1 protein stimulation, suggesting DV NS1 protein activates TLR6 of 
murine peritoneal macrophages to produce IL-6 and TNF-α. In this study, DV 
NS1 protein has been shown to be the viral protein responsible for TLR2 and 
TLR6 stimulation during DV infection. However, whether the stimulation is 
direct or indirect has not been elucidated. Studies have demonstrated that host-
derived molecules may also stimulate TLR signalling (Erridge, 2010). Hence, 
there is a possibility that DV NS1 protein may stimulate the release of 
endogenous ligands to trigger TLR2 and TLR6 activation rather than binding 
to TLR2/6 complex itself.      
As DV NS1 protein was found to be the viral protein that is activating 
TLR6, the duration in which DV NS1 protein remained in circulation in the 
mice injected with DV were investigated. The presence of DV NS1 protein 
was detected in all the sera of DV2-infected wild-type and TLR6
-/-
 mice using 
Bio-rad platelia kit Dengue NS1 antigen detection kit for day 1 to day 5. The 
level of DV NS1 protein detected from the DV2-infected wild-type mice was 
not significantly different from that of the DV2-infected TLR6
-/-




was probably a consequence of similar virus titers in the sera of the DV2-
infected wild-type and TLR6
-/-
 mice. DV NS1 protein remained in circulation 
in the mice longer than DV (Figure 5.6 & 5.16). DV NS1 protein remained 
detectable in the sera of DV2-infected mice at day 5 post-infection while DV 
were no longer detected in most of the sera by day 4 post-infection. Slower 
rate of DV NS1 protein clearance compared with DV from the plasma of 
dengue patients were also reported (Libraty et al, 2002). DV NS1 protein was 
less efficiently cleared by the immune system. The DV NS1 protein in 
circulation could also be contributed by DV in other organs as DV were 
detected to remain for a longer duration in the organs compared to sera (Figure 
5.6, 5.7, 5.12 & 5.13). Another possibility is that the DV NS1 protein does not 
degrade quickly and has longer half-life in the blood.   
The presence of DV NS1 protein level in the mice could be responsible 
for stimulating IL-6 and TNF-α level in the mice, as shown using the murine 
peritoneal macrophages. DV NS1 protein level remained relatively high from 
day 1 to day 5 post-infection. This could be the reason why wild-type mice 
still observed high IL-6 and TNF-α expression even when virus titer dropped 
to 0 PFU/ml in the sera for most of the mice while IL-6 and TNF-α of TLR6-/- 
mice dropped after the elimination of DV from the sera (Figure 5.14 & 5.15). 
This may suggest that IL-6 and TNF-α in the sera at the later part of infection 
was mostly contributed by DV NS1 protein activating TLR6.  
The Kaplan-meier survival plot was used to estimate the survival of the 
wild-type and TLR6
-/-
 mice population after DV infection for over 21 days. 
The survival plots of the DV2-infected wild-type and TLR6
-/-
 mice intercept, 




higher for a period of time during DV infection but became lower compared to 
the other population as the infection progresses (Figure 5.21). The DV2-
infected TLR6
-/-
 mice have a lower survival probability at earlier time points 
and the DV2-infected wild-type mice have a lower survival probability at later 
time points. This could be due to the replication of DV in the brain of the 
TLR6
-/-
 mice. Viral loads were detected in the brain of the TLR6
-/-
 mice at day 
1 post-infection but not for wild-type mice. This suggests that the brain of 
pups were more vulnerable to DV infection in the absence of TLR6. Sensing 
of DV through other PRRs may be more limited for the microgial cells during 
the early development of the mice and thus TLR6 appeared to play a more 
critical role. This vulnerability decreased with age as TLR6 mice suffering 
from paraplegia were found to be able to recover from it. The overall survival 
probability of wild-type mice during DV2 infection is lower than TLR6
-/-
 
mice. In the absence of TLR6 activation, the overall survival probability of the 
mice to DV infection increases. This suggests the involvement of TLR2 and 
TLR6 in the immunopathogenesis of DV infection. Activation of TLR2 and 
TLR6 by DV NS1 protein up-regulates IL-6 and TNF-α. High expression of 
IL-6 and TNF-α have been shown to be associated with fatality of mice (Araki 
et al, 2010; Atrasheuskaya et al, 2003a). Many of the DV2-infected wild-type 
mice died on day 4 to day 6 post-infection when viremia of the mice has 
already subsided. Prolong up-regulation of IL-6 and TNF-α due to stimulation 
of TLR6 by DV NS1 protein may be the cause of death for the wild-type mice. 
Prolong up-regulation of IL-6 and TNF-α may increase the risk of the mice 




Dengue viral protein, NS1 activates TLR6 and its coreceptor on human 
PBMC and leads to the activation of NFκB which in turn induces the 
production of proinflammatory cytokine, IL-6 and TNF-α. Our results show 
for the first time that TLR6 and TLR2 are the pathogen-recognition receptors 
that participate in the sensing of DV during DV infection and activation of 
TLR6 can ultimately lead to increased endothelial permeability in the HUVEC 
cell model. Using the results obtained from this study, a model to illustrate 
how TLR6 and TLR2 may play a role in the immunopathogenesis of dengue 
virus infection is proposed (Figure 6.2). In a dengue infection, the cells 
infected by DV will initiate and undergo viral replication and viral protein 
synthesis. DV NS1 protein synthesized by the infected cell secretes out and is 
recognized as a PAMP by TLR2 and TLR6 expressing cells. This recognition 
activates the cells to secrete biological mediators which induce up-regulation 
of TLR2 and TLR6. The up-regulation of TLR2 and TLR6, sensitize the cells 
to the presence of DV. More cells detect the presence of DV NS1 protein and 
are activated. This further up-regulated the biological mediators and 
proinflammatory cytokines which down-regulate VE-cadherin. In addition, as 
reported by one research group, the secreted DV NS1 proteins can bind to the 
endothelial cells via interactions with heparin sulfate and chondroitin sulfate E 
(Avirutnan et al, 2007). The bound DV NS1 protein may be recognized by 
anti-NS1 antibodies, resulting in immune responses against the endothelial 
cells. The down-regulation of VE-cadherin and the recognition of DV NS1 
protein on endothelial cells by anti-NS1 antibodies increase endothelial 
permeability, resulting in higher risks of hemorrhagic development and 





Figure 6.2. Proposed model of the role of TLR2/6 in immunopathogenesis 
of dengue virus infection.  
(1) A susceptible cell (eg. monocytes/macrophages) gets infected by DV. Viral 
replicate is initiated and viral proteins are synthesized in the infected cell. (2) 
DV NS1 proteins are secreted by the infected cell. The secreted DV NS1 
protein binds to TLR2/6 complex on the cell surface and activates the 
complex. (3) Activation of the complex leads to activation of NFκB. NFκB 
induces the expression of biological mediators that stimulate the up-regulation 
of TLR2/6. (4) Uninfected cells began to express TLR2/6 or express higher 
level of TLR2/6 and become sensitized to the presence of DV NS1 protein. (5) 
DV NS1 protein stimulates the TLR2/6 positive cells and induced expression 
of cytokines such as IL-6 and TNF-α. IL-6 and TNF-α down-regulate VE-






The effect of TLR2/6 on immunopathogenesis of dengue virus 
infection is likely to act through IL-6 and TNF. It was shown in our studies 
that DV NS1 protein is able to activate TLR2 and TLR6 to induce up-
regulation of IL-6 and TNF-α. This production of cytokines could be the cause 
of the development of dengue hemorrhagic fever as cytokines were found to 
play important roles in several viral hemorrhagic fevers (Atrasheuskaya et al, 
2003b; Marty et al, 2006). Furthermore, cytokines were found to have 
prognostic value in DV infection in other studies (Bethell et al, 1998; Bozza et 
al, 2008; Hober et al, 1993). All these findings suggest that a possible 
treatment for dengue would be to control the proinflammatory cytokine 
production during DV infection. It was reported that when an 
immunomodulator, tetracycline hydrochloride was administered into Tick-
Borne Encephalitis virus patients, the concentration of IL-6 and TNF-α were 
reduced and the patients have a faster clinical recovery (Atrasheuskaya et al, 
2003b). This study suggests that modulation of the amount of IL-6 and TNF-α 
can have a positive effect on patients with viral hemorrhagic fevers. Since 
TLR6 activation during DV infection can contribute to the production of 
proinflammatory cytokines, immunomodulation approaches that target TLR6 
can reduce the proinflammatory cytokines. The reduction of proinflammatory 
cytokines can potentially prevent increase in endothelial permeability and the 
progression of the disease to the more severe forms. 
Recent studies have shown that TLRs may be responsible for the 
manifestation of autoimmune diseases, allergy, cancer, infectious diseases and 
sepsis (O'Neill, 2003; Romagne, 2007). In our study, the activation of TLR6 




TLR6 in the immunopathogenesis of DV infection. The roles of TLRs in 
human diseases are not fully understood but there are in vitro and animal 
model data to support TLR roles in disease initiation and progression 
(Hennessy et al, 2010; Savva & Roger, 2013). There is a growing interest in 
exploring TLRs as the therapeutic targets for these diseases (Gearing, 2007; 
Hennessy et al, 2010; O'Neill, 2003; Romagne, 2007; Savva & Roger, 2013). 
It was proposed that inhibition of TLR function might limit disease 
pathogenesis in conditions such as sepsis, rheumatoid arthritis and systemic 
lupus erythematosus, in which the immune system is inappropriately 
overactive (Hennessy et al, 2010; O'Neill, 2003; Savva & Roger, 2013). 
Antimalarial drugs such as hydroxychloroquine which act as a TLR7, TLR8 
and TLR9 antagonist are used for the treatments of rheumatoid arthritis and 
systemic lupus erythematosus (Hennessy et al, 2010; Sun et al, 2007b). TLR2 
has been implicated in the pathogenesis of systemic lupus erythematosus, 
diabetes, Alzheimer’s disease (Chen et al, 2007b; Urbonaviciute et al, 2008). 
A TLR2-specific monoclonal antibody, OPN-305 which inhibits TLR2-
mediated proinflammatory cytokine production is being tested for the potential 
treatment of inflammatory diseases (Hennessy et al, 2010). Drugs or 
antibodies that target TLR2 are likely to have an effect on TLR2 and TLR6 
signaling as shown by our PBMC model, in which inhibition of IL-6 and 
TNF-α was achieved by the blocking of either TLR2 or TLR6. Our data 
suggest that targeting TLR2/6 do not completely eliminate the immune 
response, just reducing the magnitude of the cytokines produced. The host 
may not be vulnerable to pathogens in the duration of TLR6-targeted therapy, 




potential for intervention in dengue virus infection and amelioration of disease 
symptoms. Besides using small-molecule agonists or antagonists for targeting 
TLRs, the use of microRNAs in the regulation of TLRs may be available in 
the near future (Fabbri et al, 2012; He et al, 2014a). 
In our study, we have found that TLR2 and TLR6 were involved in the 
detection of the presence of DV during DV infection. From our results, there 
are evidences that other PRRs are also likely to be involved. It would provide 
a better understanding of the DV infection if the identities of those PRRs were 
elucidated. Some of the proposed PRRs are TLR3, TLR7 and TLR8 (Tsai et 
al, 2009).  
As mentioned earlier in this chapter, direct interaction of NS1 with 
TLR2/6 complex has not been shown by us. The reports of TLR2 activated by 
endogenous ligands released in the presence of foreign pathogens may suggest 
a need to elucidate whether NS1 activation of TLR2/6 complex is direct or 
indirect (Erridge, 2010). 
Knockout of TLR6 was found to increase survival of the mice during 
DV infection. We did not check the effect of TLR2 knockout on the survival 
of the mice during DV infection as knockout of TLR2 will implicate another 
TLR, TLR1. TLR2 can heterodimerize with TLR1 or TLR6 to detect different 
PAMPs (Farhat et al, 2008a). The effect of TLR2 knockout on the survival of 
the mice during DV infection can be investigated in the future to further 
support our findings. The feasibility of using TLR6 or TLR2 antagonist for the 
treatment of dengue virus infection can be investigated using our murine 




From our murine model results, DV NS1 protein is likely to be the 
viral protein which induces IL-6 and TNF-α production in the mice during 
dengue virus infection, especially towards the later timepoint of DV infection. 
Introduction of DV NS1 protein alone into the mice may be able to induce the 
symptoms seen in DV2-infected mice and should be further investigated in the 
future to know the role of DV NS1 protein in the pathogenesis of DV 
infection.   
In conclusion, DV NS1 protein is found to be responsible for triggering 
TLR2 and TLR6 during DV infection in our study. This stimulation partially 
contributes to IL-6 and TNF-α expression during DV infection. Expression of 
IL-6 and TNF-α down-regulates VE-cadherin and increases endothelial 
permeability. Activation of TLR6 may play a role in the immunopathogenesis 
of DV infection in the mice as survivability of the mice increased in the 
absence of TLR6. Lastly, our results provide an insight into the possibility of 
































Ab Kadir R, Zainal Ariffin SH, Megat Abdul Wahab R, Kermani S, Senafi S 
(2012) Characterization of mononucleated human peripheral blood cells. 
TheScientificWorldJournal 2012: 843843 
 
Abe Y, Sekiya S, Yamasita T, Sendo F (1990) Vascular hyperpermeability 
induced by tumor necrosis factor and its augmentation by IL-1 and IFN-
gamma is inhibited by selective depletion of neutrophils with a monoclonal 
antibody. J Immunol 145: 2902-2907 
 
Adkins B, Leclerc C, Marshall-Clarke S (2004) Neonatal adaptive immunity 
comes of age. Nat Rev Immunol 4: 553-564 
 
Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, 
Bernal-Rubio D, Shabman RS, Simon V et al (2012) DENV inhibits type I 
IFN production in infected cells by cleaving human STING. PLoS Pathog 8: 
e1002934 
 
Akira S (2006) TLR signaling. Curr Top Microbiol Immunol 311: 1-16 
 
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 
499-511 
 
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate 
immunity. Cell 124: 783-801 
 
Al-Alimi AA, Ali SA, Al-Hassan FM, Idris FM, Teow SY, Mohd Yusoff N 
(2014) Dengue virus type 2 (DENV2)-induced oxidative responses in 
monocytes from glucose-6-phosphate dehydrogenase (G6PD)-deficient and 
G6PD normal subjects. PLoS neglected tropical diseases 8: e2711 
 
Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M (2002) 
Enzyme-linked immunosorbent assay specific to Dengue virus type 1 
nonstructural protein NS1 reveals circulation of the antigen in the blood 
during the acute phase of disease in patients experiencing primary or 
secondary infections. J Clin Microbiol 40: 376-381 
 
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of 
double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. 




Ali MH, Schlidt SA, Chandel NS, Hynes KL, Schumacker PT, Gewertz BL 
(1999) Endothelial permeability and IL-6 production during hypoxia: role of 
ROS in signal transduction. Am J Physiol 277: L1057-1065 
 
Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX (2001) Mutational 
evidence for an internal fusion peptide in flavivirus envelope protein E. 
Journal of virology 75: 4268-4275 
 
Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, 
Huber-Lang M (2008) Interaction between the coagulation and complement 
system. Advances in experimental medicine and biology 632: 71-79 
 
Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, Logan 
SM, Aderem A (2005) Evasion of Toll-like receptor 5 by flagellated bacteria. 
Proc Natl Acad Sci U S A 102: 9247-9252 
 
Andrews BS, Theofilopoulos AN, Peters CJ, Loskutoff DJ, Brandt WE, Dixon 
FJ (1978) Replication of dengue and junin viruses in cultured rabbit and 
human endothelial cells. Infect Immun 20: 776-781 
 
Aoki C, Hidari KI, Itonori S, Yamada A, Takahashi N, Kasama T, Hasebe F, 
Islam MA, Hatano K, Matsuoka K et al (2006) Identification and 
characterization of carbohydrate molecules in mammalian cells recognized by 
dengue virus type 2. Journal of biochemistry 139: 607-614 
 
Araki K, Gangappa S, Dillehay DL, Rouse BT, Larsen CP, Ahmed R (2010) 
Pathogenic virus-specific T cells cause disease during treatment with the 
calcineurin inhibitor FK506: implications for transplantation. J Exp Med 207: 
2355-2367 
 
Arias CF, Preugschat F, Strauss JH (1993) Dengue 2 virus NS2B and NS3 
form a stable complex that can cleave NS3 within the helicase domain. 
Virology 193: 888-899 
 
Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, 
Calderwood SK (2002) Novel signal transduction pathway utilized by 
extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 
277: 15028-15034 
 
Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A (2009) NS5 of dengue 






Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G (2003a) Anti-
TNF antibody treatment reduces mortality in experimental dengue virus 
infection. FEMS immunology and medical microbiology 35: 33-42 
 
Atrasheuskaya AV, Fredeking TM, Ignatyev GM (2003b) Changes in immune 
parameters and their correction in human cases of tick-borne encephalitis. Clin 
Exp Immunol 131: 148-154 
 
Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, 
Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, 
Puttikhunt C et al (2006) Vascular leakage in severe dengue virus infections: a 
potential role for the nonstructural viral protein NS1 and complement. J Infect 
Dis 193: 1078-1088 
 
Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk 
W, Malasit P, Atkinson JP, Diamond MS (2007) Secreted NS1 of dengue 
virus attaches to the surface of cells via interactions with heparan sulfate and 
chondroitin sulfate E. PLoS Pathog 3: e183 
 
Azeredo EL, Neves-Souza PC, Alvarenga AR, Reis SR, Torrentes-Carvalho 
A, Zagne SM, Nogueira RM, Oliveira-Pinto LM, Kubelka CF Differential 
regulation of toll-like receptor-2, toll-like receptor-4, CD16 and human 
leucocyte antigen-DR on peripheral blood monocytes during mild and severe 
dengue fever. Immunology 130: 202-216 
 
Azeredo EL, Neves-Souza PC, Alvarenga AR, Reis SR, Torrentes-Carvalho 
A, Zagne SM, Nogueira RM, Oliveira-Pinto LM, Kubelka CF (2010) 
Differential regulation of toll-like receptor-2, toll-like receptor-4, CD16 and 
human leucocyte antigen-DR on peripheral blood monocytes during mild and 
severe dengue fever. Immunology 130: 202-216 
 
B.D. Lindenbach CMR (2007) Flaviviridae: the viruses and their replication. 
1104 
 
Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, Beatty PR, 
Harris E (2009) Tropism of dengue virus in mice and humans defined by viral 
nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg 80: 
416-424 
 
Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson 
S, Diamond MS, Beatty PR, Harris E (2010) Lethal antibody enhancement of 






Barbalat R, Lau L, Locksley RM, Barton GM (2009) Toll-like receptor 2 on 
inflammatory monocytes induces type I interferon in response to viral but not 
bacterial ligands. Nat Immunol 10: 1200-1207 
 
Baronti C, Sire J, de Lamballerie X, Querat G (2010) Nonstructural NS1 
proteins of several mosquito-borne Flavivirus do not inhibit TLR3 signaling. 
Virology 404: 319-330 
 
Barton GM (2007) Viral recognition by Toll-like receptors. Semin Immunol 
19: 33-40 
 
Basilio-de-Oliveira CA, Aguiar GR, Baldanza MS, Barth OM, Eyer-Silva 
WA, Paes MV (2005) Pathologic study of a fatal case of dengue-3 virus 
infection in Rio de Janeiro, Brazil. The Brazilian journal of infectious diseases 
: an official publication of the Brazilian Society of Infectious Diseases 9: 341-
347 
 
Basu A, Chaturvedi UC (2008) Vascular endothelium: the battlefield of 
dengue viruses. FEMS immunology and medical microbiology 53: 287-299 
 
Bauer J, Herrmann F (1991) Interleukin-6 in clinical medicine. Annals of 
hematology 62: 203-210 
 
Beg AA (2002) Endogenous ligands of Toll-like receptors: implications for 
regulating inflammatory and immune responses. Trends Immunol 23: 509-512 
 
Benarroch D, Selisko B, Locatelli GA, Maga G, Romette JL, Canard B (2004) 
The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase 
activities of Dengue virus protein NS3 are Mg2+-dependent and require a 
functional Walker B motif in the helicase catalytic core. Virology 328: 208-
218 
 
Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, Buurman WA, Cardosa 
MJ, White NJ, Kwiatkowski D (1998) Pathophysiologic and prognostic role of 
cytokines in dengue hemorrhagic fever. J Infect Dis 177: 778-782 
 
Beutler B, Brown T (1991) A Cat Reporter Construct Allows Ultrasensitive 
Estimation of Tnf Synthesis, and Suggests That the Tnf Gene Has Been 
Silenced in Non-Macrophage Cell-Lines. Journal of Clinical Investigation 87: 
1336-1344 
 
Bhamarapravati N (1989) Hemostatic defects in dengue hemorrhagic fever. 




Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake 
JM, Brownstein JS, Hoen AG, Sankoh O et al (2013) The global distribution 
and burden of dengue. Nature 496: 504-507 
 
Bhuvanakantham R, Chong MK, Ng ML (2009) Specific interaction of capsid 
protein and importin-alpha/beta influences West Nile virus production. 
Biochem Biophys Res Commun 389: 63-69 
 
Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, 
Wagner H, Kirschning CJ, Ter Meulen V, Schneider-Schaulies S (2002) 
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 
signaling. Journal of virology 76: 8729-8736 
 
Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, 
Jin X (2007) Primary human splenic macrophages, but not T or B cells, are the 
principal target cells for dengue virus infection in vitro. Journal of virology 
81: 13325-13334 
 
Blackwell TS, Christman JW (1997) The role of nuclear factor-kappa B in 
cytokine gene regulation. American journal of respiratory cell and molecular 
biology 17: 3-9 
 
Boehme KW, Compton T (2004) Innate sensing of viruses by toll-like 
receptors. Journal of virology 78: 7867-7873 
 
Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE (1994) Tumor 
necrosis factor alpha is an autocrine growth factor for normal human B cells. 
Proc Natl Acad Sci U S A 91: 7007-7011 
 
Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, 
Tryggvason K, Gordon S, Russell DG (2009) MARCO, TLR2, and CD14 are 
required for macrophage cytokine responses to mycobacterial trehalose 
dimycolate and Mycobacterium tuberculosis. PLoS Pathog 5: e1000474 
 
Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza 
PT, Kubelka CF (2008) Multiplex cytokine profile from dengue patients: MIP-
1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86 
 
Brandt KJ, Fickentscher C, Kruithof EK, de Moerloose P (2013) TLR2 ligands 
induce NF-kappaB activation from endosomal compartments of human 





Brandt WE (1988) From the World Health Organization. Current approaches 
to the development of dengue vaccines and related aspects of the molecular 
biology of flaviviruses. J Infect Dis 157: 1105-1111 
 
Braun N, Michel U, Ernst BP, Metzner R, Bitsch A, Weber F, Rieckmann P 
(1996) Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha 
(TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-
alpha production. Neuroscience letters 215: 75-78 
 
Bsibsi M, Ravid R, Gveric D, van Noort JM (2002) Broad expression of Toll-
like receptors in the human central nervous system. Journal of neuropathology 
and experimental neurology 61: 1013-1021 
 
Bulich R, Aaskov JG (1992) Nuclear localization of dengue 2 virus core 
protein detected with monoclonal antibodies. J Gen Virol 73 ( Pt 11): 2999-
3003 
 
Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of 
dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180 
 
Campeau E, Gobeil S (2011) RNA interference in mammals: behind the 
screen. Briefings in functional genomics 10: 215-226 
 
Carr JM, Hocking H, Bunting K, Wright PJ, Davidson A, Gamble J, Burrell 
CJ, Li P (2003) Supernatants from dengue virus type-2 infected macrophages 
induce permeability changes in endothelial cell monolayers. J Med Virol 69: 
521-528 
 
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An 
endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl 
Acad Sci U S A 72: 3666-3670 
 
Cassaday RD, Malik JT, Chang JE (2011) Regression of Hodgkin Lymphoma 
After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's 
Disease: A Case Report and Review of the Literature. Cl Lymph Myelom 
Leuk 11: 289-292 
 
Cervantes JL, Weinerman B, Basole C, Salazar JC (2012) TLR8: the forgotten 
relative revindicated. Cellular & molecular immunology 9: 434-438 
 
Chambers TJ, McCourt DW, Rice CM (1989) Yellow fever virus proteins 
NS2A, NS2B, and NS4B: identification and partial N-terminal amino acid 




Chamorro S, Garcia-Vallejo JJ, Unger WW, Fernandes RJ, Bruijns SC, Laban 
S, Roep BO, t Hart BA, van Kooyk Y (2009) TLR triggering on tolerogenic 
dendritic cells results in TLR2 up-regulation and a reduced proinflammatory 
immune program. J Immunol 183: 2984-2994 
 
Chang S, Dolganiuc A, Szabo G (2007) Toll-like receptors 1 and 6 are 
involved in TLR2-mediated macrophage activation by hepatitis C virus core 
and NS3 proteins. J Leukoc Biol 82: 479-487 
 
Chareonsirisuthigul T, Kalayanarooj S, Ubol S (2007) Dengue virus (DENV) 
antibody-dependent enhancement of infection upregulates the production of 
anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-
inflammatory cytokine production, in THP-1 cells. J Gen Virol 88: 365-375 
 
Chaturvedi UC, Raghupathy R, Pacsa AS, Elbishbishi EA, Agarwal R, Nagar 
R, Misra A, Kapoor S, Mukerjee R, Mathur A et al (1999) Shift from a Th1-
type response to Th2-type in dengue haemorrhagic fever. Current Science 76: 
63-69 
 
Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA (2007a) Both virus 
and tumor necrosis factor alpha are critical for endothelium damage in a 
mouse model of dengue virus-induced hemorrhage. Journal of virology 81: 
5518-5526 
 
Chen HL, Lin SR, Liu HF, King CC, Hsieh SC, Wang WK (2008a) Evolution 
of dengue virus type 2 during two consecutive outbreaks with an increase in 
severity in southern Taiwan in 2001-2002. Am J Trop Med Hyg 79: 495-505 
 
Chen J, Ng MM, Chu JJ (2008b) Molecular profiling of T-helper immune 
genes during dengue virus infection. Virol J 5: 165 
 
Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM (2007b) Toll-
like receptors in inflammation, infection and cancer. International 
immunopharmacology 7: 1271-1285 
 
Chen RF, Wang L, Cheng JT, Chuang H, Chang JC, Liu JW, Lin IC, Yang 
KD (2009) Combination of CTLA-4 and TGFbeta1 gene polymorphisms 
associated with dengue hemorrhagic fever and virus load in a dengue-2 
outbreak. Clin Immunol 131: 404-409 
 
Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks 
RM (1997) Dengue virus infectivity depends on envelope protein binding to 




Chen YC, Wang SY, King CC (1999) Bacterial lipopolysaccharide inhibits 
dengue virus infection of primary human monocytes/macrophages by 
blockade of virus entry via a CD14-dependent mechanism. Journal of virology 
73: 2650-2657 
 
Cheng HJ, Lei HY, Lin CF, Luo YH, Wan SW, Liu HS, Yeh TM, Lin YS 
(2009) Anti-dengue virus nonstructural protein 1 antibodies recognize protein 
disulfide isomerase on platelets and inhibit platelet aggregation. Molecular 
immunology 47: 398-406 
 
Chiewsilp P, Scott RM, Bhamarapravati N (1981) Histocompatibility antigens 
and dengue hemorrhagic fever. Am J Trop Med Hyg 30: 1100-1105 
 
Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, 
Green MG, Baffi JZ, Ambati BK, De Falco M et al (2009) Small interfering 
RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. 
Proc Natl Acad Sci U S A 106: 7137-7142 
 
Chuang TH, Ulevitch RJ (2000) Cloning and characterization of a sub-family 
of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 
11: 372-378 
 
Chuang YC, Wang SY, Lin YS, Chen HR, Yeh TM (2013) Re-evaluation of 
the pathogenic roles of nonstructural protein 1 and its antibodies during 
dengue virus infection. Journal of biomedical science 20: 42 
 
Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ (1994) 
Correlation between detection of plasminogen cross-reactive antibodies and 
hemorrhage in dengue virus infection. J Infect Dis 170: 1304-1307 
 
Churdboonchart V, Bhamarapravati N, Futrakul P (1983) Crossed 
immunoelectrophoresis for the detection of split products of the third 
complement in dengue hemorrhagic fever. I. Observations in patients' plasma. 
Am J Trop Med Hyg 32: 569-576 
 
Clark RB, Cervantes JL, Maciejewski MW, Farrokhi V, Nemati R, Yao X, 
Anstadt E, Fujiwara M, Wright KT, Riddle C et al (2013) Serine lipids of 
Porphyromonas gingivalis are human and mouse Toll-like receptor 2 ligands. 
Infect Immun 81: 3479-3489 
 
Clyde K, Kyle JL, Harris E (2006) Recent advances in deciphering viral and 
host determinants of dengue virus replication and pathogenesis. Journal of 




Cole GA, Wisseman CL, Jr. (1969) Pathogenesis of type 1 dengue virus 
infection in suckling, weanling and adult mice. 1. The relation of virus 
replication to interferon and antibody formation. American journal of 
epidemiology 89: 669-680 
 
Colpitts TM, Barthel S, Wang P, Fikrig E (2011) Dengue virus capsid protein 
binds core histones and inhibits nucleosome formation in human liver cells. 
PloS one 6: e24365 
 
Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, 
Finberg RW (2003) Human cytomegalovirus activates inflammatory cytokine 
responses via CD14 and Toll-like receptor 2. Journal of virology 77: 4588-
4596 
 
Cooper AM, Mayer-Barber KD, Sher A (2011) Role of innate cytokines in 
mycobacterial infection. Mucosal immunology 4: 252-260 
 
Court N, Vasseur V, Vacher R, Fremond C, Shebzukhov Y, Yeremeev VV, 
Maillet I, Nedospasov SA, Gordon S, Fallon PG et al (2010) Partial 
redundancy of the pattern recognition receptors, scavenger receptors, and C-
type lectins for the long-term control of Mycobacterium tuberculosis infection. 
J Immunol 184: 7057-7070 
 
de Almeida LA, Macedo GC, Marinho FA, Gomes MT, Corsetti PP, Silva 
AM, Cassataro J, Giambartolomei GH, Oliveira SC (2013) Toll-like receptor 6 
plays an important role in host innate resistance to Brucella abortus infection 
in mice. Infect Immun 81: 1654-1662 
 
Dejana E, Vestweber D (2013) The role of VE-cadherin in vascular 
morphogenesis and permeability control. Progress in molecular biology and 
translational science 116: 119-144 
 
Dennehy KM, Ferwerda G, Faro-Trindade I, Pyz E, Willment JA, Taylor PR, 
Kerrigan A, Tsoni SV, Gordon S, Meyer-Wentrup F et al (2008) Syk kinase is 
required for collaborative cytokine production induced through Dectin-1 and 
Toll-like receptors. Eur J Immunol 38: 500-506 
 
Desai TR, Leeper NJ, Hynes KL, Gewertz BL (2002) Interleukin-6 causes 
endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 
104: 118-123 
 
Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, 




receptor 2-mediated pathways and inflammatory activation. Gastroenterology 
127: 1513-1524 
 
Duchini A, Govindarajan S, Santucci M, Zampi G, Hofman FM (1996) Effects 
of tumor necrosis factor-alpha and interleukin-6 on fluid-phase permeability 
and ammonia diffusion in CNS-derived endothelial cells. Journal of 
investigative medicine : the official publication of the American Federation for 
Clinical Research 44: 474-482 
 
Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, 
Balmaseda A, Harris E (2008) Phenotyping of peripheral blood mononuclear 
cells during acute dengue illness demonstrates infection and increased 
activation of monocytes in severe cases compared to classic dengue fever. 
Virology 376: 429-435 
 
Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, Foxall RJ, 
Doleman JF, Elliott RM (2005) Variation in gene expression profiles of 
peripheral blood mononuclear cells from healthy volunteers. Physiological 
genomics 22: 402-411 
 
Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, Moser B (2009) A 
rapid crosstalk of human gammadelta T cells and monocytes drives the acute 
inflammation in bacterial infections. PLoS Pathog 5: e1000308 
 
Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B (2002) An RNA 
cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase 
NS5: crystal structure and functional characterization. The EMBO journal 21: 
2757-2768 
 
Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, Chaturvedi V, 
Strong BS, Qualls JE, Steinbrecher KA et al (2013) Immunosuppressive 
CD71+ erythroid cells compromise neonatal host defence against infection. 
Nature 504: 158-162 
 
Erridge C (2010) Endogenous ligands of TLR2 and TLR4: agonists or 
assistants? J Leukoc Biol 87: 989-999 
 
Erridge C, Bennett-Guerrero E, Poxton IR (2002) Structure and function of 
lipopolysaccharides. Microbes and infection / Institut Pasteur 4: 837-851 
 
Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, 
Fadda P, Mao C, Nuovo GJ et al (2012) MicroRNAs bind to Toll-like 
receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci 




Falvo JV, Brinkman BMN, Tsytsykova AV, Tsai EY, Yao TP, Kung AL, 
Goldfeld AE (2000a) A stimulus-specific role for CREB-binding protein 
(CBP) in T cell receptor-activated tumor necrosis factor alpha gene 
expression. Proceedings of the National Academy of Sciences of the United 
States of America 97: 3925-3929 
 
Falvo JV, Uglialoro AM, Brinkman BMN, Merika M, Parekh BS, Tsai EY, 
King HC, Morielli AD, Peralta EG, Maniatis T et al (2000b) Stimulus-specific 
assembly of enhancer complexes on the tumor necrosis factor alpha gene 
promoter. Mol Cell Biol 20: 2239-2247 
 
Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-
Beckmann U, Roschmann K, Jung G, Wiesmuller KH et al (2008a) 
Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum 
but does not lead to differential signaling. J Leukoc Biol 83: 692-701 
 
Farhat K, Sauter KS, Brcic M, Frey J, Ulmer AJ, Jungi TW (2008b) The 
response of HEK293 cells transfected with bovine TLR2 to established 
pathogen-associated molecular patterns and to bacteria causing mastitis in 
cattle. Vet Immunol Immunopathol 125: 326-336 
 
Feldmann M (2008) Many cytokines are very useful therapeutic targets in 
disease. The Journal of clinical investigation 118: 3533-3536 
 
Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara A (2009a) Pathogenesis 
of Flavivirus Infections: Using and Abusing the Host Cell. Cell Host Microbe 
5: 318-328 
 
Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara A (2009b) Pathogenesis 
of flavivirus infections: using and abusing the host cell. Cell Host Microbe 5: 
318-328 
 
Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, Layrisse Z 
(2004) TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic 
manifestation in dengue fever patients. Tissue antigens 64: 469-472 
 
Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W (2009) 
Depletion of macrophages in mice results in higher dengue virus titers and 
highlights the role of macrophages for virus control. Eur J Immunol 39: 2809-
2821 
 
Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V (1999) 




mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. 
Journal of virology 73: 6104-6110 
 
Fong DJ, Hogaboam CM, Matsuno Y, Akira S, Uematsu S, Joshi AD (2010) 
Toll-like receptor 6 drives interleukin-17A expression during experimental 
hypersensitivity pneumonitis. Immunology 130: 125-136 
 
Friberg H, Jaiswal S, West K, O'Ketch M, Rothman AL, Mathew A (2012) 
Analysis of human monoclonal antibodies generated by dengue virus-specific 
memory B cells. Viral Immunol 25: 348-359 
 
Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, 
Alexander HR (2002) Induction of permeability across endothelial cell 
monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-
dependent mechanism: relationship between the procoagulant and 
permeability effects of TNF. Blood 100: 1334-1339 
 
Garcia-Rivera EJ, Rigau-Perez JG (2002) Encephalitis and dengue. Lancet 
360: 261 
 
Gearing AJ (2007) Targeting toll-like receptors for drug development: a 
summary of commercial approaches. Immunology and cell biology 85: 490-
494 
 
Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL (2001a) Cutting 
edge: bacterial flagellin activates basolaterally expressed TLR5 to induce 
epithelial proinflammatory gene expression. J Immunol 167: 1882-1885 
 
Gewirtz AT, Simon PO, Jr., Schmitt CK, Taylor LJ, Hagedorn CH, O'Brien 
AD, Neish AS, Madara JL (2001b) Salmonella typhimurium translocates 
flagellin across intestinal epithelia, inducing a proinflammatory response. The 
Journal of clinical investigation 107: 99-109 
 
Girard R, Pedron T, Uematsu S, Balloy V, Chignard M, Akira S, Chaby R 
(2003) Lipopolysaccharides from Legionella and Rhizobium stimulate mouse 
bone marrow granulocytes via Toll-like receptor 2. Journal of cell science 
116: 293-302 
 
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Grp B 
(2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors 
may predispose to significant increase in tuberculosis risk - A multicenter 





Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal 
antibody-mediated enhancement of dengue virus infection in vitro and in vivo 
and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427 
 
Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 
59-74 
 
Grisendi G, Anneren C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, 
Luminari S, Maur M, Frassoldati A, Palazzi G et al (2010) GMP-
manufactured density gradient media for optimized mesenchymal 
stromal/stem cell isolation and expansion. Cytotherapy 12: 466-477 
 
Guan Y, Ranoa DR, Jiang S, Mutha SK, Li X, Baudry J, Tapping RI (2010) 
Human TLRs 10 and 1 share common mechanisms of innate immune sensing 
but not signaling. J Immunol 184: 5094-5103 
 
Gubler DJ (1998a) Dengue and dengue hemorrhagic fever. Clin Microbiol 
Rev 11: 480-496 
 
Gubler DJ (1998b) The global pandemic of dengue/dengue haemorrhagic 
fever: current status and prospects for the future. Ann Acad Med Singapore 
27: 227-234 
 
Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic fever: the 
emergence of a global health problem. Emerg Infect Dis 1: 55-57 
 
Gubler DJ, Reed D, Rosen L, Hitchcock JR, Jr. (1978) Epidemiologic, 
clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J 
Trop Med Hyg 27: 581-589 
 
Gurkan OU, He C, Zielinski R, Rabb H, King LS, Dodd-o JM, D'Alessio FR, 
Aggarwal N, Pearse D, Becker PM (2011) Interleukin-6 mediates pulmonary 
vascular permeability in a two-hit model of ventilator-associated lung injury. 
Experimental lung research 37: 575-584 
 
Gutsche I, Coulibaly F, Voss JE, Salmon J, d'Alayer J, Ermonval M, Larquet 
E, Charneau P, Krey T, Megret F et al (2011) Secreted dengue virus 
nonstructural protein NS1 is an atypical barrel-shaped high-density 





Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, 
Vazquez S, Morier L, Alvarez A, Gould EA, Kouri G et al (2007) Neutralizing 
antibodies after infection with dengue 1 virus. Emerg Infect Dis 13: 282-286 
 
Guzman MG, Alvarez M, Rodriguez R, Rosario D, Vazquez S, Vald s L, 
Cabrera MV, Kouri G (1999) Fatal dengue hemorrhagic fever in Cuba, 1997. 
International journal of infectious diseases : IJID : official publication of the 
International Society for Infectious Diseases 3: 130-135 
 
Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, 
Hunsperger E, Kroeger A, Margolis HS, Martinez E et al (2010) Dengue: a 
continuing global threat. Nature reviews Microbiology 8: S7-16 
 
Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L (1990) 
Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic 
study. Am J Trop Med Hyg 42: 179-184 
 
Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, 
Busse LA, Zukowski MM, Wright SD (1994) Lipopolysaccharide (LPS)-
binding protein accelerates the binding of LPS to CD14. J Exp Med 179: 269-
277 
 
Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus 
monkeys by passively transferred antibody. J Infect Dis 140: 527-533 
 
Halstead SB (2009) Antibodies determine virulence in dengue. Annals of the 
New York Academy of Sciences 1171 Suppl 1: E48-56 
 
Halstead SB (2012) Controversies in dengue pathogenesis. Paediatr Int Child 
Health 32 Suppl 1: 5-9 
 
Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to 
pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to 
antibody response and virus recovered. Yale J Biol Med 42: 311-328 
 
Halstead SB, Rojanasuphot S, Sangkawibha N (1983) Original antigenic sin in 
dengue. Am J Trop Med Hyg 32: 154-156 
 
Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M (2011) Exogenous 
ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine 





Hannon GJ (2002) RNA interference. Nature 418: 244-251 
 
Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, 
Akira S, Underhill DM, Aderem A (2001) The innate immune response to 
bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103 
 
Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. 
Oncogene 25: 6758-6780 
 
He X, Jing Z, Cheng G (2014a) MicroRNAs: new regulators of Toll-like 
receptor signalling pathways. BioMed research international 2014: 945169 
 
He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, Huang H (2014b) gammadelta 
T cell and other immune cells crosstalk in cellular immunity. Journal of 
immunology research 2014: 960252 
 
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, 
Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-
stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529 
 
Henchal EA, Putnak JR (1990) The dengue viruses. Clin Microbiol Rev 3: 
376-396 
 
Hendarto SK, Hadinegoro SR (1992) Dengue encephalopathy. Acta 
paediatrica Japonica; Overseas edition 34: 350-357 
 
Hennessy EJ, Parker AE, O'Neill LA (2010) Targeting Toll-like receptors: 
emerging therapeutics? Nature reviews Drug discovery 9: 293-307 
 
Hidari KI, Suzuki T (2011) Dengue virus receptor. Tropical medicine and 
health 39: 37-43 
 
Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, 
Shimizu M, Maini R, Feldmann M et al (1988) Excessive production of 
interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J 
Immunol 18: 1797-1801 
 
Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ (2000) Cutting edge: 
repurification of lipopolysaccharide eliminates signaling through both human 





Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC, 
Qureshi N, Michalek SM, Vogel SN (2001) Signaling by toll-like receptor 2 
and 4 agonists results in differential gene expression in murine macrophages. 
Infect Immun 69: 1477-1482 
 
Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, Imbert P, 
Pecarere JL, Vergez-Pascal R, Wattre P et al (1993) Serum levels of tumor 
necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta 
(IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331 
 
Hochdorfer T, Kuhny M, Zorn CN, Hendriks RW, Vanhaesebroeck B, 
Bohnacker T, Krystal G, Huber M (2011) Activation of the PI3K pathway 
increases TLR-induced TNF-alpha and IL-6 but reduces IL-1beta production 
in mast cells. Cellular signalling 23: 866-875 
 
Hofmann S, Grasberger H, Jung P, Bidlingmaier M, Vlotides J, Janssen OE, 
Landgraf R (2002) The tumour necrosis factor-alpha induced vascular 
permeability is associated with a reduction of VE-cadherin expression. 
European journal of medical research 7: 171-176 
 
Hordijk PL, Anthony E, Mul FP, Rientsma R, Oomen LC, Roos D (1999) 
Vascular-endothelial-cadherin modulates endothelial monolayer permeability. 
Journal of cell science 112 ( Pt 12): 1915-1923 
 
Hotta H, Wiharta AS, Hotta S, Homma M (1984) Dengue type 2 virus 
infection in human peripheral blood monocyte cultures. Microbiology and 
immunology 28: 1099-1109 
 
Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY 
(2000) Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J 
Gen Virol 81: 2177-2182 
 
Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM (1997) 
Antibodies against dengue virus E protein peptide bind to human plasminogen 
and inhibit plasmin activity. Clin Exp Immunol 110: 35-40 
 
Hung NT (2012) Fluid management for dengue in children. Paediatr Int Child 
H 32: 39-42 
 
Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: 






Igarashi A (1978) Isolation of a Singh's Aedes albopictus cell clone sensitive 
to Dengue and Chikungunya viruses. J Gen Virol 40: 531-544 
 
Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despins S, Mayette J, Hobdey SE, 
Bisaillon M (2009) The flavivirus NS5 protein is a true RNA 
guanylyltransferase that catalyzes a two-step reaction to form the RNA cap 
structure. RNA 15: 2340-2350 
 
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive 
immune responses. Nat Immunol 5: 987-995 
 
Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the 
innate immune system. Science 327: 291-295 
 
Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, 
Antel JP (2005) TLR signaling tailors innate immune responses in human 
microglia and astrocytes. J Immunol 175: 4320-4330 
 
Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR (2000) 
Dengue virus nonstructural protein 1 is expressed in a glycosyl-
phosphatidylinositol-linked form that is capable of signal transduction. Faseb J 
14: 1603-1610 
 
Janot L, Secher T, Torres D, Maillet I, Pfeilschifter J, Quesniaux VF, 
Landmann R, Ryffel B, Erard F (2008) CD14 works with toll-like receptor 2 
to contribute to recognition and control of Listeria monocytogenes infection. J 
Infect Dis 198: 115-124 
 
Jersmann HP (2005) Time to abandon dogma: CD14 is expressed by non-
myeloid lineage cells. Immunology and cell biology 83: 462-467 
 
Jessie K, Fong MY, Devi S, Lam SK, Wong KT (2004) Localization of 
dengue virus in naturally infected human tissues, by immunohistochemistry 
and in situ hybridization. J Infect Dis 189: 1411-1418 
 
Jeyaseelan S, Chu HW, Young SK, Freeman MW, Worthen GS (2005) 
Distinct roles of pattern recognition receptors CD14 and Toll-like receptor 4 in 
acute lung injury. Infect Immun 73: 1754-1763 
 
Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce 
B, Broxmeyer H, Manolagas SC (1992) Increased osteoclast development 




Jin X, Block OT, Rose R, Schlesinger J (2009) Dengue vaccine development 
and dengue viral neutralization and enhancement assays. Antiviral therapy 14: 
739-749 
 
Jindadamrongwech S, Thepparit C, Smith DR (2004) Identification of GRP 78 
(BiP) as a liver cell expressed receptor element for dengue virus serotype 2. 
Archives of virology 149: 915-927 
 
Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine 
testing. Journal of virology 73: 783-786 
 
Johnson CM, Tapping RI (2007) Microbial products stimulate human Toll-like 
receptor 2 expression through histone modification surrounding a proximal 
NF-kappaB-binding site. The Journal of biological chemistry 282: 31197-
31205 
 
Juffrie M, Meer GM, Hack CE, Haasnoot K, Sutaryo, Veerman AJ, Thijs LG 
(2001) Inflammatory mediators in dengue virus infection in children: 
interleukin-6 and its relation to C-reactive protein and secretory phospholipase 
A2. Am J Trop Med Hyg 65: 70-75 
 
Julander JG, Perry ST, Shresta S (2011) Important advances in the field of 
anti-dengue virus research. Antiviral chemistry & chemotherapy 21: 105-116 
 
Jung YO, Cho ML, Lee SY, Oh HJ, Park JS, Park MK, Park MJ, Ju JH, Kim 
SI, Park SH et al (2009) Synergism of toll-like receptor 2 (TLR2), TLR4, and 
TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a 
spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-
deficient mice. Immunol Lett 123: 138-143 
 
Kaisho T, Akira S (2006) Toll-like receptor function and signaling. The 
Journal of allergy and clinical immunology 117: 979-987; quiz 988 
 
Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, Han SH, Lee H, Paik 
SG, Lee JO (2009) Recognition of lipopeptide patterns by Toll-like receptor 2-
Toll-like receptor 6 heterodimer. Immunity 31: 873-884 
 
Kariko K, Bhuyan P, Capodici J, Weissman D (2004) Small interfering RNAs 
mediate sequence-independent gene suppression and induce immune 






Kato D, Era S, Watanabe I, Arihara M, Sugiura N, Kimata K, Suzuki Y, 
Morita K, Hidari KI, Suzuki T (2010) Antiviral activity of chondroitin 
sulphate E targeting dengue virus envelope protein. Antiviral research 88: 
236-243 
 
Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13: 816-825 
 
Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. 
Trends in molecular medicine 13: 460-469 
 
Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other 
innate receptors in infection and immunity. Immunity 34: 637-650 
 
Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, 
Matsumoto T, Maeshima A, Hiromura K, Nojima Y (2012) Interleukin-6 
promotes destabilized angiogenesis by modulating angiopoietin expression in 
rheumatoid arthritis. Rheumatology (Oxford) 51: 1571-1579 
 
Kim YM, Brinkmann MM, Paquet ME, Ploegh HL (2008) UNC93B1 delivers 
nucleotide-sensing toll-like receptors to endolysosomes. Nature 452: 234-238 
 
King CA, Anderson R, Marshall JS (2002) Dengue virus selectively induces 
human mast cell chemokine production. Journal of virology 76: 8408-8419 
 
Kishimoto T, Akira S, Narazaki M, Taga T (1995) Interleukin-6 family of 
cytokines and gp130. Blood 86: 1243-1254 
 
Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F 
(1976) Properties of the K562 cell line, derived from a patient with chronic 
myeloid leukemia. International journal of cancer Journal international du 
cancer 18: 421-431 
 
Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal 
dengue antibodies are important in the development of dengue hemorrhagic 
fever in infants. Am J Trop Med Hyg 38: 411-419 
 
Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, Maki 
N, Hatakeyama T, Sawada K (2008) Up-regulated expression of Toll-like 
receptors mRNAs in peripheral blood mononuclear cells from patients with 





Kou Z, Quinn M, Chen HY, Rodrigo WWSI, Rose RC, Schlesinger JJ, Jin X 
(2008) Monocytes, but not T or B cells, are the principal target cells for 
dengue virus (DV) infection among human peripheral blood mononuclear 
cells. J Med Virol 80: 134-146 
 
Kouri GP, Guzman MG, Bravo JR, Triana C (1989) Dengue haemorrhagic 
fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. 
Bulletin of the World Health Organization 67: 375-380 
 
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. 
Annual review of immunology 20: 709-760 
 
Krishnamurti C, Kalayanarooj S, Cutting MA, Peat RA, Rothwell SW, Reid 
TJ, Green S, Nisalak A, Endy TP, Vaughn DW et al (2001) Mechanisms of 
hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 65: 
840-847 
 
Kroeger KM, Carville KS, Abraham LJ (1997) The -308 tumor necrosis 
factor-alpha promoter polymorphism effects transcription. Molecular 
immunology 34: 391-399 
 
Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones 
CT, Mukhopadhyay S, Chipman PR, Strauss EG et al (2002) Structure of 
dengue virus: implications for flavivirus organization, maturation, and fusion. 
Cell 108: 717-725 
 
Kuno G, Vorndam AV, Gubler DJ, Gomez I (1990) Study of anti-dengue NS1 
antibody by western blot. J Med Virol 32: 102-108 
 
Kupper TS, Min K, Sehgal P, Mizutani H, Birchall N, Ray A, May L (1989) 
Production of IL-6 by keratinocytes. Implications for epidermal inflammation 
and immunity. Annals of the New York Academy of Sciences 557: 454-464; 
discussion 464-455 
 
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA (1993) 
High levels of interferon alpha in the sera of children with dengue virus 
infection. Am J Trop Med Hyg 48: 222-229 
 
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA 
(1991) Activation of T lymphocytes in dengue virus infections. High levels of 
soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and 
interferon-gamma in sera of children with dengue. The Journal of clinical 




Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, Meager A, Ennis FA 
(1989) Human T cell responses to dengue virus antigens. Proliferative 
responses and interferon gamma production. The Journal of clinical 
investigation 83: 506-513 
 
Kurane I, Kontny U, Janus J, Ennis FA (1990) Dengue-2 virus infection of 
human mononuclear cell lines and establishment of persistent infections. 
Archives of virology 110: 91-101 
 
Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annual 
review of microbiology 62: 71-92 
 
LaFleur C, Granados J, Vargas-Alarcon G, Ruiz-Morales J, Villarreal-Garza 
C, Higuera L, Hernandez-Pacheco G, Cutino-Moguel T, Rangel H, Figueroa R 
et al (2002) HLA-DR antigen frequencies in Mexican patients with dengue 
virus infection: HLA-DR4 as a possible genetic resistance factor for dengue 
hemorrhagic fever. Hum Immunol 63: 1039-1044 
 
Lanier LL (1998) NK cell receptors. Annual review of immunology 16: 359-
393 
 
Lee E, Wright PJ, Davidson A, Lobigs M (2006) Virulence attenuation of 
Dengue virus due to augmented glycosaminoglycan-binding affinity and 
restriction in extraneural dissemination. J Gen Virol 87: 2791-2801 
 
Lee HK, Lee J, Tobias PS (2002) Two lipoproteins extracted from Escherichia 
coli K-12 LCD25 lipopolysaccharide are the major components responsible 
for Toll-like receptor 2-mediated signaling. J Immunol 168: 4012-4017 
 
Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC (2001) 
Immunopathogenesis of dengue virus infection. Journal of biomedical science 
8: 377-388 
 
Levy A, Valero N, Espina LM, Anez G, Arias J, Mosquera J Increment of 
interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein and 
apoptosis in dengue. Trans R Soc Trop Med Hyg 104: 16-23 
 
Levy A, Valero N, Espina LM, Anez G, Arias J, Mosquera J (2010) Increment 
of interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein 
and apoptosis in dengue. Transactions of the Royal Society of Tropical 





Li D, Wang X, Wu JL, Quan WQ, Ma L, Yang F, Wu KY, Wan HY (2013) 
Tumor-produced versican V1 enhances hCAP18/LL-37 expression in 
macrophages through activation of TLR2 and vitamin D3 signaling to promote 
ovarian cancer progression in vitro. PloS one 8: e56616 
 
Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene 
expression through the NF-kappa B transcription factor. Mol Cell Biol 10: 
2327-2334 
 
Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, 
Vaughn DW, Nisalak A, Ennis FA, Rothman AL (2002) High circulating 
levels of the dengue virus nonstructural protein NS1 early in dengue illness 
correlate with the development of dengue hemorrhagic fever. J Infect Dis 186: 
1165-1168 
 
Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, 
Espevik T, Ingalls RR, Radolf JD et al (1999) Toll-like receptor 2 functions as 
a pattern recognition receptor for diverse bacterial products. The Journal of 
biological chemistry 274: 33419-33425 
 
Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-
Gutierrez A, Calderon-Amador J, Herrera-Rodriguez SE, Brizuela-Garcia A, 
Heras-Chavarria M, Flores-Langarica A et al (2005) Dengue virus inoculation 
to human skin explants: an effective approach to assess in situ the early 
infection and the effects on cutaneous dendritic cells. International journal of 
experimental pathology 86: 323-334 
 
Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS 
(2003) Antibodies from dengue patient sera cross-react with endothelial cells 
and induce damage. J Med Virol 69: 82-90 
 
Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, 
Kao CL, King CC (1998) Study of Dengue virus infection in SCID mice 
engrafted with human K562 cells. Journal of virology 72: 9729-9737 
 
Lin YW, Wang KJ, Lei HY, Lin YS, Yeh TM, Liu HS, Liu CC, Chen SH 
(2002) Virus replication and cytokine production in dengue virus-infected 
human B lymphocytes. Journal of virology 76: 12242-12249 
 
Lindenbach BD, Rice CM (1997) trans-Complementation of yellow fever 






Lindenbach BD, Rice CM (1999) Genetic interaction of flavivirus 
nonstructural proteins NS1 and NS4A as a determinant of replicase function. 
Journal of virology 73: 4611-4621 
 
Littaua R, Kurane I, Ennis FA (1990) Human IgG Fc receptor II mediates 
antibody-dependent enhancement of dengue virus infection. J Immunol 144: 
3183-3186 
 
Liu Y, Wang Y, Yamakuchi M, Isowaki S, Nagata E, Kanmura Y, Kitajima I, 
Maruyama I (2001) Upregulation of toll-like receptor 2 gene expression in 
macrophage response to peptidoglycan and high concentration of 
lipopolysaccharide is involved in NF-kappa b activation. Infect Immun 69: 
2788-2796 
 
Loke H, Bethell D, Phuong CX, Day N, White N, Farrar J, Hill A (2002) 
Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an 
association with variation in the vitamin d receptor and Fc gamma receptor IIa 
genes. Am J Trop Med Hyg 67: 102-106 
 
Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, Day NP, 
Farrar J, Hill AV (2001) Strong HLA class I--restricted T cell responses in 
dengue hemorrhagic fever: a double-edged sword? J Infect Dis 184: 1369-
1373 
 
Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, 
Mahieu P, Malaise M, De Groote D, Louis R et al (1998) Tumour necrosis 
factor (TNF) gene polymorphism influences TNF-alpha production in 
lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy 
humans. Clin Exp Immunol 113: 401-406 
 
Lozzio BB, Lozzio CB (1979) Properties and usefulness of the original K-562 
human myelogenous leukemia cell line. Leukemia research 3: 363-370 
 
Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki 
A, Flavell RA (2004) Recognition of single-stranded RNA viruses by Toll-like 
receptor 7. Proc Natl Acad Sci U S A 101: 5598-5603 
 
Luo KQ, Chang DC (2004) The gene-silencing efficiency of siRNA is 
strongly dependent on the local structure of mRNA at the targeted region. 
Biochem Biophys Res Commun 318: 303-310 
 
Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ (1992) 
Isolation of an mRNA encoding a soluble form of the human interleukin-6 




Lytle CD, Sagripanti JL (2005) Predicted inactivation of viruses of relevance 
to biodefense by solar radiation. Journal of virology 79: 14244-14252 
 
MacDonald PN, Dowd DR, Haussler MR (1994) New insight into the 
structure and functions of the vitamin D receptor. Seminars in nephrology 14: 
101-118 
 
Mackenzie JM, Jones MK, Young PR (1996) Immunolocalization of the 
dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA 
replication. Virology 220: 232-240 
 
Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the 
spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. 
Nature medicine 10: S98-109 
 
Mady BJ, Erbe DV, Kurane I, Fanger MW, Ennis FA (1991) Antibody-
dependent enhancement of dengue virus infection mediated by bispecific 
antibodies against cell surface molecules other than Fc gamma receptors. J 
Immunol 147: 3139-3144 
 
Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, Jones EY 
(2000) Nonstandard peptide binding revealed by crystal structures of HLA-
B*5101 complexed with HIV immunodominant epitopes. J Immunol 165: 
3260-3267 
 
Markoff LJ, Innis BL, Houghten R, Henchal LS (1991) Development of cross-
reactive antibodies to plasminogen during the immune response to dengue 
virus infection. J Infect Dis 164: 294-301 
 
Martina BE, Koraka P, Osterhaus AD (2009) Dengue virus pathogenesis: an 
integrated view. Clin Microbiol Rev 22: 564-581 
 
Martinez-Gutierrez M, Correa-Londono LA, Castellanos JE, Gallego-Gomez 
JC, Osorio JE (2014) Lovastatin delays infection and increases survival rates 
in AG129 mice infected with dengue virus serotype 2. PloS one 9: e87412 
 
Marty AM, Jahrling PB, Geisbert TW (2006) Viral hemorrhagic fevers. Clin 
Lab Med 26: 345-386, viii 
 
Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases endothelial 





Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA (1996) 
Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue 
virus nonstructural proteins NS3 and NS1.2a. The Journal of clinical 
investigation 98: 1684-1691 
 
Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, 
Yamamoto A, Seya T (2003) Subcellular localization of Toll-like receptor 3 in 
human dendritic cells. J Immunol 171: 3154-3162 
 
Mazzon M, Jones M, Davidson A, Chain B, Jacobs M (2009) Dengue virus 
NS5 inhibits interferon-alpha signaling by blocking signal transducer and 
activator of transcription 2 phosphorylation. J Infect Dis 200: 1261-1270 
 
McGregor WG (1999) DNA repair, DNA replication, and UV mutagenesis. 
The journal of investigative dermatology Symposium proceedings / the 
Society for Investigative Dermatology, Inc [and] European Society for 
Dermatological Research 4: 1-5 
 
McKimmie CS, Fazakerley JK (2005) In response to pathogens, glial cells 
dynamically and differentially regulate Toll-like receptor gene expression. J 
Neuroimmunol 169: 116-125 
 
Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa 
PB, Ebel F, Busch DH, Bauer S et al (2004) Antagonistic antibody prevents 
toll-like receptor 2-driven lethal shock-like syndromes. The Journal of clinical 
investigation 113: 1473-1481 
 
Menon C, Ghartey A, Canter R, Feldman M, Fraker DL (2006) Tumor 
necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-
cadherin. Annals of surgery 244: 781-791 
 
Miagostovich MP, Ramos RG, Nicol AF, Nogueira RM, Cuzzi-Maya T, 
Oliveira AV, Marchevsky RS, Mesquita RP, Schatzmayr HG (1997) 
Retrospective study on dengue fatal cases. Clinical neuropathology 16: 204-
208 
 
Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, 
Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T et al (1990) AIDS 
Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl 
Acad Sci U S A 87: 4068-4072 
 
Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd 
PM, Gordon S (2008) The mannose receptor mediates dengue virus infection 




Miller S, Kastner S, Krijnse-Locker J, Buhler S, Bartenschlager R (2007) The 
non-structural protein 4A of dengue virus is an integral membrane protein 
inducing membrane alterations in a 2K-regulated manner. The Journal of 
biological chemistry 282: 8873-8882 
 
Miller S, Sparacio S, Bartenschlager R (2006) Subcellular localization and 
membrane topology of the Dengue virus type 2 Non-structural protein 4B. The 
Journal of biological chemistry 281: 8854-8863 
 
Miranda CH, Borges Mde C, Schmidt A, Pazin-Filho A, Rossi MA, Ramos 
SG, Lopes da Fonseca BA (2013) A case presentation of a fatal dengue 
myocarditis showing evidence for dengue virus-induced lesion. European 
heart journal Acute cardiovascular care 2: 127-130 
 
Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket 
in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 
6986-6991 
 
Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue 
virus envelope protein after membrane fusion. Nature 427: 313-319 
 
Mogensen TH (2009) Pathogen recognition and inflammatory signaling in 
innate immune defenses. Clinical microbiology reviews 22: 240-273, Table of 
Contents 
 
Mogensen TH, Paludan SR (2005) Reading the viral signature by toll-like 
receptors and other pattern recognition receptors. Journal of Molecular 
Medicine-Jmm 83: 180-192 
 
Monath TP (1994) Dengue: the risk to developed and developing countries. 
Proc Natl Acad Sci U S A 91: 2395-2400 
 
Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, 
Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong 
T, Rowland-Jones S et al (2003) Original antigenic sin and apoptosis in the 
pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921-927 
 
Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, 
Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, 
Chotiyarnwong P, Sae-Jang K et al (2006) T cell responses in dengue 





Moreth K, Frey H, Hubo M, Zeng-Brouwers J, Nastase MV, Hsieh LT, Haceni 
R, Pfeilschifter J, Iozzo RV, Schaefer L (2014) Biglycan-triggered TLR-2- 
and TLR-4-signaling exacerbates the pathophysiology of ischemic acute 
kidney injury. Matrix biology : journal of the International Society for Matrix 
Biology 35: 143-151 
 
Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, 
Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 
receptor is generated by shedding. Eur J Immunol 23: 473-480 
 
Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A 
(2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci 
U S A 100: 14333-14338 
 
Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, 
Kurt-Jones EA, Finberg RW (2009) Respiratory syncytial virus activates 
innate immunity through Toll-like receptor 2. Journal of virology 83: 1492-
1500 
 
Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, Takatsu K, 
Kincade PW (2006) Toll-like receptors on hematopoietic progenitor cells 
stimulate innate immune system replenishment. Immunity 24: 801-812 
 
Nakao Y, Funami K, Kikkawa S, Taniguchi M, Nishiguchi M, Fukumori Y, 
Seya T, Matsumoto M (2005) Surface-expressed TLR6 participates in the 
recognition of diacylated lipopeptide and peptidoglycan in human cells. J 
Immunol 174: 1566-1573 
 
Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier 
JL, Arenzana-Seisdedos F, Despres P (2003) Dendritic-cell-specific ICAM3-
grabbing non-integrin is essential for the productive infection of human 
dendritic cells by mosquito-cell-derived dengue viruses. EMBO reports 4: 
723-728 
 
Netsawang J, Noisakran S, Puttikhunt C, Kasinrerk W, Wongwiwat W, 
Malasit P, Yenchitsomanus PT, Limjindaporn T (2010) Nuclear localization of 
dengue virus capsid protein is required for DAXX interaction and apoptosis. 
Virus Res 147: 275-283 
 
Neufeld G, Gospodarowicz D (1985) The identification and partial 
characterization of the fibroblast growth factor receptor of baby hamster 





Nhu QM, Cuesta N, Vogel SN (2006) Transcriptional regulation of 
lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in 
murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 
(IRF-2). Journal of endotoxin research 12: 285-295 
 
Nisalak A, Halstead SB, Singharaj P, Udomsakdi S, Nye SW, Vinijchaikul K 
(1970) Observations related to pathogenesis of dengue hemorrhagic fever. 3. 
Virologic studies of fatal disease. Yale J Biol Med 42: 293-310 
 
Nishioka K (1974) Serum complement level in dengue hemorrhagic fever. 
Allergie und Immunologie 20-21: 385-392 
 
Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat 
C, Panyim S, Katzenmeier G (2004) Identification of residues in the dengue 
virus type 2 NS2B cofactor that are critical for NS3 protease activation. 
Journal of virology 78: 13708-13716 
 
Normile D (2013) First New Dengue Virus Type in 50 Years. Sciencemag 
 
O'Neill LA (2003) Therapeutic targeting of Toll-like receptors for 
inflammatory and infectious diseases. Current opinion in pharmacology 3: 
396-403 
 
O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing 
adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364 
 
O'Neill MM, Kennedy CA, Barton RW, Tatake RJ (2001) Receptor-mediated 
gene delivery to human peripheral blood mononuclear cells using anti-CD3 
antibody coupled to polyethylenimine. Gene therapy 8: 362-368 
 
Oishi K, Inoue S, Cinco MT, Dimaano EM, Alera MT, Alfon JA, Abanes F, 
Cruz DJ, Matias RR, Matsuura H et al (2003) Correlation between increased 
platelet-associated IgG and thrombocytopenia in secondary dengue virus 
infections. J Med Virol 71: 259-264 
 
Okamoto K, Kinoshita H, Parquet Mdel C, Raekiansyah M, Kimura D, Yui K, 
Islam MA, Hasebe F, Morita K (2012) Dengue virus strain DEN2 16681 
utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. J Gen 
Virol 93: 761-770 
 
Okamoto M, Hirai H, Taniguchi K, Shimura K, Inaba T, Shimazaki C, 




myeloid leukaemia cell lines, but fail to trigger differentiation in response to 
the respective TLR ligands. Br J Haematol 147: 585-587 
 
Olson JK, Miller SD (2004) Microglia initiate central nervous system innate 
and adaptive immune responses through multiple TLRs. J Immunol 173: 
3916-3924 
 
Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, 
Schroeder L, Aderem A (2000) The repertoire for pattern recognition of 
pathogens by the innate immune system is defined by cooperation between 
toll-like receptors. Proc Natl Acad Sci U S A 97: 13766-13771 
 
Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED (2011) Hepatosplenic T-cell 
lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the 
groups at risk. European journal of gastroenterology & hepatology 23: 1150-
1156 
 
Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO (2009) The structural 
basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 
458: 1191-1195 
 
Pattison DI, Davies MJ (2006) Actions of ultraviolet light on cellular 
structures. Exs: 131-157 
 
Petkova SB, Yuan R, Tsaih SW, Schott W, Roopenian DC, Paigen B (2008) 
Genetic influence on immune phenotype revealed strain-specific variations in 
peripheral blood lineages. Physiological genomics 34: 304-314 
 
Pinto LM, Oliveira SA, Braga EL, Nogueira RM, Kubelka CF (1999) 
Increased pro-inflammatory cytokines (TNF-alpha and IL-6) and anti-
inflammatory compounds (sTNFRp55 and sTNFRp75) in Brazilian patients 
during exanthematic dengue fever. Mem Inst Oswaldo Cruz 94: 387-394 
 
Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, 
Gregorio GG, Hendrickson WA, Kuhn RJ, Rossmann MG (2006) Cryo-EM 
reconstruction of dengue virus in complex with the carbohydrate recognition 
domain of DC-SIGN. Cell 124: 485-493 
 
Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, 
Stanley S, Fauci AS (1990) Interleukin 6 induces human immunodeficiency 
virus expression in infected monocytic cells alone and in synergy with tumor 
necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J 




Procario MC, Levine RE, McCarthy MK, Kim E, Zhu L, Chang CH, 
Hershenson MB, Weinberg JB (2012) Susceptibility to acute mouse 
adenovirus type 1 respiratory infection and establishment of protective 
immunity in neonatal mice. Journal of virology 86: 4194-4203 
 
Que-Gewirth NL, Ribeiro AA, Kalb SR, Cotter RJ, Bulach DM, Adler B, 
Girons IS, Werts C, Raetz CR (2004) A methylated phosphate group and four 
amide-linked acyl chains in leptospira interrogans lipid A. The membrane 
anchor of an unusual lipopolysaccharide that activates TLR2. The Journal of 
biological chemistry 279: 25420-25429 
 
Rachman A, Rinaldi I (2006) Coagulopathy in dengue infection and the role of 
interleukin-6. Acta medica Indonesiana 38: 105-108 
 
Rajapakse S, Rodrigo C, Maduranga S, Rajapakse AC (2014) Corticosteroids 
in the treatment of dengue shock syndrome. Infection and drug resistance 7: 
137-143 
 
Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, 
Lerumo L, Hughes J, Hussey G, Hawkridge A et al (2011) Association of 
human TLR1 and TLR6 deficiency with altered immune responses to BCG 
vaccination in South African infants. PLoS Pathog 7: e1002174 
 
Rao DD, Vorhies JS, Senzer N, Nemunaitis J (2009) siRNA vs. shRNA: 
similarities and differences. Advanced drug delivery reviews 61: 746-759 
 
Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK (1996) 
Susceptibility of laboratory-bred rodents to the experimental infection with 
dengue virus type 2. Acta virologica 40: 143-146 
 
Reis SR, Sampaio AL, Henriques M, Gandini M, Azeredo EL, Kubelka CF 
(2007a) An in vitro model for dengue virus infection that exhibits human 
monocyte infection, multiple cytokine production and dexamethasone 
immunomodulation. Mem Inst Oswaldo Cruz 102: 983-990 
 
Reis SRNI, Sampaio ALF, Henriques MDM, Gandini M, Azeredo EL, 
Kubelka CF (2007b) An in vitro model for dengue virus infection that exhibits 
human monocyte infection, multiple cytokine production and dexamethasone 
immunomodulation. Memorias Do Instituto Oswaldo Cruz 102: 983-990 
 
Restrepo BN, Isaza DM, Salazar CL, Ramirez R, Ospina M, Alvarez LG 
(2008) Serum levels of interleukin-6, tumor necrosis factor-alpha and 





Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM (2005) Heat 
shock protein 90 and heat shock protein 70 are components of dengue virus 
receptor complex in human cells. Journal of virology 79: 4557-4567 
 
Rezza G (2012) Aedes albopictus and the reemergence of Dengue. BMC 
public health 12: 72 
 
Rivest S (2003) Molecular insights on the cerebral innate immune system. 
Brain, behavior, and immunity 17: 13-19 
 
Rivest S (2006) Cannabinoids in microglia: a new trick for immune 
surveillance and neuroprotection. Neuron 49: 4-8 
 
Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev 
Immunol 9: 429-439 
 
Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P (1991) Tumor 
necrosis factor induces apoptosis (programmed cell death) in normal 
endothelial cells in vitro. Am J Pathol 138: 447-453 
 
Robertson KD (2005) DNA methylation and human disease. Nature reviews 
Genetics 6: 597-610 
 
Rodriguez-Roche R, Alvarez M, Gritsun T, Halstead S, Kouri G, Gould EA, 
Guzman MG (2005) Virus evolution during a severe dengue epidemic in 
Cuba, 1997. Virology 334: 154-159 
 
Romagne F (2007) Current and future drugs targeting one class of innate 
immunity receptors: the Toll-like receptors. Drug discovery today 12: 80-87 
 
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, 
Faggioni R, Luini W, van Hinsbergh V, Sozzani S et al (1997) Role of IL-6 
and its soluble receptor in induction of chemokines and leukocyte recruitment. 
Immunity 6: 315-325 
 
Sabin AB (1952) Research on dengue during World War II. Am J Trop Med 
Hyg 1: 30-50 
 
Sahaphong S, Riengrojpitak S, Bhamarapravati N, Chirachariyavej T (1980) 
Electron microscopic study of the vascular endothelial cell in dengue 
hemorrhagic fever. The Southeast Asian journal of tropical medicine and 




Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, Robles AM, Estrella BD, 
Jr., Kumatori A, Moji K, Alonzo MT et al (2004) Association of increased 
platelet-associated immunoglobulins with thrombocytopenia and the severity 
of disease in secondary dengue virus infections. Clin Exp Immunol 138: 299-
303 
 
Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, 
Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, 
Tangthawornchaikul N, Vasanawathana S et al (2005) A variant in the CD209 
promoter is associated with severity of dengue disease. Nature genetics 37: 
507-513 
 
Salomao R, Brunialti MK, Gomes NE, Mendes ME, Diaz RS, Komninakis S, 
Machado FR, da Silva ID, Rigato O (2009) Toll-like receptor pathway 
signaling is differently regulated in neutrophils and peripheral mononuclear 
cells of patients with sepsis, severe sepsis, and septic shock. Critical care 
medicine 37: 132-139 
 
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, 
Salitul V, Phanthumachinda B, Halstead SB (1984) Risk factors in dengue 
shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. 
The 1980 outbreak. Am J Epidemiol 120: 653-669 
 
Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Jr., 
Ritchie TC, Hunninghake GW, Zandi E, Engelhardt JF (2001) 
Lipopolysaccharide induces Rac1-dependent reactive oxygen species 
formation and coordinates tumor necrosis factor-alpha secretion through IKK 
regulation of NF-kappa B. The Journal of biological chemistry 276: 30188-
30198 
 
Savva A, Roger T (2013) Targeting toll-like receptors: promising therapeutic 
strategies for the management of sepsis-associated pathology and infectious 
diseases. Frontiers in immunology 4: 387 
 
Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA 
(1990) Correlations and interactions in the production of interleukin-6 (IL-6), 
IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-
6 suppresses IL-1 and TNF. Blood 75: 40-47 
 
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME (1998) 
Apoptosis signaling by death receptors. European journal of biochemistry / 





Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999) 
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by 
toll-like receptor 2. The Journal of biological chemistry 274: 17406-17409 
 
Seynhaeve AL, Vermeulen CE, Eggermont AM, ten Hagen TL (2006) 
Cytokines and vascular permeability: an in vitro study on human endothelial 
cells in relation to tumor necrosis factor-alpha-primed peripheral blood 
mononuclear cells. Cell biochemistry and biophysics 44: 157-169 
 
Shaio MF, Chang FY, Hou SC (1992) Complement pathway activity in serum 
from patients with classical dengue fever. Transactions of the Royal Society of 
Tropical Medicine and Hygiene 86: 672-675 
 
Sharma RK, Sodhi A, Batra HV (2005) Involvement of TLR6/1 in rLcrV-
mediated immunomodulation of murine peritoneal macrophages in vitro. 
Molecular immunology 42: 695-701 
 
Shey MS, Randhawa AK, Bowmaker M, Smith E, Scriba TJ, de Kock M, 
Mahomed H, Hussey G, Hawn TR, Hanekom WA (2010) Single nucleotide 
polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- 
and mycobacteria-induced interleukin-6 secretion. Genes and immunity 11: 
561-572 
 
Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E (2004) 
Interferon-dependent immunity is essential for resistance to primary dengue 
virus infection in mice, whereas T- and B-cell-dependent immunity are less 
critical. Journal of virology 78: 2701-2710 
 
Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine 
model for dengue virus-induced lethal disease with increased vascular 
permeability. Journal of virology 80: 10208-10217 
 
Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, 
Andalibi A, Linthicum F et al (2002) Glucocorticoids synergistically enhance 
nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression 
via a negative cross-talk with p38 MAP kinase. The Journal of biological 
chemistry 277: 17263-17270 
 
Siednienko J, Miggin SM (2009) Expression analysis of the Toll-like receptors 
in human peripheral blood mononuclear cells. Methods Mol Biol 517: 3-14 
 
Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD (1997) 
Interleukin-6: structure-function relationships. Protein science : a publication 




Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett 
SL, Cookson BT, Aderem A (2003) Toll-like receptor 5 recognizes a 
conserved site on flagellin required for protofilament formation and bacterial 
motility. Nat Immunol 4: 1247-1253 
 
Somnuke P, Hauhart RE, Atkinson JP, Diamond MS, Avirutnan P (2011) N-
linked glycosylation of dengue virus NS1 protein modulates secretion, cell-
surface expression, hexamer stability, and interactions with human 
complement. Virology 413: 253-264 
 
Srikiatkhachorn A (2009) Plasma leakage in dengue haemorrhagic fever. 
Thromb Haemost 102: 1042-1049 
 
St John AL, Abraham SN, Gubler DJ (2013) Barriers to preclinical 
investigations of anti-dengue immunity and dengue pathogenesis. Nature 
reviews Microbiology 11: 420-426 
 
Stadler K, Allison SL, Schalich J, Heinz FX (1997) Proteolytic activation of 
tick-borne encephalitis virus by furin. Journal of virology 71: 8475-8481 
 
Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj 
S, Endy TP, Libraty DH, Nisalak A, Innis BL et al (2002) HLA-A and -B 
allele associations with secondary dengue virus infections correlate with 
disease severity and the infecting viral serotype in ethnic Thais. Tissue 
antigens 60: 309-318 
 
Streatfield R, Bielby G, Sinclair D (1993) A primary dengue 2 epidemic with 
spontaneous haemorrhagic manifestations. Lancet 342: 560-561 
 
Sullivan KE, Reddy AB, Dietzmann K, Suriano AR, Kocieda VP, Stewart M, 
Bhatia M (2007) Epigenetic regulation of tumor necrosis factor alpha. Mol 
Cell Biol 27: 5147-5160 
 
Sun DS, King CC, Huang HS, Shih YL, Lee CC, Tsai WJ, Yu CC, Chang HH 
(2007a) Antiplatelet autoantibodies elicited by dengue virus non-structural 
protein 1 cause thrombocytopenia and mortality in mice. Journal of 
thrombosis and haemostasis : JTH 5: 2291-2299 
 
Sun S, Rao NL, Venable J, Thurmond R, Karlsson L (2007b) TLR7/9 
antagonists as therapeutics for immune-mediated inflammatory disorders. 





Takeda K, Akira S (2004) TLR signaling pathways. Seminars in immunology 
16: 3-9 
 
Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, 
Takeda K, Akira S (2001) Discrimination of bacterial lipoproteins by Toll-like 
receptor 6. International immunology 13: 933-940 
 
Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, 
Akira S (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune 
response to microbial lipoproteins. J Immunol 169: 10-14 
 
Tam DT, Ngoc TV, Tien NT, Kieu NT, Thuy TT, Thanh LT, Tam CT, Truong 
NT, Dung NT, Qui PT et al (2012) Effects of short-course oral corticosteroid 
therapy in early dengue infection in Vietnamese patients: a randomized, 
placebo-controlled trial. Clin Infect Dis 55: 1216-1224 
 
Tan BH, Fu J, Sugrue RJ, Yap EH, Chan YC, Tan YH (1996) Recombinant 
dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-
dependent RNA polymerase activity. Virology 216: 317-325 
 
Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S (2010) A non mouse-
adapted dengue virus strain as a new model of severe dengue infection in 
AG129 mice. PLoS neglected tropical diseases 4: e672 
 
Tanabe M, Kurita-Taniguchi M, Takeuchi K, Takeda M, Ayata M, Ogura H, 
Matsumoto M, Seya T (2003) Mechanism of up-regulation of human Toll-like 
receptor 3 secondary to infection of measles virus-attenuated strains. Biochem 
Biophys Res Commun 311: 39-48 
 
Taniguchi T, Takata M, Ikeda A, Momotani E, Sekikawa K (1997) Failure of 
germinal center formation and impairment of response to endotoxin in tumor 
necrosis factor alpha-deficient mice. Lab Invest 77: 647-658 
 
Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, 
Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL et al (2003) 
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. 
J Exp Med 197: 823-829 
 
Teo CS, Chu JJ (2013) Cellular Vimentin Regulates Construction of Dengue 
Virus Replication Complexes through the Interaction with NS4A Protein. 





Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, Aye KM, Aaskov J 
(1997) Risk factors in dengue shock syndrome. Am J Trop Med Hyg 56: 566-
572 
 
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG (2012) 
Into the eye of the cytokine storm. Microbiology and molecular biology 
reviews : MMBR 76: 16-32 
 
Tracey KJ, Cerami A (1994) Tumor necrosis factor: a pleiotropic cytokine and 
therapeutic target. Annual review of medicine 45: 491-503 
 
Tracey KJ, Lowry SF, Fahey TJ, 3rd, Albert JD, Fong Y, Hesse D, Beutler B, 
Manogue KR, Calvano S, Wei H et al (1987) Cachectin/tumor necrosis factor 
induces lethal shock and stress hormone responses in the dog. Surgery, 
gynecology & obstetrics 164: 415-422 
 
Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, 
Beutler B, Cotran RS, Cerami A et al (1988) Cachectin/tumor necrosis factor 
induces cachexia, anemia, and inflammation. J Exp Med 167: 1211-1227 
 
Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, 
Triantafilou K (2006) Membrane sorting of toll-like receptor (TLR)-2/6 and 
TLR2/1 heterodimers at the cell surface determines heterotypic associations 
with CD36 and intracellular targeting. The Journal of biological chemistry 
281: 31002-31011 
 
Trung DT, Wills B (2010) Systemic vascular leakage associated with dengue 
infections - the clinical perspective. Current topics in microbiology and 
immunology 338: 57-66 
 
Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher 
LH, Fenton MJ, Gordon DC, Dunn IF, Goldfeld AE (2000) A 
lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and 
CREB binding protein and p300 is recruited to the tumor necrosis factor alpha 
promoter in vivo. Mol Cell Biol 20: 6084-6094 
 
Tsai YT, Chang SY, Lee CN, Kao CL (2009) Human TLR3 recognizes 
dengue virus and modulates viral replication in vitro. Cell Microbiol 11: 604-
615 
 
Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG (2006) Dengue virus 
NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen 




Upanan S, Kuadkitkan A, Smith DR (2008) Identification of dengue virus 
binding proteins using affinity chromatography. Journal of virological 
methods 151: 325-328 
 
Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, 
Bianchi ME, Kirschning C, Wagner H, Manfredi AA et al (2008) Induction of 
inflammatory and immune responses by HMGB1-nucleosome complexes: 
implications for the pathogenesis of SLE. J Exp Med 205: 3007-3018 
 
Van Snick J (1990) Interleukin-6: an overview. Annual review of immunology 
8: 253-278 
 
Villacres MC, Literat O, DeGiacomo M, Du W, Frederick T, Kovacs A (2008) 
Defective response to Toll-like receptor 3 and 4 ligands by activated 
monocytes in chronic hepatitis C virus infection. Journal of viral hepatitis 15: 
137-144 
 
Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor 
signaling. Cell Death Differ 10: 45-65 
 
Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH (2006) 
Flavivirus activation of plasmacytoid dendritic cells delineates key elements 
of TLR7 signaling beyond endosomal recognition. J Immunol 177: 7114-7121 
 
Wang T, Lafuse WP, Takeda K, Akira S, Zwilling BS (2002a) Rapid 
chromatin remodeling of Toll-like receptor 2 promoter during infection of 
macrophages with Mycobacterium avium. J Immunol 169: 795-801 
 
Wang WK, Sung TL, Tsai YC, Kao CL, Chang SM, King CC (2002b) 
Detection of dengue virus replication in peripheral blood mononuclear cells 
from dengue virus type 2-infected patients by a reverse transcription-real-time 
PCR assay. Journal of Clinical Microbiology 40: 4472-4478 
 
Wang Y, Wang J, Sun Y, Wu Q, Fu YX (2001) Complementary effects of 
TNF and lymphotoxin on the formation of germinal center and follicular 
dendritic cells. J Immunol 166: 330-337 
 
Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint Girons 
I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A et al (2001) Leptospiral 
lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat 





Wiig H (2011) Pathophysiology of tissue fluid accumulation in inflammation. 
The Journal of physiology 589: 2945-2953 
 
Wilson JR, de Sessions PF, Leon MA, Scholle F (2008) West Nile virus 
nonstructural protein 1 inhibits TLR3 signal transduction. Journal of virology 
82: 8262-8271 
 
Wong KL, Chen W, Balakrishnan T, Toh YX, Fink K, Wong SC (2012) 
Susceptibility and response of human blood monocyte subsets to primary 
dengue virus infection. PloS one 7: e36435 
 
Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, 
Louder MK, Filgueira L, Marovich MA, Wong HK et al (2000) Human skin 
Langerhans cells are targets of dengue virus infection. Nature medicine 6: 
816-820 
 
Wu SJ, Hayes CG, Dubois DR, Windheuser MG, Kang YH, Watts DM, 
Sieckmann DG (1995) Evaluation of the severe combined immunodeficient 
(SCID) mouse as an animal model for dengue viral infection. Am J Trop Med 
Hyg 52: 468-476 
 
Xie X, Gayen S, Kang C, Yuan Z, Shi PY (2013) Membrane topology and 
function of dengue virus NS2A protein. Journal of virology 87: 4609-4622 
 
Yadav M, Kamath KR, Iyngkaran N, Sinniah M (1991) Dengue haemorrhagic 
fever and dengue shock syndrome: are they tumour necrosis factor-mediated 
disorders? FEMS microbiology immunology 4: 45-49 
 
Yamanaka A, Hendrianto E, Mulyatno KC, Susilowati H, Ginting AP, Sary 
DD, Soegijanto S, Konishi E (2013) Correlation between complement 
component levels and disease severity in dengue patients in Indonesia. Jpn J 
Infect Dis 66: 366-374 
 
Yokota S, Ohnishi T, Muroi M, Tanamoto K, Fujii N, Amano K (2007) 
Highly-purified Helicobacter pylori LPS preparations induce weak 
inflammatory reactions and utilize Toll-like receptor 2 complex but not Toll-
like receptor 4 complex. FEMS immunology and medical microbiology 51: 
140-148 
 
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, 
Nakahata T, Kawai H, Tagoh H, Komori T et al (1989) Pathogenic 






Yu IM, Holdaway HA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J (2009) 
Association of the pr peptides with dengue virus at acidic pH blocks 
membrane fusion. Journal of virology 83: 12101-12107 
 
Zaghouani H, Hoeman CM, Adkins B (2009) Neonatal immunity: faulty T-
helpers and the shortcomings of dendritic cells. Trends in immunology 30: 
585-591 
 
Zarember KA, Godowski PJ (2002) Tissue expression of human Toll-like 
receptors and differential regulation of Toll-like receptor mRNAs in 
leukocytes in response to microbes, their products, and cytokines. J Immunol 
168: 554-561 
 
Zeng H, Carlson AQ, Guo Y, Yu Y, Collier-Hyams LS, Madara JL, Gewirtz 
AT, Neish AS (2003) Flagellin is the major proinflammatory determinant of 
enteropathogenic Salmonella. J Immunol 171: 3668-3674 
 
Zhang Q, Hunke C, Yau YH, Seow V, Lee S, Tanner LB, Guan XL, Wenk 
MR, Fibriansah G, Chew PL et al (2012) The stem region of premembrane 
protein plays an important role in the virus surface protein rearrangement 
during dengue maturation. The Journal of biological chemistry 287: 40525-
40534 
 
Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, 
Baker TS, Strauss JH, Rossmann MG, Kuhn RJ (2003) Visualization of 
membrane protein domains by cryo-electron microscopy of dengue virus. 
Nature structural biology 10: 907-912 
 
Zhang X, Goncalves R, Mosser DM (2008) The isolation and characterization 
of murine macrophages. Current protocols in immunology / edited by John E 
Coligan  [et al] Chapter 14: Unit 14 11 
 
Ziegler-Heitbrock HW, Ulevitch RJ (1993) CD14: cell surface receptor and 
differentiation marker. Immunology today 14: 121-125 
 
Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in 
infection and inflammation. J Leukoc Biol 81: 584-592 
 


























APPENDIX 1: MATERIALS FOR TISSUE CULTURE 
All materials used for cell culture were either sterile or sterilized.  
a) 10X Phosphate Buffered Saline (PBS) 
Material Amount (g) Source 
NaCl 80.0 Merck, Darmstadt, 
Germany 
KCl 2.0  Merck, Darmstadt, 
Germany 
KH2PO4 2.0 Merck, Darmstadt, 
Germany 
Na2HPO4 11.5 Merck, Darmstadt, 
Germany 
 
All the components were dissolved in 900 ml of Ultrapure water (Millipore, 
Schwalbach, Germany) and the pH was adjusted to 7.4 using either 1 M HCl 
or 1 M NaOH. The solution was top up to 1 liter and autoclaved at 121ºC for 
15 mins. The stock solution was then stored at room temperature. 1X PBS was 
prepared by adding 1 part 10X PBS to 9 parts Ultrapure water (Millipore, 
Schwalbach, Germany). To prepare sterile 1X PBS, the 1X PBS was 







b) RPMI-1640 culture medium 
Material Amount Source 
RPMI-1640 16.4 g Sigma Diagnostics, St 
Louis, USA 
NaHCO3 2.0 g Merck, Darmstadt, 
Germany 
 
RPMI-1640 powder and NaHCO3 were dissolved in Ultrapure water 




2) pressure through a 0.22 μm filter unit (Corning, New York, USA). 
Fetal calf serum (FCS) (PAA, Piscataway, USA) was heat-inactivated at 56 ºC 
for 30 mins before adding to the solution. The volume of FCS added was 100 
ml to make RPMI-1640 supplemented with 10 % FCS or 20 ml to make 
RPMI-1640 supplemented with 2 % FCS. The volume of Ultrapure water 
(Millipore, Schwalbach, Germany) used was dependent on the volume of FCS 
added and antibiotics added if any to get a final volume of 1 liter for the 
culture medium. For RPMI-1640 supplemented with 10% heat-inactivated 
FCS (PAA, Piscataway, USA) and 1 % penicillin/streptomycin (Life 
Technologies, California, USA), 10 ml of penicillin/streptomycin was added 
to RPMI-1640 supplemented with 10 % FCS. For RPMI-1640 (Appendix) 
supplemented with 10 % heat-inactivated FCS (PAA, Piscataway, USA), 1 % 
penicillin/streptomycin (Life Technologies, California, USA), 1 % 
amphotericin B (MP Biomedicals, California, USA) and 0.5% gentamycin 
(PAA, Piscataway, USA), 10 ml of penicillin/streptomycin, 10 ml of 
amphotericin B and 5 ml of gentamycin were added to RPMI-1640 




c) 10X Trypsin-Versene solution 
Material Amount  Source 
NaCl 80.0 g Merck, Darmstadt, 
Germany 
KCl 4.0 g Merck, Darmstadt, 
Germany 
D-glucose 10.0 g Analar, Dar es Salaam, 
Tanzania 
NaHCO3 5.8 g Merck, Darmstadt, 
Germany 
Trypsin 5.0 g Life Technologies, 
California, USA 
Versene (EDTA) 2.0 g Sigma Diagnostics, 
St.Louis, USA 
 
All the components were dissolved in Ultrapure water (Millipore, Schwalbach, 




2) pressure through a 0.22 μm filter unit (Corning, New York, USA). To 
prepare the working 1X trypsin-versene, 1 part of 10X stock was added to 9 
part of autoclaved Ultrapure water (Millipore, Schwalbach, Germany). 
 
d) L-15 culture medium 
Material Amount Source 
L-15 13.8 g Sigma Diagnostics, 
St.Louis, USA 
 
L-15 powder was dissolved in Ultrapure water (Millipore, Schwalbach, 
Germany) and the pH was adjusted to 7.2 using either 1M HCl or 1M NaOH. 
The solution was sterilized at 15 Ib/in
2
 (1 kg/cm




filter unit (Corning, New York, USA). FCS was heat-inactivated at 56 ºC for 
30 mins before adding to the solution. The volume of FCS added was 100 ml 
to make L-15 supplemented with 10% FCS or 20 ml to make L-15 
supplemented with 2% FCS. The volume of Ultrapure water (Millipore, 
Schwalbach, Germany) used was dependent on the volume of FCS added to 
get a final volume of 1 liter for the culture medium. 
e) DMEM culture medium 




17.3 g Sigma Diagnostics, 
St.Louis, USA 
NaHCO3 2.0 g Merck, Darmstadt, 
Germany 
 
DMEM powder and NaHCO3 were dissolved in Ultrapure water (Millipore, 





pressure through a 0.22 μm filter unit (Corning, New York, USA). FCS was 
heat-inactivated at 56ºC for 30 mins before adding to the solution. The volume 
of FCS added was 100 ml to make DMEM supplemented with 10% FCS or 20 
ml to make RPMI-1640 supplemented with 2% FCS. The volume of Ultrapure 
water (Millipore, Schwalbach, Germany) used was dependent on the volume 
of FCS added and antibiotics added if any to get a final volume of 1 liter for 





Appendix 2: Materials for Plaque assay 
All materials used for plaque assay were either sterile or sterilized. 
a) Virus diluents 
Material Amount Source 
Hank’s Salt 9.7 g Sigma Diagnostics, 
St.Louis, USA 
Bovine serum albumin 0.2 g Merck, Darmstadt, 
Germany 
NaHCO3 0.5 g Merck, Darmstadt, 
Germany 
 
All the components were dissolved in 900 ml of Ultrapure water (Millipore, 
Schwalbach, Germany) and the pH was adjusted to 7.4 using either 1M HCl or 
1M NaOH. The solution was topped up to 1 liter using Ultrapure water 
















b) Overlay medium for BHK-21 cells 
Material Amount Source 
RPMI-1640 16.4 g Sigma Diagnostics, 
St.Louis, USA 
NaHCO3 2.0 g Merck, Darmstadt, 
Germany 




500 ml Behring Diagnostic, 
Massachusetts, USA 
 
RPMI-1640 and NaHCO3 were dissolved in 480 ml of Ultrapure water 
(Millipore, Schwalbach, Germany). The solution was sterilized at 15 Ib/in2 (1 
kg/cm2) pressure through a 0.22 μm filter unit (Corning, New York, USA) 
before mixing with fetal calf serum and autoclaved 2 % CMC. 
c) 0.5 % crystal violet / 25 % formaldehyde 
Material Amount Source 
Crystal violet 5.0 g  Sigma Diagnostics, 
St.Louis, USA 
37% formaldehyde 300.0 ml Merck, Darmstadt, 
Germany 








Appendix 3: Materials for Western blot 
a) 10 % separation gel 
Material Amount Source 
30 % acrylamide and 
0.8 % bis acrylamide 
13.33 ml Bio-Rad, San Francisco, 
USA 
1 M Tris buffer pH 8.8 15.0 ml Merck, Darmstadt, 
Germany 
10 % SDS 0.4 ml Merck, Darmstadt, 
Germany 
Deionised water 10.0 ml Elga, Buckinghamshire, 
UK 
10 % Ammonium 
persulphate 
0.4 ml Merck, Darmstadt, 
Germany 
TEMED 0.04 ml Merck, Darmstadt, 
Germany 












b) 5 % stacking gel 
Material Amount Source 
30 % acrylamide and 
0.8 % bis acrylamide 
1.67 ml Bio-Rad, San Francisco, 
USA 
0.5 M Tris buffer pH 6.8 2.5 ml Merck, Darmstadt, 
Germany 
10 % SDS 0.1 ml Merck, Darmstadt, 
Germany 
Deionised water 5.7 ml Elga, Buckinghamshire, 
UK 
10 % Ammonium 
persulphate 
0.1 ml Merck, Darmstadt, 
Germany 
TEMED 0.04 ml Merck, Darmstadt, 
Germany 
 
The materials were added and mixed in the order stated. 
c) 10X running buffer 
Material Amount Source 
Tris base 30.0 g Merck, Darmstadt, 
Germany 
Glycine 144.0 g Sigma Diagnostics, 
St.Louis, USA 
SDS 10.0 g Merck, Darmstadt, 
Germany 
 
All the components were dissolved in 900 ml of deionised water (Elga, 
Buckinghamshire, UK) and pH was adjusted to 8.3 and topped up to 1 liter 




buffer was prepared by adding 1 part 10X SDS running buffer to 9 parts 
deionised water (Elga, Buckinghamshire, UK). 
d) 4X SDS-PAGE loading buffer 
Material Amount Source 
0.5 M Tris buffer 2.5 ml Merck, Darmstadt, 
Germany 
SDS 0.8 g Merck, Darmstadt, 
Germany 
Glycerol 2.0 ml Analar, Dar es Salaam, 
Tanzania 
Bromophenol blue 0.018 g Sigma Diagnostics, St 
Louis, USA 
Β-mercaptoethanol 0.4 ml Sigma Diagnostics, St 
Louis, USA 
 
All the solutes were dissolved in 5.1 ml of deionised water (Elga, 
Buckinghamshire, UK) and combined with the other materials to get 10 ml of 
4X SDS-PAGE loading buffer. 
e) Towbin transfer buffer 
Material Amount Source 
Tris base 3.03 g Merck, Darmstadt, 
Germany 
Glycine 14.41 g Sigma Diagnostics, 
St.Louis, USA 






All the components except methanol were first dissolved in 800 ml of 
deionised water (Elga, Buckinghamshire, UK) before mixing with 200 ml of 
methanol. The towbin transfer buffer was kept at 4 ºC before use. 
f) TBST buffer 
Material Amount Source 
Tris base 2.42 g Merck, Darmstadt, 
Germany 
NaCl 8.0 g Merck, Darmstadt, 
Germany 
Tween 20 10.0 ml Merck, Darmstadt, 
Germany 
 
All the components were first dissolved in 800 ml of deionised water (Elga, 
Buckinghamshire, UK) and the pH was adjusted to 7.6 using either 1 M HCl 
or 1 M NaOH before topping up 1 liter with deionised water (Elga, 
Buckinghamshire, UK). 
g) TBS buffer 
Material Amount Source 
Tris base 2.42 g Merck, Darmstadt, 
Germany 
NaCl 8.0 g Merck, Darmstadt, 
Germany 
 
All the components were first dissolved in 800 ml of deionised water (Elga, 
Buckinghamshire, UK) and the pH was adjusted to 7.6 before topping up 1 




Appendix 4: Supplementary Data 
Gene p-value Fold 
B-cell CLL/lymphoma 3 0.1920 1.72 
Chemokine (C-C motif) ligand 11 0.4600 1.43 
Chemokine (C-C motif) ligand 5 0.0020 31.78 
Chemokine (C-C motif) ligand 7 0.5232 -3.76 
Chemokine (C-C motif) receptor 2 0.7633 -2.14 
Chemokine (C-C motif) receptor 3 0.5126 -4.44 
Chemokine (C-C motif) receptor 4 0.0913 3.25 
Chemokine (C-C motif) receptor 5 0.0079 2.30 
CD28 molecule 0.6506 1.65 
CD4 molecule 0.2453 -1.20 
CD40 ligand (TNF superfamily, 
member 5, hyper-IgM syndrome) 0.9765 1.02 
CD69 molecule 0.0311 14.62 
CD80 molecule 0.0277 2.60 
CD86 molecule 0.9235 -1.05 
CCAAT/enhancer binding protein 
(C/EBP), beta 0.6772 1.13 
CREB binding protein 
(Rubinstein-Taybi syndrome) 0.4693 -1.28 
Colony stimulating factor 2 
(granulocyte-macrophage) 0.6907 2.45 
Cytotoxic T-lymphocyte-
associated protein 4 0.4600 1.43 
Chemokine (C-X-C motif) 
receptor 3 0.1999 -2.34 
Fas ligand (TNF superfamily, 
member 6) 0.2024 -2.48 
GATA binding protein 3 0.1404 -2.61 
Growth factor independent 1 0.1384 -2.01 
Glomulin, FKBP associated 
protein 1.0000 -1.00 
G protein-coupled receptor 44 0.1987 1.80 
Hepatitis A virus cellular receptor 
2 0.2163 1.62 
Inducible T-cell co-stimulator 0.6175 -2.75 
Interferon, gamma 0.7965 -1.22 
Immunoglobulin superfamily, 
member 6 0.2350 -1.75 
Interleukin 10 0.5471 1.51 
Interleukin 12B (natural killer cell 
stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, 
p40) 0.2815 -3.35 
Interleukin 12 receptor, beta 2 0.0375 2.01 
Interleukin 13 0.5176 -1.56 
Interleukin 13 receptor, alpha 1 0.0672 -1.30 
Interleukin 15 0.2922 -2.58 
Interleukin 18 (interferon-gamma-
inducing factor) 0.2116 1.45 
Interleukin 18 receptor 1 0.4974 1.31 
Interleukin 1 receptor, type I 0.0365 1.90 
Interleukin 1 receptor, type II 0.0399 -3.67 
Interleukin 2 0.1326 -2.20 
Interleukin 2 receptor, alpha 0.2801 -2.04 
Interleukin 4 0.0375 2.25 
Interleukin 4 receptor 0.5324 -3.52 
Interleukin 5 (colony-stimulating 
factor, eosinophil) 0.8948 1.07 




Interleukin 6 receptor 0.3490 1.11 
Interleukin 7 0.0793 -2.87 
Interleukin 9 0.6852 -1.39 
Inhibin, alpha 0.9270 -1.04 
Inhibin, beta A (activin A, activin 
AB alpha polypeptide) 0.5390 1.30 
Interferon regulatory factor 1 0.8647 1.07 
Interferon regulatory factor 4 0.4474 -1.77 
Janus kinase 1 (a protein tyrosine 
kinase) 0.6434 -1.11 
Janus kinase 2 (a protein tyrosine 
kinase) 0.1294 -1.39 
Lymphocyte-activation gene 3 0.6124 1.35 
Linker for activation of T cells 0.0613 4.69 
V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
(avian) 0.9521 1.04 
Mitogen-activated protein kinase 
kinase 7 0.0615 -1.91 
Mitogen-activated protein kinase 8 0.9230 1.05 
Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 1 0.5913 1.24 
Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 2 0.5384 -1.24 
Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 2 interacting protein 0.9645 -1.01 
Polycomb group ring finger 2 0.0426 -1.52 
Protein tyrosine phosphatase, 
receptor type, C 0.0312 -3.39 
Surfactant, pulmonary-associated 
protein D 0.9059 -1.15 
Suppressor of cytokine signaling 1 0.4825 1.40 
Suppressor of cytokine signaling 2 0.0741 2.27 
Suppressor of cytokine signaling 5 0.1447 1.18 
Secreted phosphoprotein 1 
(osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1) 0.7821 -1.25 
Signal transducer and activator of 
transcription 1, 91kDa 0.1619 1.56 
Signal transducer and activator of 
transcription 4 0.2032 1.43 
Signal transducer and activator of 
transcription 6, interleukin-4 
induced 0.2498 -1.41 
T-box 21 0.4438 1.92 
Transcription factor CP2 0.0833 1.87 
Transforming growth factor, beta 
3 0.9023 -1.05 
Toll-like receptor 4 0.2318 -1.97 
Toll-like receptor 6 0.0122 6.04 
Transmembrane emp24 protein 
transport domain containing 1 0.1020 -2.74 
Tumor necrosis factor (TNF 
superfamily, member 2) 0.0362 2.06 
CD27 molecule 0.7389 1.34 
Tumor necrosis factor receptor 
superfamily, member 8 0.6718 -1.15 
Tumor necrosis factor receptor 
superfamily, member 9 0.0316 4.98 
Tumor necrosis factor (ligand) 
superfamily, member 4 (tax-
transcriptionally activated 
glycoprotein 1, 34kDa) 0.7801 1.09 
Tyrosine kinase 2 0.2939 -1.49 




Table 8.1. Differentially-regulated genes found in DV2-infected K562 
cells.  
Gene profiling of 84 immune genes in K562 cells after DV infection was done 
using qPCR (Chen et al, 2008b). The gene expression of DV2-infected K562 
cells was compared against mock-infected K562 cells. Folds of up-regulated 
genes are highlighted in pink; Folds of down-regulated genes are highlighted 
in blue; significant p-values are highlighted in red. To determine fold change 
in gene expression, the normalized expression of the gene in the experimental 
(infected) sample was divided by the normalized expression of the same gene 




-ΔCt infected     
=      2
-ΔΔCt





Genes with fold value more than 2 in absolute value was considered to be 
differentially regulated. p-value which is less than 0.05 is considered to be 
statistically significant. 
 
 
 
